var title_f20_38_21088="Nodules in pneumoconiosis CT";
var content_f20_38_21088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Coal worker's pneumoconiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 304px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple centrilobular nodules are visible diffusely.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21088=[""].join("\n");
var outline_f20_38_21088=null;
var title_f20_38_21089="Death rates for coronary heart disease in selected countries";
var content_f20_38_21089=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F85912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F85912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Death rates* for coronary heart disease in selected countries, 1970 to 2009",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 604px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Age-adjusted to the European Standard Population.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     United Kingdom for 2008 and 2009; England and Wales for 1970 to 2007.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: NHLBI Fact Book, 2011. National Heart Lung and Blood Institute. Available at: file://www.nhlbi.nih.gov/about/factbook/toc.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21089=[""].join("\n");
var outline_f20_38_21089=null;
var title_f20_38_21090="Anatomy posterior vagina";
var content_f20_38_21090=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78927&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Anatomy posterior vagina",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal posterior wall support provided by the levator ani muscles holds the vagina closed. With increased abdominal pressure, the pressure on the posterior vaginal wall is equilibrated by pressure on the anterior vaginal wall (upper arrows), and there is no stress on the connective tissue supports. Distally, the pressure transmitted to the rectum is resisted by the perineal body.",
"    <div class=\"footnotes\">",
"     ARW: anterior rectal wall; PB: perineal body; PVW: posterior vaginal wall.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters MD, Karram MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21090=[""].join("\n");
var outline_f20_38_21090=null;
var title_f20_38_21091="Iodoquinol: Drug information";
var content_f20_38_21091=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iodoquinol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/61/40915?source=see_link\">",
"    see \"Iodoquinol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/44/26306?source=see_link\">",
"    see \"Iodoquinol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Yodoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diodoquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Amebicide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible infections: Oral: 650 mg 3 times daily after meals for 20 days; not to exceed 1.95 g daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F183821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/44/26306?source=see_link\">",
"      see \"Iodoquinol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible infections: Oral: Children: 30-40 mg/kg daily (maximum: 650 mg per dose) in 3 divided doses for 20 days; not to exceed 1.95 g daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F183813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to optic nerve damage, use cautiously in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15871292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15871293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Yodoxin&reg;: 210 mg, 650 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F183797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after meals. Complete full course of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of intestinal amebiasis due to trophozoite and cyst forms of",
"     <i>",
"      Entamoeba histolytica",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15871289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      Blastocystis hominis",
"     </i>",
"     infections,",
"     <i>",
"      Balantidium coli",
"     </i>",
"     infections,",
"     <i>",
"      Dientamoeba fragilis",
"     </i>",
"     infections",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, skin eruptions, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid gland enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anal itching, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic atrophy, optic neuritis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodine or iodoquinol or any component of the formulation; hepatic damage",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Discontinue use if hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Optic atrophy/neuritis: Prolonged use of high doses may result in optic neuritis and optic atrophy; avoid long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral neuropathy: Prolonged use of high doses may result in peripheral neuropathy; avoid long-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid abnormalities.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10253274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is very limited data on the use of iodoquinol during pregnancy and safety has not been established.  Adverse effects have occurred in children exposed to topical iodoquinol.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10253278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if iodoquinol is excreted in human milk and safety during lactation has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F183802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Yodoxin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     210 mg (100): $108.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     650 mg (100): $143.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmologic exam",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Depofin (MX);",
"     </li>",
"     <li>",
"      Floraquin (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F183783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact amebicide that works in the lumen of the intestine by an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F183799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (oral: 3% to 5% as glucuronide)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      \"Drugs for Parasitic Infections,\"",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 2007, 5(suppl):el-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21091/abstract-text/8246830/pubmed\" id=\"8246830\" target=\"_blank\">",
"        8246830",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kappagoda S, Singh U, and Blackburn BG, \"Antiparasitic Therapy,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2011, 86(6):561-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21091/abstract-text/21628620 /pubmed\" id=\"21628620 \" target=\"_blank\">",
"        21628620",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8568 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21091=[""].join("\n");
var outline_f20_38_21091=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183810\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183811\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183825\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183812\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183821\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183813\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15871292\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15871293\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183795\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183780\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183797\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183796\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15871289\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183823\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183800\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183784\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299529\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10253274\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183817\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10253278\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183802\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323202\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183793\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183803\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183783\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183799\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8568\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8568|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/61/40915?source=related_link\">",
"      Iodoquinol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/44/26306?source=related_link\">",
"      Iodoquinol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_38_21092="External cephalic version";
var content_f20_38_21092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External cephalic version",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 526px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fetus is converted from breech to vertex presentation in (A-C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Charles RB Beckmann, Frank W, et al. Obstetrics and Gynecology, Fifth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy;2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21092=[""].join("\n");
var outline_f20_38_21092=null;
var title_f20_38_21093="MRI appearance Ewing sarcoma";
var content_f20_38_21093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Ewing sarcoma appearance on MRI scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 379px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF7AisDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5XdQDxSBctg8VKc7QpwCDnNWAEluYNq4OQGoAr3Fu8IBYfKe9bOk6W0V9pU9xGrwTyAEMMg1pa5pYV7eEDJlArsn0SWaLw/axp+8E8a4A9SBQB9e+DfCWhx+FrFW0mxJkhViTAvcfSvJvEng3TNT8U3NpbaZZ/I5B2wrx+le/Q+XpWiJ5pxFaW43H0Crz/KvNfgk48QHVfEsikx3Vwwg3D+HPWgDzDUvh1Y2E/wC80y2IH/TEVU1zw3pFho63H9n23mOu5Ejs94A3bcM4GEJPQHrX01rWkWt1bSNIoGBXjGvaK9vPdtbrbtFOhjZm3ZAIIJ2g7WbB4JGR2oA8qi8M6U3mSaglpaRKBjFt5jsScAKg5Y/yFRy/D8ym+2WVoJbaVIkhKANOWkVAV9gXGSenTrXVNdz6bM0tvaRTvt2KZJGRk9SrLyD2qgut67BYy28DwQQsFSLESu9sqyeYAjkbm+bnLE9SaAOI1nw9Z2bKIYLe4t2Z41nEG1TImA6888EjnuCDVCDRrReXs4P+/Yrq7qSe6gt4ZhEkNuzukceSC7kF3JPOTgcdBjAqu8Rxz0oAyoNOsCMfYrc4/wCmYr0LwdpGjz7Fl0+zyRjJhX/CuVjhwAVHNb+iT/Z2UuSoBoA2fGvgfSvs2+CxtFLf3YlFc1pngm009UuJbCBlJ/iiBFd/q6yXthA0E2csOM16dpPhGG58NxLeIBIUzQByfg7SNF1C3Ea6XYlgv/PBf8Kp+M/CWm2cDt/ZdmC3T9wv+FaXw7nis/F1zYJ8yqSOO1dX8SowbPfgfKKAPly48HxeItTu7HTbSxjuILeS4CsgXftx8owOpzxWVqfwqn0u8FnPJay306qbaCKMt5zbA8i56LsBwSep4rX1e+urC+v/ALJhJLuB7dpMkGNWIO5SP4hjirC+P/EMMll5P2eO3tYmi8kM2LgFAmZD1zgZ47mgDAi+HNlb6sYvtqypAjSXP+gSnG0hf3Qx++G4gZX611dp4RsXs4imnxSSTOwgX7JtaREOHdgR8mOeDzwa53+3pxaWFuumxeTav5mRezhydu35HzmJcE/KvFdTF8SZ9P0trq/lWztVVrdYYN8ikuOr5OWIA6nqeT1oAZN4V0lheDTrOO9e04lVbIqd3mBDtyPmGT1HpVfVPBMcGtnSVttOFwbR7sM0QUAL1U5HBrC1H4qWH2C5ttMdrY3AxNPCsiyP84cnOflyR0HHJrN1D4r/AG+5uri4sbY3Utu1olxmQ+XCwwy7M4YnnknPNAGjB8O7C61O+le8P2W0RWkVNJl3lmfaNqYyy9fnHHFO8R+GfDtp4Xh1Dzkijluvsq5sGBAAyX+gUg469qr2fxYs4NONkbHNsVCsv2q43tgg/wCszu28D5Og5rB8QeN7LWNDXTCot7aO4e5jVEZipZQuzJPIAHXrQBLdfDCGPXNUtF10SW+npF50sVhK7+ZINyqsQyxAHJboK47QPDlxrvi230GwmhaaeYxJMSQhAyS3r0BNbsXj0/8ACXX+vXenpLLdBBsguZbdk2qFGHQ5wdoyD1rKsPFl5Y+Nv+Ent0tkvftDXAjEeIwWzkAemCaAOis/h5pl3YahqUXiffpdm6RvPHpkztuYMTlByoAU8nirOmfCG/vtYe1/tKCO1+xRXyXXlMwkjkxgBRzuAIJXrVi4+Li3WkDSbrQY20xUWNYor+aJyo3YV3Xlh8xGDVTSPixe6ZrdzfRWFuYZrSCz+zCV1CJEAFIYc7sDGaAPQ/2ePAdvp/xQ0vWrTWXuobOeW2MbafLC5la1lJDBvuALzk9TgDmvR/20hn4XaV/2GYv/AERPXmv7P/j2XUfivouj6baNp9jeTz3N0DdyTvO62sv3mfkjIU/VRXpX7aIJ+Ful4/6DMX/oiegD4vAwOfypBwg4px68Zo6kAA5NACZJGcc0m4YPtTuB1GOxpCFOcHigBo3EnHftTumMDn1pSB9QaaoyRz070AKemefoaTsfX0pygt90fWrNvaSTJujG5Se3NAFTJ464707HQ4FdLY+FL+6SORIisbdSa6jT/hvM18jPFLcW7LyFBwp96APMdqnJGSR0FTC2mYB1iYjGScV9JeGfgJdSO0sgijtnHc8gGvQdE+CeiaZcmO+lE6FQcHmgD4xgsLq4J8qB2PsK1YfCesyx7xaSbfXFfcVr4D0DTIiLLTo23fdLKKtLp1rG0dvDYwkhwSMCgD4f/wCFf+IFWPzrKWIScorA5PvWrD8LdaCq80LBD/CO1fWvjK7N5rG50iCxKFjx/DXKXV7Iu9vORT0xQB87P8MtSQTO6EKgBX3rPm8B38MYlZGYP0UV9B3c795A/H51k3G59wVtgHQ0AeByeENQi/1iEE+1Zx0m5UYePnp6Yr3S7EoYB5EPoT3rJvIFIdJYk55BFAHiklrLGWMiHAP51E4OORj0969RfTraSVsoNpHArDutDzPIWUMmPlxQBw+CwHrSqCDW7JoLhcMSspPGRxis27s2tpmRskKevrQBUBPU8+1KxB5UcmkA+Yn8qVCASfzoAaORUudp4+91pmOvH0p7Ywe59aAELlmyTkk9SaJMAH1zTVXI64p5xn9KAGquCDnjtTg23oSOuaQDao9M5zSnBOMd80AIrZPJx70jYOAB9aG6jjpShcDj60AKqkZPJHT2pUleMq6nDK2Qe/0prHn6npQMHBPOKAHpNIEC7yAOAM9KTz5hwHbHvzUYGc9vSlzjocCgBC25ssf/AK9b/hjTRPKbmcfuk5Ge9ZWlWYu5SZCFjXrXV6TZXGuzx2GnrJHZ5wzqOZPYUAbHhOyl8QeI/tOMWcBCx5H3z6Cvpj4feEIdQ1+K7u4D9nsUR144MmeB+GKz/hj8OvsVvbQmBU2jcTjiIf1avcbCzhsLSO3tk2xoMD1PufegDzv4+63c6d4KOnaWSNR1WQWsZH8Kn7x/L+ddd4E0uDRfCOl2NsiokUCggd2xyah8d21n/YVze3UcZlgQ+W7dV+lUfBfiO2u9AgCzKZUGCCeaAOg13c1mY0zluuK4S+sj5TJtyT6130rrLCGzkmsi6tMtuxzQB4drtnJZ3JLqNhPWqUVk95gRICpr0bxdpIu1YV51HrKeHdSW2uU/dMcbqAKGreG7i0HmKhK+lYXkZO1gVYdjXtk7wXunJJbruVl6muZuPBt3e5uLSMFuegoA4GC3Kgg9asxRGSJlYdK0L3T59Pn2XSMjDtikiRQTgdaAI7u5nttJRrZzuVgcV9C+FdcS68GwzXEiLMsODz7V4KkaMpR/umrbvqyWpi0+X91jpmgDV8D6ith411GeY5UscE10/jXXGv4Sqk+We9eN7dbsrtpthcE8kCuttPER1TTvshtisq8E0Acf4kstxMi/Nu9K56SzdYxlME16HPJDEhSRAWHY1g3sZnYtt2jsKAOZa0CxHqWx0rD8aWwTwdJIThvtCfL/AN9V3Qt0EZLnB7VxvxKgWPw0WVjgzpkfgaAPKaKKKACiiigAooooAKKKKAPVf2XP+S7eGf8At6/9JZa+gv20v+SXaV/2GYv/AERPXz7+y5/yXbwz/wBvX/pLLX0F+2lz8LdLH/UZi/8ARE9AHxdnkk0DPJFLt7YzjvS44z39KAGEdvT1pwHXHOKXbnjpWzovh691WeNLaFirn72KAMdULNgfjWtpWg32oTGK2tnkOMggV654W+FUE9m82w3dyn3ol7GvVdF8G2cFlaSXXl6bNGpUxIOWBoA8U0D4YSYtJ7/LrLwYUGXH1Fej6Z8LDpt1EzWSppzDcXZfmr0nQL3TtAmmn0ewM9wR5e+Qnj3FRXN7eX7b7663YOfLXgD2oAxdF8K6fauzFjKoPyq3QV2WnSwWcDJbWsUaPwSVrn7vNrbLKJ0MbDJUdRVIahLcqY7JWkkHGO1AHbw61bRdZmOzqueKbJ4gt5gSww+flPtXIxeHb69CNezGFT95V4zWlBokVsqLK+9VOF9QKALlz4nkyTK+yGMEKFrDPi4W7tLvdpBxx6VuvZaeYs20Ym7Nu7GuY1G3jE+BbqsePm4oAzrjVYL2JiWaMsep61lm5t1BkOXIOAD3qxcWlu6tsZcqeFrPRYicSAqy5+WgClfXLLK3yHJGTjtWNNqWLgRyOfL9/WumTyhGVVfmB+YnvVW/sba9XDxKFByCoxQBzc86lA8hyCfyqnLJuiwpzk4B9q1tV0jegezGF6baxLuymidcgxrjg0AVZl2y7SpBA61FtWMFgxZTx+NSSXe1yjgM3QE0ltEJ1kEbKh7g0AUmVC4Sf75GVPpVBfD99q+o2+l6TbG8v7v5UjUdPc11i+BfEN1Clxptq17ERklR0q14SfX/AId+Jodbn0/94MoVkHBBGCPyoA4bxP8ADHxT4TQf8JBYeRCx4lXDKfoRxXI3WnNb5bIKnp6mvof4tfFSTxzp8OmwaY1nZxN5kjO24s2MdcdK4nQvDuj+KLZbJZ/s2pHiPceCaAPIJFYYyCAO9AYbRnt2ru/E3hTUNDuWsdTgGY+jDo/vXFT25Qngow7GgCHIGQOc0iNznH0FMfIY5oByMetADgc4HAHenjG7cDz70wc8AdOacrcDB6e1AASvfp1pcZJPboKRQMkHvRknjvQAcjr1IoTBBwKM/NnGfrSKNi57ntQAvfIppyT0H5VJ8gGOev5ikwp65oA3/DWk3Ov6hFpumQvICRnHT6k+lfX/AMK/hvb2FnGVALoAJLjbxnuqf41zPwG8DQ28MUCJh2QS3c2OcH+EfWvpC3hjt4UhhQJGg2qo6AUAJa28VrAsMChY1GAKlorH8VakdN0p2jOJ5fkj9ie9AHA/EDU5dX1T7JC//EutT84B/wBY/wD9avOrp5vDOojVo932eQ4ZAeBXYv5SMI3z/eY+prC8RhJtOullOIVU4BoA9D8I+JI9WjiZGyrgEV33lK8Y4B4r5P8Ag14pxqU9vk7Y32rmvqXQ7r7XZiT1oA5/WreMRylsbh0r50+KiGWZfJ4lD8Yr6U8Q4hsbmRuOtfNeqv8A2h4qMXVQ2T7UAeo6OjDwNYk4Em1d4710S+ONL0HTYbeOB5Z8dh1NefWctw5KByLeIYxVGdfOnaTP0oA1tV12DVdQa5urcKp6Lisa7MU0u6JNi9qPL9cZqQAAYFAFYQAmrFnPLbvsGCnenBTUscKzLgnHvQB0ugTWF1MYpjGFxzmsnxVNYWF55Wm+WXbrtqsLGzijZvNYP3IND+Cr67szqGkfvyvJBNAGO1ulzGXfiQcisy5hkdWDDBHStzQdO1fUtUjtzYSxspwxYcV0Hi3wFrUASezQOp4YDnFAHAQW8f2dnuF5HSvPviaSfDTZGP8ASEwPwNe0at4M1XT9GFy8Mki4ywArgNX8K3PirSmgffZ26OHMhTPTPGPxoA+fKK9Nb4Z26sy/2rJuBwP3I5/Wq7/DqNGIOov/AN+h/jQB51RXoP8Awr6MZzqD47YiH+NN/wCEAiz/AMhB/wDv0P8AGgDgKK9Gsvhq96ZfIvjiNd7s6BVA+pPUngDuelQjwDblVYak+09cxcj9aAPP6K9AfwHaL01GVj7RD/GrknwovxHbvFNvM20iMMnmKrch3TdlVP8AeOB0oAs/suf8l28M/wDb1/6Sy19B/tof8kt0vP8A0GYv/RE9eWfAXwaPD3xt8OtNeLLMqzuoj2vG6m3lGVdSQR16dxivUv20cf8ACrtKyCf+JzF0/wCuE9AHxicZBH4inRxtJIiqpZ24AHOaSFJJZVSNS8jHCqBya9P8F+G1jMPmwlrmTpx900AZ/hLwW88yz6spVcZWEDljXvfhLwdbW+nQtqSi0RR+7VR8x+tTeHtFg0a3S4uts97jIDDha0prxpWWZ33BhyOuPpQBpQ3MFgrW+kIsKgYaQDJaqoIZmkmk82VujMeKzZ9QitLV5E+fLY2Dkmqlho/inxVKIbGyaysQcmeQbcj2oAt3mtRW0mxSGCdQvrWelzqd88jWlq47jA616VoPwxtLJAb2XzXwNx65rrktLHT4gLKGPK/rQB4T4e0y513WRY3Bkikg+aZWPavWbCx0/RrVYraJfPYcMRya84+KniZdNvJm0qB7bW7n5T8vBQdTWz4P1aTW/CEGovJli4iDd1PQ/rQB0rX4t5yGjEmeMn1qgXjeYoxAYHcRVKeV9zoDuCdXHrVJJjJJgg+5oAj1CSWK7Btz5WGJK56irIubXVbZ/JUJKvyOp61WleK7coqksOd3pVG8tXE63Nk2JkHzL2agDO1bTEt5FeAnP8VY1xu+0bowGbGK7FpVvrfzApjm6MhFYUlhK907QW8kpUZbYM7R70AY68vgkAdxTpgsZCrkn0FWYoF3YjUuH5DH1qOaT7NEU2gyMeT6UAUXLKeo46CqusM81g0MkakgcMKsPCEkEsz7YUG7JNVoHGsTMbfIiU4z60AZNt4S+02Zmlf5n6D0qpd+GLm0xKilkQdu9d3C7QKkQXoQDUsu8E4AZD2NAHL+E/H/AIh8LmS3s9ghHOxx1FReN/idN4mi2XFoI3T26mt/UdFttU3HaI5F7jiuT13wvM4k2plVHylRQByxuGvlht7fAmkPKnsKpO00F0Wc+TJG3ySJ2IqSS3ubSQtP8hVsKwqK5ZfLA5cP39DQB1dx4rGt6P8AYNXG/UUx5Ux7iuQnt7K4kkh1GPZIRtV1/nULPtmDEhtvFK3Mqq75VucmgDn77R2ijZlcPGhKhvUVkMuxVBAJrsrmCMLhGJQnp61kXVmXBeJcY4ANAGGpGDnoaaAQeammhCDcpDZPPtUO054NADxzk/hSDPOKFJ/KnYPbpQADAzj07d6GILDAxSZBcZz7UHnPrQAMOCT1zSjdj1/CkPJwKXLDjcB7UAfon8HrUxeE1uZEVZLmQtkf3RwP613Ncp8LSp8CaTtJP7vnPrmuroAK4DxzemfUkt0b5IBlh/tGu+dtiMx6AZrx7VrkzXU8pJy7luaAM6eOWedRGR15zWL4xleDSJ0IU5UjNajHc33iPpXN+O5gmlMFPFAHjvgS5ax8UzJu27myPTrX1v4K8QNHpoVzk8da+MoXNvrccwyPnr6g8Gq1xp0MhJ2bQTigDufGuqQS6HI6Pg7STXzn4NmGo+JL6bOY0crmvVfiLMLXwpc3C5RdpH1rxb4NXBmivXc4Z5Cfr70Aew+fEUjtbdAu777VT1AW0b7I+q+lVCxV8qfxqM4ySevrQAFd3JpcbRSLubt8vrShQOpoAcpGct0odyQNvApvemEHOT09KAEfPlyf7VemfC+6aO0SBn2K5xg968ykf5fmFdBJqL6Lp+l3aH5VlBYDuKAPeFjRTlUUH1Apx6c1mXWrxw6CdUSOSeIRCUJGMkiuO034m2Gq6FdXNupivI8gQOfmzQB6E6LIhV1DKeoIyK4j4laNbp4UvJrSNYXjG4hBjNXPBXjO18Q27LKv2a6i4dHIGfpUfxYu1tvBd5k4aTCrQB803K7oYJh/FwTVaVuSGGRWtDGtz4fYKP3kZzWPL2PtQBA+M8n8Ki65xT5PvVuxX1hDawSARzWlnaLI1scKZr/ecKf4iNuP9nGaAM3SNcttN0y9s7ixhvnuLiCQC4QtGoTdknDA55GK2JPFOhvq2o6l9mnS5vAIkhkt08mFVkDCViCTkjjAHHqatXsVtqeu6JbT6fcanqgiuDd273MUUhXAMYLJ8gx8xAGTjr1rDitpZvh1BcC0tCY9SQhtyh5V2Op3HO7G4qvGB396AKfji7trvxLJLp94t5biFAJUYEbu4JBILep+nAqa+1jRbHRbf+zNT1OzvnMQvZPsQkaVQRuUuX+ZF7IAM4ANa+s6Z5njq4gl0qO7WTT1mW2tbhIVUrbqGYHkfKwPHU471Fpd1o8ptpHuLX7BBBCtgsu0Br0qPOJzyT97G75c7fagCb4WeJIdd+OvhKOyJaysre4toZDAsBkHkzPny14QZbAUdhXd/to5/wCFXaUF5J1qID/vxPXFeCSo/aJ8DhizXjWdwboymMTlvJnx5qx/IDtxgL2xnmvTP2qbZbnwHpIcZCavE/8A5Bm/xoA+Wfh/4faWZJto+1Bs/N0Ar3HSIbbSkXcFebqWx0rk9AghggikjAQvxj1rfuxLFbK8+3yj/F3+lAGtNqxnkcEBc/xHoBTdFtdW8RXgstAizArbZLlx8qetWPCHhK88V3CTXStaaSnGehevbNLt7LQbWKy0uBEt0ABKjlj6mgCl4V8DaXoUCtIgu7wjLzTDdz7A9K6O4uo7YBVHI4wOMVA9+pIIOB2+tZ97MJpMjap7n1oAdd305yc/LngCs64nk3bEJUDnA6mq95NI7nEqRwjjd6e9Uo11DUS8eiR74iMHUZCAgGedvc/hQA3xFo1jrtg4vhbx35UpBKSNwrwu+1HUvhJrb2SyrfaTcf6uHrhz1NfRWpf8I34e0ea5l+z3MmwhN7iSWZ8cBevJPpjFePSeDoNTZbnxHM32gruRCc7M84oAzR8X/DTwbrhpYJ8YeEDvUX/C1/Cci4gnnMp6jaeK6G28HeGICHTSbe6lA5lkHU1P/wAIz4Ohh81tGtheOSGULwBQBzw+IPhsxnyr5otwycirNv4r0a4DPFqaK2MDPerJ8NeGd7xSaNExcenQVnyeE/CoctFZFQvBCnpQBo22uWy3CXMd7C7D5SuRzW1Fq1xpaS3GkywE3KlZVbB4PpXIJ4K8P3gcRyywyDkYbpQ/h2aytJlspZLp8fKCaAIpL6O3QxvdIqKS2B1zWZPryPMFsLeSeUdcjIqGG90yF1tNX0ueO6GCz9q6TTjaSPJJpSR8J8wYYIoAwTpV7qbGW+k8uHtEOK17W3S3t1jtYxGEOSPWnqzkBpHA56ZpGLISzty3HHpQA95SWDKMf3s1dgVLySBG3eYueF/iFUZcvtCqdp6n1q5p8s2myRX1tGJGjfLAjPFACLExuWjHykMQVPWmwiRrl4pBhCOK6fxra2lzp0Ov6UyrPIB5sI7HvXNaVfhLphdJgkYUmgDJ8SeC4NQsZJoid687RXkN3YXdheNBNE3knOGIr6Iu7r7OhhjAZm7/AFrkPEWiLq1nLEGCSY4OO9AHjlxHEY18lTvXhqg8wwyEMm+PHPsanvPP068ktJR+8Q4PHUetQSlo3ccEsN2PWgB86vGkO4jBXK/SoWXcAx4VadERNEpOSw4wewqJvmIwwMYPzUAY+oQNCfOSPEZbkVnXCEHcqsAexHSuqhuHg3t5QmjY8AjNUL5i4cTxA7skbR0oA5/cSMdAKU9B70sqdGXj2pE5A9qAFAJYEAgCnLtLAsfbj+dBIweMnPWkAyQO1ACcEDn6078AaZk4P6UoYDjJoA/Q/wCCF39q8BW45/dSvHz7Y/xrvq8e/Zn1FbvwfdQhgTHMHx/vL/8AWr2GgCtqkvk6bdSf3Y2P6V4nK+Sc/U16/wCK5BH4evmJx+7NeMSSHvzQAyV8ZxXJ+OSTp2c9a6SR8k4Jrl/G2X0pyOdvagDx3U0xKMDJBzmvqj4JvHqPh6IOeAgBJ7182ajArWwfuV6V7h+z/eM2juN/CAc0Abfxzi+z+CLtUwEGea8G+C8m0Towwev0r3L49XZk8BSMw+UngetfPPwyujBqzr2IyR60Ae1Fg3ORTQQfwqzbSwSQfvrcI57im3pgDotqPl/iJoAZuJ4HQUmSx9qYshAOcYoVgeAeaAHe1LGoZixPygVbtNOkunWMHDMKrXRWMNbDrGcE0AVp8YZj+FdB45tkh8OaZGDkyAfhWAn7yWKM9HYD9a3/AIlOEubC1j+5HED+NAHdfBzVTf8Ah6Wymbc9m3l4PpXk37Reir4SvE17Rj5Kz8SxL0z611nwVu/K8S3cBP8Aro8/iKr/ALWGnNd+ErWRdwUOVYigDzD4CaNq/j67mvJ9Tkgit5MtsONwr3H45E2Xg6yt1YthwhZjyQBXi37H2qTw+J7/AEwHMZTJXpx6165+0NP/AKFplv6yFqAPJdEmCXEsDf6t0rMu02M6j+FqsWRIv4ie55pl85jvJc9M96AM6QHOe1VJVUsSVXdjGSOcVqyxFUMm3MZHBrMmIA56UAbPhXwzp+t6bqD3t7HYLbywqpfCxkMW3Ak/xYU49Tx3p+oeApzdXsmmmKW3iu3gQTKUkWMPtDsSNuOnQ1zpu547V7aKYi3kdJXTAwzJnafwya2NH1PxDrWrx2NvexzXN9LhzPGg8zndtdwNwQEZwDgdqAMLWdJXSr4Wkhgk3xiUNErKCpPBwQCM4PUdqr+LPDTQeGV1U3VuysFzEIZQ+CcY3FAvH+99K6fxLaTapqE+sPNps0KBIJDYTmVd+GI3MQPmwp7dK4DxjNq/9iRO9xqZ0hpPLw0shg3DkKATtyOuKAOx/ZYsbWX4uadLNK6XFtFPJBGicOTEytuPYAMfqcV9G/tDW63Pg3T0foNRQ/8AkKWvm/8AZf1C5tvi9o1tD5Xk3qTpMWjBbasEjjax5XlRnHWvo/8AaJlaHwRZleN1+ik+n7qWgDwoywRruZ8lBtCr3Ndt4E8LS6vcQ3+tF0s4juSP+9XIeA9E/tvWI55QRZQH5zn7xFe3Q3CxxRxQ4EaDaPegDoRewRW3lwqI4o+FQDFRwXn2gOMhB/CfesZZAWLTkbc44qe2tpNRu44bQkbDz7D1NAHQRpI4VYY/Mfp7fWsLXr9bKdo7qNkKdh3q1cXr6RcyWdhdoSoy7vg4b0rl9c1H7XI8mpyp5MQ3SygADHpQBzmveIJb3TLuZ0NnpK5R3bhnPtWXYan4w8V+F4NAiaHQPDcUYRrxc+fcRD+Hnpn261Fbl/GusHULtTB4bsmIt4MbROezH1rtrhIrnSlFm6+YPvAnARfagDG0Cw0nw5Zpa+H7Ztg4aaclmPqeakkuEZnmkYu3p1rT0HQNS15QIIvItgCPOkGAfp610sun+HfC8JF8/wBpuQOVz3+lAC+EvB1nqGlxX+qGSUzjekSsVVF7dO9c58QPD9p4burWSwDmG43ZRm3FCMdD6c1Zl8b31tCV0NLdLYE7Y5xnaPbn9KwJtR1TWb2Oa+fzZZTsQkYVfYD0oAotJHIquWcMT19KiWxmkuxHCrDd6961rjTLm0uZIdTZSwb/AJZ9K3dHmtYHjGoo4j3Da4HIoA5eXRL2IRgW0yTFuXx8uKk8mWzbPmlTGck+tely61ezWEtsbX90RtWY8ceuK5ZIDZXTPPaPdwkcgA0AUYPs18yzzwxzSEgjK1V8SeE7XUdSS6tXOnylApSPgNW/ZqrWs7abAoByXRuqj2qbTtMvNY0iW4s5Y3MDnER+8SOcUAeb3/g9raKRvtTvIOdnpWOwutPLhsSx44J6ivSJ9XiW6kmMO2dl8oxuMEH6VxutJtuRuXaSfmHrmgDPt70zxRycbVOCPWrLXU6oyqflbkCqml2NrCtxc3M58wtiKEHipG+bJzgelAF55Zfs0SrJkHkr2qrKXkO919uO1RxMQy7SfKzyfSpDceXNIG5XqPegCaOZ43Tzz+7B696knHl3EkfXow9x1qqZPNZN4+QsOamvAy375HChQD+FAHD/ABI0WO5SPULNf3x+WQDivN4yIkYTqxmztX6V7Vr0e6yES58yV8VgTeFWmYrsUSp8oJ70AeeR2zNHLPE4EQ4P1qtLAzR7QNhc5z610WuaRHo4awRy7A7nIPU1zqXUlxE0T4whwh9KAGxb4WMOC24HkdqhWMPE6E5I6E1qaFMYp7oXO3aYiqE+uKyZVZTtJIRup96AMe7t0juAN2QTVVvlZwo4HFb08CTRMu0YT+Md6xrqHy3JkBGRkY9aAICR16Y6ClVvl5P0pm0kZP4mkwcZFACk7foaPMP+RQSWXBxxTcD2oA+u/wBkHVUkW/tHceY8CMBnrtPp+NfS9fEn7KuqpaeOLSJyQHLR4z/eGAa+26AOf8esV8LXhXuAP1rxhpOB7V7H8Q/+RTvOM9P514mz8fhQAjsSfxrI18ebptyuMkDNaDPzgVVuCJFlU/xKRQB5lPArWqSdcjB9q7v4E3pV57ZjwpxtFchDFmynSQjcrkAVqfBSc2/ie8h27mbn6UAd98bb0v4V8jaQ2eM9K+efDtx9l1mEhtqlsGvbPi9LNcaZImRtVsY714SY/LuQwI+U5FAH0XbOr6ch6syg5qAHFQeCXbUrG2RCOUxzVm8ia2unhfqpoAaxzgelOhcBx7dahJ96QNntQB0thcfZYZLmRxuIwgrAmkLyM56sSxpss7Mqpk7V6CoWYng0Aa3hyxfUdXtYohlt2SParPxHcDxH5QOfKQKfritr4QKsniYlv4YSR9a5bxvMZfFOqH+7NtFAF74WS+X48s1PAdD+JxXdftETWsHwx1GS8IGMbM9SfavO/hurN480ts4xuzTf2yb+5h0GxtDJ/o0zZVR/e96APLf2W9WhtfiVCrZWSdSpOeo9K99/aIyBo/y8bmya+YP2fbaRvinpJH8BLEetfUf7RAb7HpJz8pkIIoA8XiOLqE5531c8RoI7xlwASAaoEhZY29HH861vGa41GF/78QIoAxjMTZtCDyDwKzLkAx4NWlOJcnoap3Rxke+aAKbnPbFa3hq/n8P6zYaybKeaKCTcoA2iQ4IADEYrIfvXo8HjTRoJdAsbmaaS3gtbdbhpLgvbxEZPyRYx5obGT6EmgDnrLUDJpd7a65Zazd3NzPFdTSWqqrqVRlAIYYAIb07VwPjHWLNvDMekx3Gri8W9+0C3eUG1EeCAdv8Az09T0r1mfXJ9O0S4D+IWl1f+yZ457m3vTL50zSKYl8wH5mCbsDtk15X4qtYW8AxXS2uj+cNT8r7QtyftuNn3THnAT3oA3v2aUcfGnw4zE8/aeP8At2lr6P8A2ld7eB9Ojj+/LqkaD6mKWvA/2cLcL8VvDT8kj7Rk/wDbvLX0d8crZ7rQdEjjTfjVo2b2HlS80AcP4ZtBouh21pGo+0EBpMd81vDb5J5OR0+tZ8EYtgTu8w9Ax7VL9s8mEh4w6+o9aANCMtIwiALu3Ax611E17F4b0dYo9smpzpnI/h9z9K5MXpsY/LiQGaYby5/gFZ95dyymNpZN+7IJNACvM0hJJ3Eklmz94muQ1+afxHq6+HNPbbZW+Jb2cHhu4XNbWq340rTLi6cALEMIO7N2rI8IQNaaE7vlbq+YzSE9QCcgUAbb+WtvHbQIIrSIBUReAAK6vwn4bgnP9qao5h01E4Vm2h/c+1ctosR1G+WEgi3HMj+1bni3XGvkTTdPAW0gIVAP4vrQBsa744c/6Locfk2yDaJiuM/7o7CuJnjku5RNOWk3Hqxzk+tbdz4Xv7W/trS9kRmmQsoQfdxXX6L4XtRAI3JZUOXZv6UAcFp2hTzuNqlmByBjtXWweDby5WNyyQKMYBJBFXNQ8Tadpkv2bQ7Vby5Hysw4Vfx71xmoeOvsd8X8Q6+LOLdnyYScgenFAHfp4SjVFN5ebnHOWHf8a1kTSY0WKQ2zle5wea+d9f8Aj14YspZ/7Nju9QmLfKzu2K5C5/aCuvtRNroxWNj3PNAH1h9q097iRXvrdU6BNwFaeY3jxYm3Y4x1BGPwr42l+NSyyux0ttvByGPWtPS/jFAVKSi4tZG6FWPFAH0fJ4cuvtbuQoEnUxH+lZX9n3PhPUVv7RpPs7kC4gPR19frXG+E/i/hYYZrqO6Qtj95w2PrXrVneWHiqyilt5QUUneh5NAHP+P9GsdX0uHV7MqtyxXa448wH19xivINbDG+YyvyPl/Gvco9GeW0vtHkLIqHzbV+3+c1414oga3v5YLqIrNEcMPU0Acxbl45iJRmYk7XPpUrvKsmXT7p7d6c4G1QwO/sfSlVCpGZMrjk0AWopCUlVCp4yRQxUrsKgFjwaqQxoRlSwdjzjvUF/JKZYVTOUOQPWgDRQeYQr5AQ5J96t3/N1IMjlVIz9KjtIDfQPJbSA3MfzSReoFJq0F/a6oItSsJrVJY1aGRhgPxzigDI1ZpjJAIyC2cirJkJZGdj5i/e9zVG9fzb9Js4jg+XA9a1beS3OmOJlxdSPlCfSgDm9e0hLiJrj/loxy2eteY6rpbadeyxluSdy4717M375H8xSVLdvSuT8XaOkyb4h8+QQaAPP7GYXF3DDsO7cAwP1re8W6bFYtbAL8soxwO9c95rWWoRzshGxxu+mea9r+IWjDUPAWl6vpluGSPDO/sVFAHh2x1DKThFP51DcR7o+V3HqAaXJW4mjZyVLbsmpHmAUKPvYxn0FAGC8Z2biRuJxsqB1ZDg8DqK6S20v+0Hmb7kNuhZ39TWZpuj3+rXS2mk2d1qN2+4xwWsLSyMBySFUE8DmgDOAJUkU3ntW9q/hDxLotl9r1nw7rWn2oYKZrqxlhjyeg3MoGawCOaAO8+EGpf2d4vsJtpO2eNuDj+Kv0VjcSRq69GAIr8wvDlx9m1SFyCVDAkA88V+lfhW5F54Z0q4H/LW1ib8dooAz/iIQPCV7kE9MD8a8OZgMAnmvcviEqt4Rv8AfnG0EY9c14Q2eD7UARs3znB5qAsfOIxTycMaiZvmPPNAHI6nEsWryxuQqNlhXO6Lfy6T4nE1o5XceTXT+LYhHcRzLkuwwa4S4Ktex7iVOc5FAHX+MdbfUVyWyW+8K8/1KLYwYZGRW/LiRwAeKqalbKwbGcAUAeifDS8dtNtyrYZCO9ddqE39p6pIsQHmgdB3rzr4cTA6e0XQiuw8PX62fjS3+0JmNhzQBYkRonKOMMOopFfb0FbXjBLYarJJbPkScgDtWBuGck4AoAdQAzEBRkmpTCRAJn+WM9PetvRNN+2rC1iN7udp9qAOy+GWmtpaXOpXCk4jwuK8x1qQz61fTnpJKWr267vYtDtbKMjdAq7JT74rwzUWB1C6ZPuNIzL9M0AdH8JlEnj63VhkCFmH5VmftosG0bSFUAujkn2ra+DkLy+NxID8scLZrkP20ZGjudGWM/I4JcfyoA8r/Z3S5f4p6VKiNsUneTX05+0FJvj06PYw2v8AeI4P0rzf9knQReajPrkigxW0W1AB/F616F+0HcqZ9JhByMMSPTjigDxqfg5HrXQ+NodsWmyr/HEAa56TggnseldL4rLXGhWFw6lCVAVfagDj25jOOorPnYEZyCTV+Ngsg35KHrRPpDgmWBg0BG7PpQBjsaSSNkQMwwD0NSW8YnmIX7opmtTiBYYCQWoAZcXCGxgijPIJJAFea37fadbkPTL4rugSkMm4YKgmuBtf32sIT/FJzQB9C/s+wCP4meHdvYT/APpPJX0n8Swf7FtXXG5LpWGf9x68A+BUIX4h6CygADzv/REle+fFH/kX7c9hdKT/AN8PQB5v5xlbJwo6kUsZWSU7DiBPmbPeqTN5iugJjj/v09H2KyqMo/ANAC3dyJ3dtx24yPoO1VLi5LmHbmNWGMntSSyeXIehUmq7obx44WkCIXGG/u0AY/jKQzarpmjyI6jIlfd/EOoraguFeWUyLtCAogHYdq5u/wBWufEfj65vJVU2enwraxuvRio21r2rnLIvzFsHJoA6/RojD4OmuY2/fmTa4H92qGlQCeUSRM7Mx2gH1rQ8GTq82oWUjKYzDuHPU1sfCzSjd3N5cToVSCQqgI70AdrpemvARNqLtcXrqBvb+AegrG8danNbH7Iki21nsLSMvBI710r37ASBRvVDgsK+dPjp4rltoxA5PnXchTaDyF6UAcX8QfiXNcE6Z4aAtIYGINwn3pK8xmD3kjz3byXEknJDnPNbEels10sUQBQc5oui+nSARRK93IwCrigBdF8Iz3cEt3mC2t1HLMBkUk2k20T7FupJJMYU7TivoT4bfCyPVFTUtdfNjtEn2dejH0NexQ+DfC8tuvl6NZGPHH7ugD4KuLCG2HlwTmQdWbHQ1nbZI7oK4V43H3iOnFfQnx9+Gtt4Yh/t3QYMafK22eIc+W3r9K8LuBDIVeLBAGKAM5LtrO+jV8hD92QGvXPhB46vNK1pbWe44374zn7w9DXkupWxeBo+rDmNRTdHuTbSW8ykiSKQZ9aAP0b0W/g1nT7XUIOAwPHoehFeX/GeyVdThmiGJJogSfXBx/hU3wN8TJqFs+n7s5TzVGeh71s/F+2D2FtcAfPEH/EcUAeHMo38EFuAansrmBLkxzRFoVGDimTW8ZBljYh5cHHpVSZzC+yLBd2+YUAX72BYVV7aUbc8Z7CmBUViXYncfvela3goad/bIvdbUmztlLPGejGqfiC7t77W7l7SDybOQ5jHtQBT08nTrn7Vav8Av1bqejD3ra+IHxFk8Si2spbAWptcyF92dzY7egrFKg4RBxkVzniKaOWWPBO1Gxv9TQBd02RPLDv8zSks4NakzB7a3VwFYN8pH0rJtYwAmWwvUmp2mDRKGJODwaALsZeNmj3AoRioJoY53ZS2JFU4zUERZQSfz9Kk3O0YBQbuu72oA8+8V6QqM8+fmKkEAd69m+B+q3GsfCHU9CvbNpbhcpD8ueMAD8q4rULNLi22yIDvyFPvX0L8AtGbR/AEK3CoLiSVnZh6cYFAHyH4y8M3fhy8FteQFZCu7ke9coRuIcjCEd/Wvr/9qfRrefwlbauuxbm2k2k93Qjp+GP1r5LnMUrGNuIcZyKACC68m3a3ViIn/wBZ71kTmaK5W4hZ4CQVTy2KkD6j1rQYKqYHKnp61XIKTJC+WbIJJHQE0Adj4RuZ7n4NfEw3E8spWTSseY5bH7+T1rzDP1r1fw/EsPwq+KKoBjdpTD/v+9eU/N2BoAlspDHcIQepxX6JfBG+F/8ADPRnEvmmOPyi307V+c6k7hjrX3D+yRqkd78PJ7VAwa1nw2fVhnj8qAPWPGSb/C+pAAE+SxGfWvnzBYdc4HNfRHipBJ4b1NScZt35/CvnZDjlTwRj8KAK7kb+KiZgsu3qTUzg5YgcCqVz/rUYcetAGZ4syuneYi5Knk15c7GS6GG4U5Ga9ev4hPaSqQCCK8k1JTb3rBQAvI6d6AJ0ugJggBOTya0RF5ykk4GK560Lm5GRlc966JGBdVBoAvfDssJrpOysQK7AxPJqQnAxsGM1w3hTUIdLnvpLhJmUNkiKJpD+Sg025+J9qL1YbCwnkVnCFpTtxzjhRkn6cUAemtI0hyxJJ7mlhMSuGlBZB/D61inXrTtDqWP+wdcf/EVopIJERlyAwDfMpUge4PI+hoA2LmT7TbqGIBJ+UD+EV1HhGUaDbXF2o3q4ATPY1wSudy85wa6VL7ydJeNz94jaO1AHdzlb7wfczztuyd2fQ14/cZDtn1r1KGUTfDfUCD86jjFeU7iYkz1xQB2Pwke6XxLL9gCmfZyr9CtV/wBr7R1uPD1hqLAFkJQqaufBbP8Awm8n93yDVv8Aa6X/AItzE4yGWcYIoAp/sexBPAt03OTLg/rVf44XZuPFS25XAhXg+tdX+zLo0ml/DmCSQEfam8wZ9K4v40SI/jScL95FAP5UAefSdsDnI/Gut8fEJpekxAY/dgkfhXLqdsqH0INdB49kMtvpxJ5KZ/DFAHGSfKfYVE13LAGQMfJbqvrUkhxyeeKqTENHn0oAfG0NuhdDuLfw+lZF+nnS+cOTngVYbk47UxsLg9RQBRv5j9jmkIAITBrifDqCXWYeCfmzXX68+zSrhs4yuKj8B+BvEVzfWt9/YepG0dQ8cot22uD0IOORQB7t8FoinxA0UgYGJc/9+Xr2j4sHHhuAHO03Kgkf7j15b8K7Zrbx/pUU0bRzIZVdGGCp8l+CO1ep/FdgvhyDcMg3Sj/x16APKgnmIIyd0W0H3zUM9yesZyoGMY4FJdSFYHVAU3fdI9KjDf6KsRXGe47mgCDqx56c1n6rObS0ACs6M3JHpWpNCAkaB8Ow5xWD4llMMNnFuCh5QuT3oA1WtbGCwi/shcQkB5h/tH1/Gm2ziNw5TcU5ZR3FMtSY5GhYFUkXIx3IotXMN2smRgcEHvQBqaI0smqRvagxM7YAPpXu+i2jadp85dVEx+dgvrivFUIa+jlxgN8yle1e4WRafSIiWKuyAFj1PFAGPcTPFpk4iXbgbiO9fKvxTLzeNLY3ZDBclc9O1fWL7zcyxSAFGXB96+W/inZG08VeZOpMTMVGf4aAOSKzWV55ijLzPwPQVRnimg8b2d7qUbfY4CHKgdQa6Zx52leYiZkiYhWI6isW5upTdJJIfOZ1CbD7UAfbnhU2w0mxNj/x7zwCZR6cD/GtdFWGIjOFGTXi3wk8eabJZNbXdx5EkaiK3Vz0FeuS3Blt0eB1ngfqwNAHK/E29s734e6+HUSReQwXI/i9a+GbQbbZFGAOc19afG7xHaaJ4YnsIWjN7cnAiB7d6+UmTZI0q7fmPKDtQBXkVluI5CCBjbk1lpGlvPc7pQQfmwD0rXmDSNGN25GPQdRVKcQDUZFdPm24NAH0T+zZeJHd6YyEyPITET7HNe9/ESJX8PtIwB2OOvoeK8B/Zqsi+tWjgbFiDNt/Ovd/inceT4QuVQbpXZdoHsQSaAPBb9h50giA4cgKKrS2cihXmj8p25Ga09IiW816wLYWIMXlz3xUHjK8a91aeWLHlRyGKNV9B3oAp+cYrCWJ2DNIe3pUBlfyQJuWK8AdaaI4pEZo1YsPl5Nb/gbTYr23v9VvQW2SCGFO3TrQBJ8NdCl8Sa9JYyb4re3Te8hHUen61g/Fjw7F4U8X2thAWltJh5q5Hfqc16v4cvl0Se7uI1RHWIlgB2q+3hMeNrq313U1UDy8QrjqMYzQB4LuXBdjtUnIFPyXRY4x05r0Txt8OJNMh+2W6MyqOVHIrP8ADfgqXW7Ca80+UGaPIaP+7xQBwNtK8+pSrC52RjDir6N5haIcMCMVn6bA9nPdwXHy3KyEP+dPN9FbypIDzuw2fSgC9MwnQxD92qK2CfXFdH8PPiLJpEMOk3NwXBYjLE+mK4m7vBJk2qs6bvzrj0s9WudfFyLfyraNz84FAHovxr8Ytq9munxzEwB/mXPevEEKsCoI4HOan8QahNPrdynJO7IBrPIzNsVSEyGY/wBKALe9WDMiMVVcnHrUbXCXVsJozslzh19B2qSMTCYRMoVWIfP+yKbdJHPc+chxEfl46HFAHoem3enXXwY8fR2Gmm1uIU0sXVwbt5vtB+0MAQhACd+ATXjoYjgHj6V614Ztli+FPxGVVwjjST9f9KevK5p4fNbEIHNAFReCK+qv2L9ZHn6xpB6mNZh9Qcf1r5UB5r3L9krWVsPiWlq45vImjBzQB9pa+qtoeoK/3TA4P/fJr5yVgEGANvQV9K30YlsbiNujRsDn6V80TKqFlTkKSv60AVpmKlQehqpdj5c+lT34EaRnJI3D8Kil+bcD0xQBCpDJ17c15r4qi8u7fA43Zr0ZciMr6VwHimIrfKW5DGgDmmyuMcHrW3byByhyRVBokMgXBOe/pV+zVBFt/I0Aa/g8CLWpwP4+a6y/0uxvZUe7tbeV1IKu6AsCPQ9a47Q3EWuJt7rXeOAU5HPUUATR9aQ4LEnpUcbEj5uDT9wPB6UANBwc9qvmbNkqHsc5qhn0qRCSpyce1AHaeGLwyeF9WtnPylRgVxLjCgdwK1tFu2t4bxAcLIorIkOXNAHoPwPg3+Jryb/nnBj86d+1oyH4f20TH5nuVx+Yq/8AAWItNqs5H91c1yH7YF6IbPQ7dnwskoZh7A0Ae2fDqzFh4I0eBf4bdT+YrwT4rtnx9qfPcda+gvA12l94Q0m4ixte3Tp9K+ffiuuPHepn/boA5BFMlxGhPBPJrV8b3Cy31vDG3yRRAVlI3lkuOx61BdSNPKzuck+tAFSfhBg5JqhIGC9eM1cmOBn0qnK7EHjg0AQEVG69QKeaibnAFAGJ4rITR5OcZIFX/g9p+q+IdTmtLSS6nWGPJTziFjXpwM4rJ8ZkDTEHOS4rsPgNo51C31BorU3MxGQoTdgDvQB7x4QtfI+MMQJIZJWUr7i0xXffFqZIdCsPMIG+9VBnufLkP9K4Dws3kfGO2tyu0+e6lcYxizPFbf7SVy1p4b8NTA4C65ED7gwTj+tAHFnyhHOGbft5X2pbWIPFBI/JDEkVBExICCIFn9a1NOiMuiTORsljl24oAxrsmO5KqAfMOc+lYPiGB7u50yAIWVZPMYj0BrcliWJ7osxaRWAx65FVTL9mjuLtzgpGUUH1NACSybWjYdIzwPapVx52WXBb5x6VmTXKw2m2ZJHYosh8pC7HPYAc1H52sX0CNZ2MdtAp4lvZRux/1zTP6sKAO00+4DMC4xsIIHqK7Dx18Q7PwT4PuNS32l5ehEkh05rtYZZVJCkqMEnAy3ToDXlMWiz3kJn1XV7qfjaIbc/Zo8f8AO8/ixr034eeH9CuPCtzYf2baCGdGtbwRxhWlRhg72HzHIPUnNAHCeFPjR4l8e6oq+GfAwVI2AmuZtQJgjH+0wiHPsMn2rS+PPheS90221YOqBR+8CZ278c49sivYrHSLLRLCKx0q1htbRF2xQwoFVR7AfnWNeQRSWUulasqyxy5Iz0B7fzoA+W/CHiGIeZZaxCFEeVQgferWn0/T4LkapEQ0NumQmPvMaxviV4O1Lw5rgmKs8JcmFkGRt7UzRPEUAFpZPEGBfMpPbigB0tmmnXovSzENH5yoOMHPStLQ/H/AIk0iKWxguGNtJ8x3HJQVt3CRXtvJI0IFrt2iUetclcWqxxQsxJDsQXHTANAHOeKNbnvbtp7uZ7iRvuuT0rBie1vOXkeO4X7q84Y1a1KYR3jWqQtKyksAo7ZqgbqGWZSiZCn05BoA0tMXzbhFVdrINzD0qg8Mdxf8jln3M3oK2RGLbTjMjYlmPOPSuv+FPwx1HxdrUckitDpyuGZmBGQO1AHuf7NekmLRpdRli2l/ljJHRelb/xK1dZrqa2iwy2yYY9txroNcu4PC3hsWGmIPtAj2Iq/w+5rx7XhPp1mEuZPMe4PmSEc/hQBjwFrK4nmlB2lcrj1rMWcNM8pU4bkD39aW4uJriVYg37nrVeQbM+ZIEVSMe4oAWQ/YbaS4eTvkLWp8OfEHlaXOl0u223naMcsx6VgX+NRvTKzAWqDao9a6P4fRQDxNby3cYNpB8yx9iRQB65pHhWfUbBRPGY4rohpHbqE9B9a9Jt4Ut4I4YVCxxqEVR2AGBVK21i0lt1kD7MjhT1qwl9bMAfNUZ9TQAalAlzYTxSgbWQ9e3FfOPhDx1b+DLjWkmBeW5mJjHYDNel/FvxtDpuiXFhpku+9mG1mQ8IvevnJ9E/tO4mvpJv3UYyB3NAHSatq+g6ldPdo2yaVtzketZt3/Y8dwHadWXbnbWYdLhEm2FcR7cjPUmsXU9MOQQpyuSfpQBs6lrOm2ttvt5FCN/CKzNP8UXInAit2ktFbcRt6mud0jSG1HVcSKVgXnnpXolvZwWtusK7dq88CgCDxZo+leIbO21PToltbyNf3ydM151eWltat5bklmOOlemPCesfDjn6j0rNu7CNwwmgQt2b0oA4JjA3m7M5ICKD2HeqV/GsuY7dgAqgLj171sahEIriX91s2cD3rIaNYmTAxHuLfiaAPSbHS7yw+D/jKa8a18u7g0ow+VdxSvxdEncisWThh94D0614+YsHDRgnua9P0GQSfDr4jDI4h0rkD/p8/+vXAPGm48k+9AHNV3PwTvxp3xN0C4LbQtwoJJxwTXDGrulXTWOo2t1ESHikV8/Q0AfqFOnm28iA/fUjI9xXzLLEYGeJjyruD/wB9GvpDQboXuiafdDpNbxv+ag184+KbuKz1bVXdZmRLpkxDC8rcn+6oJ/SgCjcp5gCHoDmon6n6Vn3GvWZKlYtSznn/AIltx/8AEVz/AIs8bxaPHbSQWVzMJHKus0EtvgY7F0AP0oA6TBJYjgVxPi4ZmUbcnkir2geM7LWm8uK2vY5CcH9yXUH/AHlz+ZxTPFMYE8TkcHIoA5W037hu5UdzV1vkUkcD2qjJL5UzKfuk9fSrMsytGuD1HFAFiwnCa3anOMjFekD54gVOD2ry+MBNR09ic8816baHcvPHAoAekm9PUjg1J7EEU2BAbhyo4A5p6sG6jpzQAfSlQY5FNyOSBT4+RQBKjdQvemSrjPFSRgFc4xzUcpzuUZz0oA9k+BVsY/D11MR/rZePwzXkn7aCZn8P4bkkjH41778NLI2Pg+xQjDOu8/jXzx+2ROsmt6FCp5QgMPqaAPon4ZxCDwJosQPItlz9a8P+MFs0Hjm8Y52yAMM17x4BiWHwZo6ryPsyHP4V5V8fbLZqtpdrk71weOlAHkrjMZCnHPSqzdOatAE4HqarSgKzA8YNAFG4XPc1UmBAGR1q7LzwaqSYUkc0AVyOPeoGB6461NIeDz1qJuFxn6UAcp43cmO2QepNek/BXR573SJDDbvMuM7FUsfrXl3jWYPdQp0KrmvcfhvpT3Pguzhtrd5pGTzNsec/XigDuNBkW3+PGk22NjtcSqVxjGLFj/Stb9riRo/h9ojIcN/bkGD/ANspq4/RH8r9pvQbXG3bLNle4xYNXWftgKD8NdLYsF2axC+T7RTUAcrbzAxwSs5B8kMcdjW5p9yBpk4MgLZycmuT8Mzm48PWtzjeWQIxrVj2/vBL8rMOMdKAIbxvMmaQHDEhj71Q1iKSexKKQTIwYn0xV5wfs4BUiVm+X3FZXiHzBp0QR/LZJV3e4oAC/lQwHbuKDBb2xU2nXQhkMMynypOhNPADpGVUjA5B71XWNZLhJGwQmCF96ANMzLGpCnLDjHpXWeCtYXSb+JpCRbz/ALuT0JPeum0HwvpfijT7TUokMCsmyVMclqwvF/hT/hHikjSb7CR8Ie6N2BoA9VtQZrdv42XlGHcGsrVbNXgKTj55BgSf3awfA+vtPGLV3PmJwpPceldtgX8LKV2upzg0AcNd6chspLLWYUubPG1J2GSteF+OPhJeWd1Jc+HJRJbMDIo7nnt+de9/EnXdI8K+GbjU9akK2sQ2hFI3yueiIO7H/E9Aa8k+A1/qvi6PxL4ovHwjTx2VvBklIY0Bcov/AH8Uk9zzQB57o3iOfR7YafrVvKtqMqxI6mjT5JNRuk0rTWjlimkBG4/dBr6C17QtJ1eA2mp6YogUbhKq8k15+fhlolpHdXVnfzQv95dp5AFAHkHiOdNB8RMllGLrUEHllVGVParWh+H7DSYZtS8QSR+ZO29bVOoNdBfQWJ1VNL8OWbzXBXdNezDkH61veAvB2n3gvZsvqurwnJRjlVoAd8LPD/hzxXqEovj9nljOYoH4yK96N/YeEdGZbGGIbVwqL6+teX/EX4ePpvhS28U6ZKbTVIArSRJwME9veuMa91O7mRptQIDKMhietAHZeIPGd1eysscZSST70jn+VcreXsyyBbq4EvmcfN2+lc7qEWq3Vwyx3CkDgc0mn21zbTmbUx57Rg4ANAF24vzbl47dfNlY4yOwqgI5pJ912xbP3UpyXYWZnityrN1yOlbOg6Vq+uJNLpOmS3Kwj52C/wAqAKKRnd5KD7i5P1q7pl62n3SYbcRwayX1LEjZgdZFbbIp6giobm+dlL/ZyingNigD0iDxkwnUlj8nG3NU9X8c3I8xfM2jttNcHaPcSsgYYjf+LFWTbiKUBQZQx6nnFAFmK8vLq9knuD5iTfKQ3UVatYpLdpokwyt8oAppMSsPlOO+Kkhl8mSNuq7smgCPyy8hwhyg5qjqkDNCHjBCkEGtm7hmQeZEQYyckrVe5IkQszjZ0C0AYGhWgy5Y7YvX0rccRoEii+fIzuNVIxHFMMqfJPGPpV+6v4LkFY4BCEXG7pkUANhQMryu2NvQCq8mJUZcEK/f0pyHEbBFJQd6VEz5hY9sigDC1mxjaNN4yemcdRXD6tZrBcOVJK4+X2r1CXy7m2IVf3n3cGuM16z8tR5ZDMpwRQBY8JIqfDn4iBTuJg0wnP8A1+iuZWzR1DELz7V3Wjam938LvGmntY6XbrZ2+nYmtrNYp583qD97IOXP1rmbW3DW6MyHJ9qAPNKcpxTKWgD9Gfghqg1f4XaDcAkssAiYn1XivNPGkK2/jHXFAAD3AfH1UVa/Y+1c3vgK8sWcsbOcBVPYEf8A1qn+KkHkeM7hlH+uiWQ+/GKAOKvBtAIOBnNZ+pWFne+W15aw3PlnKCVAwB9QD3q/dgvEwzz1FQKSY1PcigCgU8sLsQRjoFxjFY3iWMfZw5zxW/cjDdyB61i+JRnTHI5IoA4i/jDru6EdPeqsm9bcu3y7elaUB82zUsnIHNZ2qSFbd+eG/SgBumytLeWpYkgNgV6xZjCg4J4ryDQzie3IPVuK9gsQwijOcjHWgCxCwSVjnG4YNIuAT6CmyYSZTjIzUqxiabap470ANVgSQOlSKMADNOniSNQRgKOtWEtJJ1jjgUtNMdqge9ADxE32GKX+F2OD9Kk0WxfUNWt7ZATvcZx6V1nxB0UaLZ6NZQjJjh+cgdWrW+EmiH7eb6ZeVHAIoA9XsbdLSzhgjGEjQKK+O/2vb7zfH1pAMbYI0P48V9l18G/tM3Rvvivqao3yxYTn16UAfZvw1m+0eAtCl67rVP5VznxwsftHhyKZUJeJ+vtV74ISSSfC3w/5oIZbcJz7V0viewTUtFubeQZBXNAHyXFlriMd9wpmr2ktvqUsEq7XzuGe4rpT4bmGpKUB8tZf5Gup+LfhuOPTrPVYIyJQgSTHegDx2dSrFT1HFUJc98lqvy53sCaozZLDg88CgCB8ADPU1CcMPapZlKsQ3bioDyfSgDhfFZEmsbF9AK+k/Dvh29bwppsa6ZPNH5CkHyiQeOor5uvY/tPihUHeVR+tfSMeltLYxxWtnJPMIskRKWPTrxQBR8Pkx/teaTb7dvliUbMY2/6A1d9+2Gu74Y6dxnGrRHHr+5mrzbwshj/bG05CpUqjAqeMH+z24r1D9rcBvhxpoIznVo//AETNQB5V8OLtrjw1boRtAGCK6eaArGEDbg4yCe1ee/Cm+aSynt5CB5RIA9+K9Hjge6jQO+1lGDigBl4jQ+S28GMr8p9/SsTxDCJrFEYHLyA1sKFDiKQF/K5VT61R1KWUCSWKPzGDAbMdKAEKny1hWUZ2KC3pio54VUiQcgcAinqixnzdvLAb19DSs4MfBwuelAHofwb12e11WbSbqRTazDfGTwVavQPiKLaXw7Lb3JG5yGQe47187iWSzdbiNmVlPDKa6f8Ate91WwWB5HaRRnLHtQBd0tJLPMgY7Wwdw/hIrudD8QNcSJDfkpJ0jlHQ/WvOtGvFUSQXLGPJ+UOMA1fW4eCR1DDjnnoB9aAOu+KSW+vWOn+FDFDcPrEmJmZA/k20eDNKM9GwVRW6hpFParvhrwhpHhLSX03QYfI055nm8veWwzYzyeccAc+leYeCPFF1Fqd54imhM0F6Bb2ob+C1QkqR/vsWf3BX0r0NfiDo8wAaB42P3ge1AHReWvlbGAZDwFNY+qNZaVC7mCLBUu27sBWTqnjOJY2+xgB2+5k/rXkXi3xTdarK+m2sxdpPlmmB+VR3FAE3hLT7/XtS1fVoFVYbqRoY1UdApPNZn2q78G+MIP7KuP3gGbhF53cdK9P0zU7TwN8MisCpJdTAhDnue9eNWSPcXT3TfNMSTI5PPNAG7r/i7V/FF3HJdzyRadEMJbZ4J9cVmh1dcSREkng00puAaFxknGDTgp3CBTlR940ARXNtGZFkBbggfLUkzFZWSNiCgB2t3rf8KaBNrF95VrGfJjPz98V3WpfCy51GGCZP3c69GHce9AHlKu2z95gyODx6V6V8NfiTB4b8PS6bqdoTJEzPG0fG/PrXn+uabPoeqz2V0paYNgH1GaqS7oJWJADYGM0AEl42pa3qV9Kqo9zMZCgHTNQTvL9oKnBiCkAEVIDy7KoEx4PvTiUkVkkBDAcj1oAz4S0rqsYJ2npWuQPJeSdhHtwMDvTLa0ihVCr7WPUYrZ06G2khurC5Tzbm5AMD9gc5oAyXkTLHYREOD70vyyeaEjLKBge1WbuCSyb7NMuHj+99ar+dtjcLwzHnFAE1h5kW63DZVlPB7VFMGjhUGPLBsZp0ZKSnaMkjGT2qQs0QUKCyrktmgDOkVVLBiSPvcdqa0STxq0hZY1HHvVm6lCoJSgGeSBVjw+9vLdfa9QP+iRYPlf3jmgCaPSbmHTPtlxmK1P3Vbq1Z3m7iHGNh4xXZ+INabxUznyBBp9uNkKL/ADrk9VRIblvJjzFgLu+ooAqM4MkighQBwaxtato3QsMtkfMR2NbKAFTH5Zxxg+tNv0jjtGjwFBHOfWgDE0SDyfAHxB7s1vp2P/A5Kbo8kZ0y3Mgy23n862YoLKH4deMprbUXub+S307zrT7HJGIMX0f/AC0Y7XyTj5f6Vi6bDILCH5cfL0oA8XpaSloA+mf2KNU8vX9d0xm4lgWZR6kHB/SvVfjVCYvEmm3Cj/W27J9SGr5s/Zf1U6Z8W9MQthLoNA34ivqn452//Ev0m8UcxXGw/Qj/AOtQB5PNzu7ZFVRFJBEqty3UGrs64w45B5NVpg6Nk5wRxmgClOM8nrVHVYg1jIGHatCdcoWBqteoXsnz1K0Aec2M+8yRnggkYrL1wskQGOucgVbsgEurgN98OcVU1cGQEOAGzwaAKuhEedbMvQPXtVgM2yYPavE9JJSeNFAALjPtXtmn4FnF7rQBMw+6D/FxmtW5gW1aKMjllz9ay50/dAng5qTXr1k1W1gY8rCuKANTTLaK6v4oZgXic8gV6L4F0OKTXXupHWOO2PyIR1rzjRJjb6xBIflCfNk11t14i/s+9Bt2+98zEUAei+LvDw1WUXAJJVePatXwzpaaZpsaqS8jDLMaz/BfiBNYidNwMiAHiunAAGBwKAAnAyelfnR8WdRbUPiTrcxIP+lMvH1r9CtbuVs9HvrhjgRQu+foDX5na3dG71q9ugcmSdnz+NAH6IfCSJYfhvoCrjH2VTW34luzY6Fe3AGSkZIFc18FLgXPww0Bwc4gCn8K6vWrQX+mT2pGRKu00AcJ4a02G78NQ6lKArtmTBrI+IGsveeGrizW2RuBtINaHxR1JPCvheysbL5WY7QBXiV1r944O5sg9RQBj6mmNiiIIwHJ9a5p7rbq1vC543V0N/cmV2J6AVxd1FK/iGKQKdg70Abd6VM7445qoSM8Dp3qaYbnPHNVnbCsT0ANAHLeGbcXvjeFeoExNfQ+pWV1f2j29lBNPOqZCxEhv0NeEfDFA/jMzNyFJP617br1hcarYSw2NrJdzhSwjjXc1AGZ4SjMX7Yemo6lXWMhgeoP9ntnNen/ALXJYfDjTCpAP9rxcn/rjNXmPguFo/2vNPSRSjRwYZSMFT/Z5BBr0j9sNGf4aaWqqTnWYc49PJmoA+d/h7N5OurFv2mY5avbNDfNwnnkbC27PtXz9p8/2XUopUG0ggA17Zplx9p0+B93ykYGPWgDV1VY21C5Mfy7WXb7jFZM+9JyqnOOc+taupSF4oZwBuPyECq8duhmw5A3qcE0AZaxt57vkvuxuWnSkJKtyYmSFSVZT39xVx7WWzlUso3P0A7iorh2dk8xCIh1BHWgCOVVwqpkr1XNaXh+R5b8KcCUjCqO9MS1+3o8mnNukt0+eKtbw9Yx2/l3swKXH8IPagB95KiXQtNXtl2dVkXqKxfFypNDa6NptwXOpko7A/NFbrjzWz9CEHu4rc1hBNJ9ohJkzkEHsao2elW8d5/aDfLdGMRlh/dBzj8zQBWu7YW0CxW77Y0AVE6BQOgqkyu4LPtUKMnNbmozW8Ns094VAHIHc1w2s6hJqCgIDBbk9uCRQBFqutC4iFrp5Yno8v8AdFU4LdYIWt7cHD8vIerGnRoLQ+XFFui6txVhFKMrMQUPKgUAOv74XVpDazTOUg7ZqlaQhLiSSJmMLDrUepRGEOCvzS96vxObW0SNCDGQNxxQBEkaTShYySw5wKekbPIxQkFTUoeOC6EkQwVH50ttCZN+1tu7LGgD1b9nsiZtXLgBwQvP0r2qLAQKOwxXzX4B1g6LK2JNiOeWHevVH8aW0Phq4uZpNrMpVT79BQB558bHhPjNGgVWCRDdt9ea4H/WhpSpY5yc9qu6vevdXzXZlMjserc8VRhXG9jJuV/4R2oARxEAzHiQngU7BV1Z1HnYpoQhY9w3SbsiluJvNxEi4mJ6+lAArLNcESMFfjPtVq1uhb3MLK2RG2V9TTBYyJlpUG11wWp91aTW6Qo8HlyABkb+8KANO81BLu9uJDEJEk+96rWf9kto5S9vLvU/NtPaq8iyR7nJKTOeMdCKdFEQAw+WU849qAF8tTHIWfA6g+/pSgy3MTbVwUA/GpYwt7aspXY4PBprCaPaquvHB96AKpZQ/wAwBATGD61RgZdxMj7Ru6dq2biJZnZQAHVc56A1mXMaRMqOA+V3fL2NAFgzTRwMqy7IiecVHI7mEIp3KpzzUtqgNqvnISueTToI/Nuo0xjc2D6YoAQTExrlBhOc4qvexJdweaTuyeFFalxYsl2Y0IP8qqsRHAwSFi+Svyrk/gKAMu3G7wl47CAKTBpwz6f6dHWFbXtwkCKillAwD611NtamLwl413JII3TThlkK/wDL6nGSK55bfCgRfc7UAeKDrSUveigDoPAGotpfjLR7uN9hjuUO70GRmvvz4rQC/wDAVxcRfP5eydSPT1/WvzljcxyK69VIIr9EfA10vir4M6fIx3G507Y3+8Fx/QUAeO7gYiD0PSoLht6IvUjtT4H32ke7rjn696hmO2dMcBuKAI2XMDZGD2qnMA1k2OuK07po2UCMFcdc96z3wY3Gec0AeZXOy11IpJ1kY4rG1UsLh9x5zxXS+MbLyAJkGX3dT2rjryVi7b80ATaWc38YA4LV7bYLiwgz1rxHQMNf7Q2WDDj0r3HTRmzhHoOaAJb47Yq5fVr9r3xTbgZ+WMLXU3gJXb6jiuei04Prfm5CkdAaAOo1KZGaAIMNtwxFS3IzbJICSzdc0uq2X2a4gDBfmQHI6GiRsxeUeQDkUAdr8Hbh4/EkkYyUa3ZmA9q9X8M6xHrmmfaoxtIkeNh6FTivOfgzp+dRub3OQsWwfia9O0jTINKhlitRtjklaXHoScmgDjfjvrA0T4X6zcbtrugiX6k1+eZPzdxk19kfth6v5HhLT9MjPz3Eu9h7CvjVmO8j04oA+/v2b5jL8KtMDHOzK16hXh/7M93J/wAKgUxnMqTFfpkivcB05oA8N/aIlzeaZFnsTivHDxuBr1n9oJs69YqeyE15K3TnqaAK8UZnuAgFV9RtljdWUAYNbmkxKqS3En3R8oz3rD1OXzJm2/dzwKAM92wTVG/k8uzldscKeauSZOayNfkMekzn8KAJPhBai41y4kbpjj35r0rxZY3uoadNaaVZXN5chSwjgQuw9+K4n4J24Zbi4zznFdr438PeIb/Tt+i28zyPyrRTqhx/30DQBd8BwtF+1XZrIhSRYArKwwQRYHIPvXpP7W2f+Fa2JH3hqkePr5U1eeeBIHh/aitBKCJFjCvk5+YWBz+tej/tYJu+G9i39zVI2/8AIUo/rQB8iLId4SYZbsa9J8Aa2qhLa5bCxDdz3rzVm23SqejdR6VoBtpXyJNoTgtQB7xPtuWD2zfI/IWkkO1csMheDivNvDXiuS3lWG6JBHCe9eh2V9b3EbOj5lYAgetAD5Yi0MU6SOzKTtz29qcsrmIrOA7E9qfKjrbpiVVLHJUU4R/KqY+XG5jQBJpssttd5tQscznMv+7Ucd/dT3Jkm/1SthQO9LH8kDmIHzJTgsfSrFirGcR4H3cAe9AG1YW0k7bol2DqwPpUWralbaerqEV3Iwqj1q14mvrXStMtIdNuBLezg+aP7lcBNlZz5zlpZDwT2oArahLPeyeZfHbsPyx1VMLGfe3zKwyF7Crztm6cbd8qjpTTDcPJGchPbNAGfOdi4BC7uPrVG41RogsdhaPLJjBJHA963Y7ECYtL+8Vegq6ITGCAEQP6elAHluqtrqXcb3EZ+zfeOPSuj0bVodTZYYAGIAU+ma6qURTxvAQH428+9cKNF/4Ru+ntlDCC4xKso/hoA66eyeIZcL1AODwKets20op5B7dxWDpr30V8WYSXFi43HvzXUeDLO98XaiNP0YGOfO+eZxxCnTJoAroi28uyQEI33QfWl1lpZpEszIfIVd2AeD3rpvHPgvUPCFot9qN0l/peQjyBdrRsemRXmmq6zD9oxFdBRxjJ5NAGv5QMWCwGOg9ackMiLwnI5I9qZp7ebAhlDDIyD61eV5kkJSIsoHJ9aAKgYLIkhbaw6Cr2ixRPJPI43y4yKRjbpZRSNEJHZuvpVlLxIrgPDDtZhgjHQUAaM5hjtMXPyR7CVJ9awo9Sa9dUeZZfLTb7irGqzrfRxQufkzwRTPDOkWU+qmCMlJHyCx6GgCs5ZF3AeaP4Se1SSbhLFcBcpjJrrvEXgbVdDtkvrZBdWrD5lXtxXLWdys0TK8ZjX+6RyKACMgl5o+I2H3aftSVTFj5uu70p8S+WRtAMbcClZFhkWJW+Q8lv6UAVVtxIGhlLKy8hh3FV2t8gPBgxg7Wz1zWymLlt64GOM1C0Csz7AVROvuaAMzcbdDbkbgTn61YQpFETg4PT1zQsyNdoJ4ysynA9KtRoSpVgNwbcKAKwmYxBvuluOe1QzxywPHNbXtxbn+GS3maKRfXDqQRn2NW5kVyZpuERTkVTv5PNt4mhjKKM43d6AHQz3t94L8XLd6jqV+qS6YIlvL2WcKWuskgOxAOF61UgtLZYVEgO8DnitLRA0ng7xSxQqWu9KH1xPIalC/8ATLNAHyzRRRQAtfbX7H2rNqHw1uLCeQO1ncsqr3CEcfyNfElfSn7F2tiDxNq2ktx9pgEi891NAHRX1odN1zWNPb/l3u32j/ZPIqnccqmf4TXafFawWy8dNMgx9st1k+pBwa5GddquMe4oAquvBNVWT5iRjB7VcPzAVARhuaAOK8dxv9mBXgE55rzi6B355wehr1Lx6udMZgORXlch3IOehoAn8PL/AMTHKDksCa9z0zItYwOcivC/D+E1DKsR81e7aU26xiI645oAskZI3c0lvaRNdqZAAp4J9qk9RUuzEIf1PSgDb17S4rOytGtpGlhz95jk1jSj94VHTNakVwbnSjDI3zRnIBrKOQp5oA9e+Cse3Rr1yPvSgA/hXoCy5uHiIPADA+tcv8LrM2nhK2LDDTEyV05j/wBMWTPGwrj8RQB8eftgas1140t7JX+S2hx16HrXzwDlh616T+0Nqbah8VNbJJxHKUA+leaDryaAPtX9ju5+0/D28hcZ8u5PWvfa+cP2Lnz4W1ZM/wDLYHH519H0AfP/AMfznxNa+gh5rymYYHHGeleuftAQY1q0kH8SYry2CNJblFc/KvJoATUSbextoVOMjcRWBhXn2u20E9a1tWuPtF2zAYUfKv0rMYqqO5wSeFNAFS5AWRgDlRwCO9cx4wkKaVsH8TgV0UjEVynjOQGK3iA5LZxQB6L8IrNodDEuNrN196h8caLf67NJa6Lp7Xd598rGo3bR1JPFdF4IgFt4ftwT/AOK5HxzoureJL0Wfh+wub+7T94yW67mVemT7UAek+BIjB+0pYxSLskVNhU9iLDkV6J+1SW/4VxaKv8AHqMYP08qU/0rzjwPE0H7TenwyIY5I0Ksp4IIsCCDXov7Vkjx/D3TmjI3f2rHwRnP7magD5GXaQd2GkPU+lPiAkU4BBNJfwhLs+Sy84fip45EjeN+DkYx70AOluE8sAr+/BA3+lbfh3Xru2xiRWZcgAnk1zYXcr7wMg5xT2iDIJYw4C87h0oA9f07Xre6gRrhSsp+U+1dNHc2wiyHHKDB9a8i8E39y+oRxSxo9sDhpH6fnW1rmofZPFsdjpcouoSuWKnIQ4oA7u51INGhKgKOCBVWWa4kLNC+2HHyuDzVAWklqkbXkgLyHKqKcIJZtys5ig7JQA5p4lmVWkLyEYLdTTre0kmjlJLMqYIY1btLW1WNZDES68Zqxeu8yiOBfKi4z70AVYEjX5gBuYYzjmkkePfyjE4xxU48px91ht43etTBAWG0AAjOT3oAo5dF2KAR60wxsVyG+bPINTsQs+0ggdaaDJcu0MULBj1fHQUARmIpdqyjO1MgikECy25W6haUN0JGSKNQ8UWumiK1h06WadSAZAmQ1LHrWvXFxN5dlFFGw2xhhigDIuZr3wxGb+1QTQ7tqwuM5/CpvBPxPn8I6zNqL6Iz212AtzHEuGAz1HvVy4aa+urMaptBgT5gv3WbNEiRRR72iDHOOFzxQBv/ABA+NnhDxf4J1PSjHfW9xKgMaSoASwOR39a+ZmIstTsL68LzWhYF064Ar6h+HHhvw3q2rX9pqdhBJNLbsYnZQNnHJrzSy8O6fI99BLAJEiuHiBxwQKAN3RdS03V9PS40u6hbgKlux+YVeaG4QBZhsJHO3pXF3XgLS1lW50+eWwvF5UKflJqO1j8ZaBI0nnJqdrI2ShOSBQB1skqw5jCk56ADvVhMMV46ryfSufh8eWLyrb32my287nG4rxmtiNb66uRNHHsscZBHc0AAhVThRmIHP40Ij+eHhcpKvRhVyJDIjbeGXqpqWCFlidsDcRgfWgD1j4b6xcaroMul6qDHc7T5Lt0cexrzPxbbpFqTlYjFOjFHXGA3vXqPge6tZfBsVjJJH/alopIB+9u5wR/KuN8Qag2ph/7Rswk0bbSyjr70AcVasZtuwYU9j2p6BXIiYclutabQWZXA3IxHpUflLkDjC9DQBViiZGyeBG3ygd61Ynt5LsLOhSNhlscYqmImLOSeAPlHvUiXJldYbhQkg43Y60ALrnh5J5s2tyCDyDnkVz8LPZ3LJMWlKnH4V1cdsYwxibdJ0ps+jG8kVYGWFn/jbtQBgzX+n5KiUcfeWsKe7kvLshAfs68Litnxlpek2upR2+nZe4CAzOOhNQ6TaJbK08vCDhU9aAL1ldu2jSaXa6bIou5baSW6kvFcfuXLjZGIwRuyRyxwPXvaffGxQMvy8VZ0yKS5mjis18rzTjJ7A969X0zwb4cgsII7u4jluFX53MoGT1oA/OmilooASvSf2etX/sX4r6JOSQsknkMM8ENxXm9XNHvJNP1O1u4SRJBKsgwfQ5oA+8PjvZlI9F1SNeYZmgkP+y44/WuAVfNhKbAxYYHt716v4pJ8U/CQXkAzJJaR3a5H8QAY/wBa8n0p/ORCgy08YK49cc0AZwUAYHaoWHBzVuOMruSUYZSQRUciYUdMmgDkfHSxtocwzg4rzLS7H7RZu393ue9epeMogdFuGwOFNcT4b06V9NSTB+ckg0Ac1p4KaiqYx81e7aMP+JfCcdVrxC8Uw6z6HdXuHhxi2mQEnIAoA0oYTKfkUlx2qa6VYkWLgv1YjsavaTGzx3D5IKcjFZ4zJI3cseSaACyyJgp4LcVI9sxu/JIIYtgfjSW5+zzJJt3Mhziu+0HTbfxFrFld2sWyKHBlU9c0Aeo6NbraaVaQJ91IlH6VakIRWc9FBNOAwABwBWX4quvsXhvU7nOPLt3b9DQB+cvxGuje+N9buS24vdP/ADrmh1q3qUrTX1xK5yZJWYn8arKPmAoA+wP2LP8AkWNX+Xnzhz+dfSNfPv7G8ITwLfS8ZafH86+gqAPEP2g4i1zZOMnjGBXk08TWqRBxhm5NfRfxQ0lb+K1kZchWxXgvi0iDWWQKP3YwBQBy9ycFiemazpiD0z+NaFwC0jMTgVUKbisanIJyTQBRlX5BiuN1pGu/EttbjsR0rtbgrlsdB0rmNCtzd+Ns5JCHNAHtemxiDR4VxyVFeceJ9I1bXNbS10BHkuUBkfbMIsJnB5JHrXpcn7u3jjzwFry/xN4e1LxD4gt7bSbN7uVAZXRCMhc4ycmgD1TwRG0P7TtlE4AKAqcHPIsCDzXcftfTGH4b6WVIBOsRLz3/AHM9cX4JhMP7TVrG67SgK7fQixIIrqv2z22fC/Sm9NZi/wDRE9AHy8+Gjyi4yB9KCUSJY+rH9KraaztbKVyS/PsKvLEhyy48w4AHrQBGcE7hkHGCPWtHTYTL1bbZqCXz3NRfZXUqrECRyAPxq3qIaKKO1Qj5eZCO9AEOp3ouI1jsy0NpjaMcHIqHw3qn9i3kd0wMrKSrg8kmmuqlijEADpj1qhNGY7iaNSSshBUjsaAPYfDSXF9p0mp6nuzId0Uf90V0strJFGjOA5kAZf8AZqnYM8VtakAbPKHXvxW3DPHfLGl4phI53DpgUAVNpCKHwCeQR3q9pFhLq90llYQvLO3LN2UetSQXkLy+Vb2263Q43HvXqPgG900xzCNYbeY4UAnBYCgDg/FHhx9BS3N1GzRMNoMYyM++K5yVFaAxEMCjZK45Ar6Ek1DTbgzwST28pi/1iEg4rzDWrSWK8YrbIJipIYDgjNAHK2ulXM0TSLBt9C/pU8cEdurLvBdhh6nlvL+8MbyTbDHlWjHYVU8lW8xQSdx5oAgiVPPQqkTRp0BAzmq08c0s4QZ3ZJJHatQ2zADMQDDgMO9NcMoEfO5u47UAc1qkDRWw2qQUbOT3qzbbvKUYVg/OT2q5exSygwlCYR8u73qvpq7Q9s6nemdpPcUARfvIHZrWQpMUZNw7ZqppegnTbNoNRuCkjlp045Ynmt3TEh+2rNd4EMB3svrjtXW/EyGx1TQdJ8R6bEPKjby2wMYHQA0AedadOghcXEBZzwCew9abLmGdDHkq/QjpV0FvthZVBjI5X1FJLCvlloP9WTgKf4TQBmXel2V/bMtwiFs8EAAg1kQRat4ecLazfaLLdyhHSukMSp8xySPT1qJ4nnjxtOOrHFAE0MzSFXKAM4y3tUk0oYholIXgfjVOwVzdeXCxI7lvT0rRCkSuso2jOABQBe8O3wsNSUy580nJat7xgixXMN7F88VyPmx2NcyYGb92ibtp27x1JrsGsIn0pNPuLj/SSu5QexoA42THmBoxuPQg0lujC447/eB7VotZTB0hlwkkWen8VKApkUHt1OOtAEMVs0sm5jgZwPpUrWRG4OA/O7dU6xMQdjYXuKmt42k3R7sAHrnrQBzviC0vdMjF/pzGVFPzJ7VgtrtxdQsysViPvzmvSTbgwGFlwmMHPevPp9Oil1aeGJCkFr85I6E0AU4oZJYVlKkM7YBPWuj1K2aAWEQA8xU3t+NJZQJeyoXbYE+ZR61tSWrXl9DcTDairtA9RQBDoULwkTvksRhSOgrWW0crli7E96mtowI8oR5Q7VcXagCrKcCgD4KpKKKAClFJRQB9+fs46r/wkHwesIrg7pIVe1cH07foa4q/0u40DUzbnhI3Lwn2z0rL/Yp1l2s9c0eUjClZ4x3x0P8AOvTPivNbre2saxj7RG24n1BoA82lczTyOfvFsmoXV3J2Lux2qxcoF1KcKPlkAcD0qSC1OyaXBIUdM0Acj4xi3aBdnoQppnw90zz/AAnBOI97L1I7Crni0hfD97kc7DXZ/AvRnl8HwTkAxvwy9aAPnPxhB9m8TvtzsD5U17D4WYNo8JHHFc58d/Db6Z4iWWCPakhyABW38PWM+jBjzsHINAHXWMnk2FwVPzMefpVQR/vFCnGauQoWtJfLGGBqaziCBZXT5wcLnpn3oAg1Ixu0RjQIVXDY/i969V+G9pGtnBfRDaZlMbgdMjvXmeqI4vW88KZSvRemK9I+El0W024tWOTG+4ewoA76uF+OGonS/hbr9wvXyNg/E13VeO/tV3v2T4T3Ue7BnmSPHr1oA+EZHL8n60i8NTpMcYxmmjlvagD7U/Y3BPw8vHPQ3RA/DNe+14j+yPAsPwwDKMGScsa9uoA5Xx7Fe/2OzWkqjadxLjpXzDrVy93qM8szBpNxBI6GvqX4hy+T4Rv3BwQlfJ07EliB1P50AVpSHXHFQyEQxlhjJ4FWpFURjaPnA5NZUrOchugoAoX0nlRPL6DOKqfDa3e51Ga9cfM7kj86h8TXDQ6e6qCXfgY7V1Pw1sWt9OhDg7iM5oA7HUCREXyc4xiuA8U+DvEeqaxZXVlomo3FqVz5scDFSPXNd1q5IUBRx3rgb3S9S1fxXHbaUszlIjK6LPsXHTJyQKAPUPA8bw/tN20boU2AqVIxtIsSCMV1X7aX/JLtK/7DMX/oieuW8CFT+0rbhGVgpZSUYMMiyIIyOOua6n9tLP8Awq7Ssdf7Zi/9ET0AfKXhp1eF4y4DoSQD6YraWH97GygADqQehrh7aeS3uElQ/Mpzj1HpXoEDrd2Ed3bqGjkABHoR2PvQBf0lJJJ5FdFdYlLE1WXyry4kVz5asTgn1FaVvALa0WJNwlblz/ICqN1D821lKscAdBz60AULmB4WDTrtI4HPBqC9gZwskXyMvzKPUVsMsgliFwRIqjocUPD5TALho3HDcce3SgD0Tw3fx65oNlLFIC0KhZVB5BrpBIxR04YAYUmvFNHv5vDGoJfWYZreQ4liPcV7NoV7pniC2F3pk4JUZeAkZB+mKALlq03lxAoMDIOO9X0hWJl8wEqeeDyDRaJsY5BC4zzjj9KsFSJY3ifcQOQf/wBVAG7ptmg8OzzRwAyuxGf4sU7StaaErb6lGJoR91upX2qnpd9NaXHnN8yD70fb+VbV7pNtfIL7TGJkcbnhz0/SgChq1ro9y7XEDGKZxnA6Gsy3gjEbPCq8cHNXFtplOCmMZyD2/SlmG1kVkK5HIHf9KAMmSMlxiQ47CnrEpJVsBT94+lapsMsZkGSg+7n/AOtSLatuxIvLDJ5/+tQBizQbsKhwqHP1rI1OzljIuIG5zlvYV1wQpGXKjHTae/6VWa33xN5g+V/T/wDVQBzlu8d3YhFiw4bMh9RmtnTb6KLTr3SLsg2FyP3a/wBxv/11SlidG+T5Iuhx/wDqqubbzmJYvxx1/wDrUAVGsJoUUS5GOFdedwp0dvLKP3S4kHGD0Nblm80e2OR/MhUYKnJP8qouzxXDhpGUFtynngflQBUFvJEhi8tTJ1YnpVVf3YK7vkJ+ZR3rUBR2lzK5B/iyf8KpvCqeXIMlM4J5/wAKAM6VQCywxsuDnIHar1g6yguQWZemaluZ5dpCJtQ8bsHn9Kg0+d0u2iRC2B8w549+lAGrZPNBLE6qrFjux2U066dprxpZJP3jHJYdqijLqFLbsMeeT/hU0ULPIcghc9DnmgC1LuvbdWP+vj/i9RVix0qbUyBp5iGOWDnFQokpVsAp2A5pzK5EZtpJImQgllJGaAHNbMkkkM6bZ1JUrSw2zyThUXDJya1dTP2+WG6Q7W2AO2T1rOmuzGxud+2IcMeeaADV5/IgVpMKSCAK4/y1ZmgR8l8tI3r6Cr+o3j38Et05YZcJGmTkj1pNOsSu8nJJwADmgCXw/ZIZJHuBtULtQV0C2mDbRlS0ijkDsKjjshDbr5JLyDnHPWuh06CT7IpAJuZfvk54FAFERwQo0hQgKOnavMtT8dRW1/PCqDCNiuy+Keuw+H9DaOBwX2nk5r5K1PxJHc3883zne2c5NAHI0UtFACUUUUAe1fsn61JpfxSt7bdiG+iaFge57V9L/GiNYrjSZ8Y81miLe/UV8O+BNVbRfF2k6gjlGguUbP4197fFqBdS8A/bIV3tEY7lCPT/ACaAPKJYiJAxPzLwauRKUtQFIJbqKjUGSCOXgh1BzTYfmcAnC0Acr45UR+Gr9l7DGa9o+A9r9i8EW0DqNzqGDYryXxwsR8MXMWMB5VQZ+te8eF/LsvD2nQwRkMtuuSPpQB5v+0LpbTyW0iRZRQSWxXmvw6lME9zCy/u2H3TX0J8RrP8AtDT7USHIJwa8R17SJNA1pJbdT5MgxQB1FsOCqtgY61PGAiSKWLKRxVWzlWS3R0H3hzVnBKhR2oAW62yPFj5iBya7r4TYFxqKY6BTXFeXuRW6V2nwuQx6rqCk/wDLJT+tAHpFfO/7Zt0Y/Bul2+cb7guR64FfRFfLP7bF1+70G1B/vMRQB8qN1pBnJpDSqcUAfd/7KgI+FdscYBlbFex15Z+zTEIfhLpQHU7ia9ToA4b4zXRtvA90FBzIwWvmaY5Cr3UV9E/Hify/CMaDrJMBXzpM3zHJ4oAqyZy3NZ9y5bA4z6irdy/yEDrWRqc62lszsfnPAFAGHqzfa9Ritlb5QeTXq3ha1Edom3ooFcF4Z0wzSPc3Cku3TNeoaYvk2cSYA4oAq6uNo+teZ+JIDceL7VXQFBExCsM54r0vVGDzMOled+JTt8U2zKTkRsKAOs/Z5UJ8X9CVeBuueAOP+PeSvVP20Bn4XaWP+ozF/wCiJ68w+AJA+Mmgr0Obg/8AkvLXp/7aJx8LdL/7DMX/AKInoA+LiemOhroPCusyWFwtsf8Aj3kbd16GsDnbnjrjBoDYYFDyDQB7Q8iX9u11CANvUgDGKiCiRQGABPK+o965Dwf4iSwnQXjk2suQy5r1C20oX1uL6wcPaHnAblRQBzrQksEVCSq8tnrRFbhA6SRsUAzkHOK3YLeSORimGVjjaeDUsEQikmDE/McFW7UAc1AECOLlNwQ/KKpw28+n3DXWk3ElpOp3YDfK34V0s9id7IWBQ9GBqO6s1ZIljfEYBDk96ANTRfifKhhtvEkGFbrMnGa9a0V7DW7c3GjXkTxkDClua8FubOPBRQjoB0Y1lRW95p0u/SLyaBlbcFVzjNAH1C2ltAMzkgDhsHvW1YRQWFq4tJz9rl/iJ4xXzvpHxZ8SaUVivYkukH3yWya9D0b47aDdwhdVsTDgYbGaAPRUJ8w/bAGDKQWU9aZ/ZkLxmQyEsOgJ7VT0zx/4K1VI3W9EIOMB8iuii1Pw7ePiDVoGUgfKHoAwjp8u1nicqvfJ60whD94FWHGc12Sx2k0X7u6iaPoDvpG0yGT/AFTxspHIzQBxckDXGYZoD5K8+aDTV09iWjjb9wo7nk12zaZK0O3cgXptBNU59MMK/MAM9PmoA4HV7MMhdIyqfdNUYfLWMowPHT3rttZawsrWSa9uo44lX5ua8n0r4gaPf63PprTmKONv3cxBw1AHRoiiGQO2S/P0qvdhHSNSuWxj6itUfZp9jJfW7Kw/vGho4yBtu4BjgHJoAxAImijVSAoODUIQmYomGTOcdq1GhiSUn7bbhT15NK6QKnFzGWPdc80AYckc+7a2GRmHHoKdCsaatcbY8FoxjFa8Nqq7y8yiPGS5J4Fcu3irR28aCzjkLIY9glGcbqAOkWFtitIoAHIFWYoy3zEAL1OacIWcgRSq/fr2qfyYooo5r+5SOHpgGgCjdG6a3Z7THmMwAz6Z5qzavaCRfNmKkfe64z3rHvPGuk2VwYIyZfKPUA9K53WvFltqEBjsLdhGWznBoA7LWdSsoJlFrIJIT94A1zF/q/8AaSNHbxlLYHGPU1gaaklxKG+ZUzyCTXS6fEIQC8Y8pWydgJJoAs6ZalpYppRgIPlU10VlamSRmChR6kVr+HfDk2qb5GhaGB1ysjg9fYV1Gn+G7LTV36hcee47HgflQBj6PpH21diLt2fx460viLVLbQdKneYASKhIbFWfGXjjTPDOku8g2LghQP8ACvkb4p/FK71m6ltrJ/3LcZz0FAGP8UfHE2vX01uztsHAweBXm+7HBGaeWaR3d/mY9SfWmbc84NAEdFLSUAFFFFAD0ODkDkciv0R+G9wPEvwa0oud7T6f5ZJ9QCP8K/O1eDX3V+ydqx1L4XRwu4ZrSYxY9BigDl9Ec/Z/IlUh4XMbL9DViRN0+NpGGwBUl/pd1oniXVDLGz2Mt0dkg/hJOcVf8oCYNIVAb9KAOf8AFelfadHtpcEo92kZ+ua+gLWyW3063ijXIVFGfwrz2exmmsvDWlzWe1JrsT+fnrt9q9WAAUAdAMUAc74lsFuNDLoP3kZ3VzHiHwz/AGxocQVMyFfvAdOK9E8kNA8TDKtkfhVbRo2iszG4+6xA+lAHzZ4fnkttSu9HvQUnhb5d3GRXSwKScdxXR/GfwVJdRJ4j0OPGo2fzyog/1qd65bQ9Qi1OyiuYhhmHzKeoPegDQcfukcflXafDfD6jfvtxtjRc1zNlDC8Tox+c8rXWfDdSLrUweq7Af1oA7mvjX9s29MnjbTrQHIit8kfWvsqvhn9rW4874qzqP+WcKL+goA8SNKpxk0lOUA5oA/QL9m1WHwl0hn6sCa9PrzT9nWXzfhTpJAwoBC16XQB5X+0AXHh6zKnKebyK+fWXdxX0d8dYGm8JqU6rJmvm145pAdp2KP4jQBUu5UhLY5YfpWPpOmza9qm8q32OM9T/ABGtO1sjq9+NPtmJUHM8g/lXdvaQaZZJBbAKFAGB3oAoabpy26PlQQOFrUB2QAjqB0p6J+4BJxntUDlmQY4OaAMyfc8jsTyfWuJ8USpFr1rLOmV2lRt65rt7tcdTk9a5bxbbAmynYAhJl3fQ0Abn7PqKfjHoLgMDm44P/XvJXp/7aXPwt0of9RmL/wBET1558F4Et/jpoaxjCkTsOf8Ap3lr0T9tL/klulf9hmL/ANET0AfFxH4+lCgDHrinHj09fpTT0oAcrlQpznB6DtXV+FvFt7ot4r287G3I+aJjxXJhsdBgmjdx754PegD6V8MeLdC8TRhbjbbXijg5AGa6C48OPIkUgdJS4ySrcCvlGG5lilVopGQr1KcGuu0P4ia9pj7VvZHgI5RiTQB7e2i3UDO8sBxnAPUVkSwiJphIjYBxgjiuYs/jNqwhW3kWKWE9Cw5Fb1v8X0v4kjutItybbguBjfn1oAz5oIDKypITITzz0pohUJIsU0SspyctWz/wnfh67fN3ohgmI3DaeDUf/CR+FLhPNu9InikPGQTzQBkT6U8vh5tTfy8GXyshuvGelY0liNqgRJz1JPFdimp+EZIDbFL9IFfzTGGYru6U9pPBzeUrzXS+ecLy3y0AcW+lsSDEoBA+6GprRz2ZDRCdJMdmNdpNZ+EYbxreTUriJlwUkJODWgdO8N37RrJq5iYDCk5w1AHn8Wr62qhE1C6UryAGPNWrfxL4oEy7NQu17/eNdt/whekNJut/EEfmAZ2k9R+dbFp8PNJmeAyeLbZA33l3DI/WgDgofHvi0PvXUZwU4AYnmmS+O/F0wd5dSc5PTca7C88AR2121tFrVrcbuUcEc/rWNL4F1bLLE1vLtPZuooA5qbXdUu3Vr+6eaEHJjLHBrf0jxxb6Vpdxp8vhu2uUl5Wcg7l/SnT+C9VdowlsmV6gE81asfhz4ku5G+zWQc4/vHAoAyLbxjZxMW/s6ZMtkjLYFd74b+L/AIT06MRajoVxIT1YR78fga5++8A3mjzxx608I3rnarfdNZc/h2BpJGF9bxqPuqcUAeqn44/DwqFfQr7p/wBA9T/Ws3VPjT4MngZLDw7cgno724jx+VeaRaNEYm36nAv97gcVTnTS43EX2zzynJCqOaAL/iDxwmrFkhhkhgP8IyKwIZ4Y1eaIBT2znINXBcaSSpEbFQeBj/69Wpb7Q7QgpZNJK3QEcfzoAZZa3qMbfup52yMDGauONZ1CQRvFdSxj1BxmoYPGH2eQFdMhjUHaDtrUg8Z3loXmuZIxFtO1FA4PagB9l4O1S62MUWA5535rp9O8GwxxM15fRxL0OD3rgNR8RaiES6l1EskhztVvug1TPimNF3NcllzyGb/69AHuGleH/DNsCbq/Z19B3NdJFrPhXR0/4ldoZ2X7zOuQK+Zp/H8ETHMygJ93Hc/nWTefFC6WIwxfvA5y3HagD6w1DxrcfZ/tFxd29lbLztjPzEfjXnniz4x6TaRyR2IJl25Mrk5J/OvmnXPGN/qMhHmuI8Yxk1zUsks5zK7OR6mgDrvGHjvVPEd5KZpm8g8KCT0rjs85yT605h8qjvTQDg9sUAAJx1wO1SLwo5FR/LjmnqTtHAoAhopaSgAooooAWvrb9ie/Dab4gsAMFZEmyO/avkmvo39jC/WHxlqdmWYefa5A7HBoA+ivENidSuNf0xshzGl1Fgfn/KuL0qBNUmtIIiRLKwjbPbHWu98SXk+l+OdDkt4TLHfI9tKo9uQfwplh4SXTPF11q+9Y9PCmQR56P3PsKAGWtlcyfEaFJmkNnp9nmJSfl3Nxmu5rnfB0cs8V3qtznzL2QsgbtGOFFdFQAUUUUAIyhlKsAQRgg968R8V6EnhDXWkRSNLvpCYiOkTnqpr2+s3xDo9rrulTWF8m6KQcHup7Ee9AHllmqtMB0OK7T4dpj+039ZFGfwNcJp2k6nYak2jakMXUeTa3H8M6dvxr0vwRp1zp+ksL5dtxI5Zh/KgDoa+Cv2opC/xX1E9cYA/ACvvWvzx+P179u+J2rtg/JKV/WgDzqgelFFAH6Bfs3TRyfCrTEi+7Hla9RrxL9k6+juPhwtuhy0L8/jmvbaAOC+Ll3bw6Kq3TARbsnPevmfxDqn24NYaRHyx5YD7tev8Ax3lm1bVbLR7WTMrnJUHoK4ay0m30qFreSMJcA8yEdaAK/hvSrfR7BRGP37jLsepNTaiAZEDZyT1zUxBXG3kCs+5l3z8qcrQBprIjQ4GeKrO+48ZAFQWco8xlOdtWLh02kAjJoAy5wTKNx4PSqXiK1+06dLEgG4Jx9avyndMqjkL+lRu+Sd3QmgC/8D7Xd8TfCl3v8yQCdJD3H+jyda7r9tHn4XaV/wBhmL/0RPXG/AkJbfFe1t+7NM6g+8L19Qa1oula7apa65pljqVsjiRYryBJkDgEBgGBGcEjPuaAPzAxzxye9GOepNfpL/wrrwT/ANCd4b/8FcH/AMTR/wAK68E4/wCRO8N/+CuD/wCJoA/NzaSCD2600jB9q/SX/hXXgn/oTvDn/grg/wDiaP8AhXPgj/oTvDf/AIK4P/iaAPzaB+b5clf5U7gkgA49a/SL/hXPgj/oTvDf/grg/wDiaX/hXXgn/oTvDf8A4K4P/iaAPzdjO3Pr2PrQJHXO12XPXBr9If8AhXPgj/oTfDf/AIK4P/iaX/hXXgnH/IneHP8AwVwf/E0AfnQuqXiYJnLBeBu5q3H4i1HCo8odBzgiv0L/AOFc+CD/AMyd4b/8FcH/AMTR/wAK58Ef9Cd4b/8ABXB/8TQB8Ax+LtRifPlwFG6hlzkVYg8XTJMpktIyAc8gV97/APCuvBP/AEJ3hv8A8FcH/wATR/wrvwT/ANCf4c/8FkH/AMTQB8JP40glkxc2EU0fY7eRVi28ZWLSlbjTwYgMJ65r7l/4V14Jxj/hDvDf/grg/wDiaP8AhXfgn/oT/DnH/UMg/wDiaAPiKx8aaQizefYuZSNqNnpzSx+KPDqhpRbzmUnoWr7cPw78FHr4P8Of+CyD/wCJo/4V14J/6E7w3/4K4P8A4mgD4rTxdocd750TXCx44Xccg1LH48sbZfNtr26ExbBBJxivs/8A4V14Jz/yJ3hv/wAFcH/xNH/CuvBP/QneG/8AwVwf/E0AfGU3xC2SZh1Schhkk5qUfFK+jt5FttauoiwxkE819kH4deCSefB/hw/9wyD/AOJo/wCFdeCf+hO8N/8Agrg/+JoA+Hrzxmt6spvNQu7mU/xu54qh/wAJLahk3NLJt77iM193/wDCufBP/QneG/8AwVwf/E0f8K58Ef8AQm+G/wDwVwf/ABNAHwWvimBZJGMT7X7E1DD4lQS7oYAsh45A5Ffff/CufBH/AEJ3hv8A8FcH/wATQPh14JU5Xwd4cB9tLg/+JoA+BZPEU0YYhFErfw7RxWPLrl/IPmkGQfSv0TPw98Fsct4Q8Ok+p0yH/wCJpP8AhXXgjP8AyJ3hv/wVwf8AxNAH51Prd85w03fpiopNTu5Swe4fGOlfoz/wrnwR/wBCd4b/APBXB/8AE0f8K58Ef9Cb4b/8FcH/AMTQB+cJubgrtaeQg8Y3GozIzKCWJ2+pr9Iv+Fc+CP8AoTfDf/grg/8AiaP+Fc+CP+hN8N/+CuD/AOJoA/NtWCsT1GM/Smn5s84I/Wv0n/4V14JHTwd4b/8ABXB/8TSf8K48Ef8AQm+G/wDwVwf/ABNAH5sAdDkUvVgegr9Jv+Fc+CP+hN8N/wDgrg/+Jo/4Vz4I/wChN8N/+CuD/wCJoA/Nkn5uepoIwuRzX6Tf8K58Ef8AQm+G/wDwVwf/ABNH/CufBH/Qm+G//BXB/wDE0AfmxjJHIGf0pMkcA1+lH/CuPBH/AEJvhv8A8FcH/wATR/wrnwR/0Jvhv/wVwf8AxNAH5rUUUlAC0lFFABXq37OGuLonxMsJGB2S/umI9Ca8qrd8EXj2HirTbmM4Mc6t+tAH6H+Mf3N9oN2ACYrwJz6MCKm8YwS39taabBI0ZupgJCvXyxy1ZXxCuwfBVrqnaGSC5OPTj/Gt/RbldVEepoB5LxARd+vJoA1Yo1iiSOMYRAFA9AKdRRQAUUUUAFFFFAFHVtMg1KBVlG2SNt8ci/eRvUVl+G9dlvdRv9Lv4fJvrIjJHSVT0cV0Vc9cwCHxxZXKqAZ7V4mPrggigDoJGCIzHooya/NX4l3q6h441q5Q5D3L/oa/RjxPeLYeHdSunOFit3bP4V+ZWqy/aNTu5R/HKzfmaAKnagUUUAfW37GWphrHUdPH8I3/AI5r6amJETEHBAr4m/ZK1k2Pjh7Z2AilT8zX2Zqk22N1JwuwmgDwMX8Go/GS7iLF/KjwD71peJNNhnMgb72fvVx3gUCb4ta5M4O5eFrv9ZnILZA5PpQBwE2nzW5xBJx6HmqU9lNKSRIFeug1AruwOCaxdRu47WPaTyehoAprZNGn72Tn2qJoXPyo/TuarR6vG0uwuH9ieaum4DrnZtHqKAKmHSQmTpThJFuAPSllkww/jHpUaIrSBsAL0xQB0HwpeEfGjw+yAgyidRn2t5DX1XXyV8N5w3x58JQxgbV+1E+3+iy19a0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH5V0tJRQAUUtJQAVYsX8u9gf+64PXHeq9SQMVlQjrkc0Afom8Y1X4Nxq+T5mmqcn1Cj/CtD4WOjeCNORG3GNNp+tVPAUBuPhHpkJcyGTT8A49QaofCd7jTEm0a+iZHGZYmPcd6APR6KKKACio55oreMyTyLGg6sxwKWGVJo1kidXRuQVOQaAH0UUUAFY06mXxVakH5YYHJHua2a5nw3qf8AbGvavKsRSK0f7OpP8R7n9KAOc/aG1f8Asj4Waq6ttecCFfx//VX57OxZix719lftk6x9l8J6bp6n5ppt5HqBXxr1NACUUUlAHZ/CPUzpXjiwnDEfNivuzXtRkuNCgntjkvHkn8K/O/Q52ttWtZUOCrivt3QNWN54Ht2zkrGMUAeV+DL+5sviXqEnllopBycdDXoGr3IeR2J+UnIrxiPxXP4X8Z31zIkc1vKeUbqKvXvxWspHY/ZwEPYHpQB2GpSs7jYfpXK66JGRvNYJkdSaxLv4l2xBMEaA+5rhNW17UfEl+I4nZYyf4eKAOgupbe1ct9pBf/ZNbuj6ys9sEEoZx2J5rjrjw5dWtqJPM87jJB61R0dUeVxcl4CvrxQB6ilzn6+9WbeYbgGXvmuAF3qNou+3mS4gHQN1xUll4o1CeTyhYgE8b88CgD0f4Mqbv496PdY+SMXCqff7PJX2DXx78CFCfF3w+WY+Y/2jcOx/0eSvsKgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/Kuiprq2mtbmS3uYZIZ422vG6lWU+hB6GrVnpkr67babeJLbSyTpC6uuGTcQOh+tAGfRWt4o0oaP4o1TSYHeZbS7ktkYj5n2uVBx6nFZ9zbT2t1JbXMMkVxGxR4nUqyt6EHkGgCGp7XJmRQAdzAc/Wlms7mG9NnNbypdh/LMLIQ4b0x1z7Vc0iymbXYbR4ylwswRo5AQQwOCCPWgD9GPhwrJ8PdEVRlhaLgH1xVDxbqMejrb6jc3kFveIMBexHcVf8AD0NxH8P7CC2J+0C2WMEdQeh/LmrWiaXZ3GkRi8tYbhwzozSqHLbWK559cUAcEPjJp6rtZrZpB6MRUbfFl7w7LT7Fbk/xOxau5k8D+F7lvNOjWRJ53KnX8qqX3w68LagI2GnRIFPBhOM0AeSeJvGiT3kMFzJdanduw2xRg7AfoOK2Ljw78Q5rOLUNBvf7LKruFsTncPQg169pnh/R7BIzY2FsuzhXCAnj3rVVgyhlIKnoQaAPI/A3xX379N8ZBLXUoPleRVIViPavQYfFugTLlNWtPxkA/nWF4h8C6P4wto7y4tkt7t8kyIOTz3rmbf4J6U7BnvpHi/2O9AHo7+J9EWF5f7UtGVRk7ZAx/IVU8FyxXcF9fW8eyG5uC6cYyPWuLuvg/oFnp08+mSzxzldyuX3BjXe+DrE6d4cs7d5BIwXJYdKAPlD9snVftfiuwsg3yWyEY9+K+da9j+KrJ4z+OC6XLK8UM9+tsZFGSoZsEjPcV5VqFg0GuXOnWweZ47hreMAZZyGKjgdzQBQpala2mW6Ns0UguQ/lmLad27ONuPXPGKeLG7OofYBbTG98zyvICHfvzjbt65zxigCO2bZOjhc7TnmvrH4aag0nhVI2ORs6V8owW08l6ltHDI1yXEYiCncWzjGPXNfRPw4meHRjBNujkjG0qeCpBwQRQBzuqWlrH49Z76NXjcYUN0zVPX/C1hdXbvHbJGDyMUfEhJPOS5jfa6P1qW01hrizhO0sQBk0AYg8FWZfoRj3rb0zRbXTl+RFz64qdbtmboB+NNe84+7k0ASyAEYz+FY93ZwTBldAwPtU8lyzk/L09Kh84k5xigDLbSjE6+S37vPKE8VYDhGEMSbGx6VdU7uT1pREC249aAO6+A2f+Fq6AG+8DP8A+k8lfXtfIfwLdE+LWgI5+djcbff/AEeT+lfXlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+emveLPBOua7e6vfeGtZ+13cxnk2aooUMTngeVU2qeNPBupeJ5NdufDWr/bnnW4O3U1ChlxjjyunArzCigD0jUfFXgnUNfudYuPDWsfa57lrp9uqKF3lt3A8rpmna74u8F614ivNavfDWsfbLu4a5k2aooUMTngeV0rzWigD1DUfG3g7UPFcniG48M6t9ve6F0dupqE3ggjjyunFaOga94U1rxr/AGhb+GtUXUbq7NwxbU12b2fdjHldM149XqXwJ0CbUPEcN0AdiuAv59aAPuDQ11iHTIRHb2Cq2ZMNO5I3EsR9z3q1Zw6raweUkViRuZuZX/iYn+771LcXaaVpEUrgsiKAfyqfS9StdTtxNZTLIvcA8r9RQBUs4tVtbaOFIrEqgwMyv/8AE0lnDqtrbpCkdiVXOMyv3Of7vvWxRQBkWkOq2sAiSOxKgs3Mj9yT/d96W0i1W2to4UjsSsahRmR//ia1qKAMi0i1W1tkhSOxKp0Jkf8A+Jos4dUtbdYUjsSoJPMj9yT/AHfetehiFBJOAKAObf8AteAWlglrYyRgDDee4wF9fkqHV7vUvD/hyacwWTxW8ZOBO4Y/Q7a2bC4+1Xk0g+4o2qa5b4w3n2fwlPGDzID/ACoA+Q9T8Z+FLTx02uzeGtSfVI7v7XldUHl7927p5fTNZVt4t8FW+vx6wnhfVjepci7BOqrt37t3Tyuma4jxA/marO3vWbQB6S3i3wU+vtrL+F9WN610bskaqu3fv39PK6Zq1D478IReMB4lHhfVDqQvDff8hQbPMLbunl9M15ZRQB6Xp/i3wXa+IodYh8L6sb6O5F0CdVXbv3bunldM12XhnU2na6vXUIbqV5igOQu5i2M/jXhumwmW7Qe9ex6HEItNQDg4oAh8aIbqzfb1zkVyPhvVDbA210QvYGui1u7AjZc5FcFquCd6nDKcigDvDMOoIINQyT471yNjqrGMJuJwPyq6t+Tgg5oA6BX96XdnpWMl8SvPQVIt8Me3tQBqeZjJFSJNnknish71dh29fU1B9swPmY5oA9U+CjZ+MfhQg9ZLn/0lmr7Gr4k+AV35/wAavCSZHD3R4/69Jq+26ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD8q6KKKACiiigC1p1nJfXSQxKTk8kdhX1h8HdHt9KtIGBAcKM14N4Ft4QqOIxuIGTXtHhG4lQBVcgelAHvWv6nFLo2xWVjj7ua5XRrt9Pt45tP2W6y3Kxyy+USQu1mIyTjkqB04zXNQ3c73IDSsR0xV2/t0aMZMu3glPNbYSOeVzg/lQB6w2rm600y2ssdu6su9pEL7RnnCjkk9APeqE2tXNrbqlzcRLJHJG8rPgSeW0gGCg6Hb19MjvXE6a73BSKWSXZnOFcrz9QRXqWn2NtHY28awpsQiQA8/N/eyep96AM/Qb+5u7pZJLmG4trmHz0WNMeTyBjOec5PX+6a3qgtLO3tA4toUiDtubaMZNT0AFc54n1iO3X7Oj/ADt1xW7eMUtnKnBx1rxfXLiaTX2DyMw3dKAPWfDrKbAEd+TXm/xvvd1h5acgKRXe6GSNKXH92vJfi+7FWBJxg0AfHHiBcalKcdWP86zK2fE//IQk/wB41jUAFWtMjSbUbSOQZR5UVh6gkVVpyEq6lSQQcgjtQB9D+Lvhpp+hpqL2UVvvl1oRxrEzE2sXlu3ktnvwjd+COasvpNha+Grm4kvGS4gjdvLDwgHAyB80gb/x36Zrm/BmX0v7VI8klw43tI7lizH+I56n3615v46uJZtadZXLAdM0AO1LXxOcIM56YrJjvmN3DI0KTBXB8lwSr8/dOOoNUHpclcFSQQcgigD3xYrS51tNNs/BPh86nZ2qTXziOVbW2eTBKSKGLMVHAwc7mIxxWN4lvdJ07wfqsi+GtPt4p7p7PTJp4Hju2I5klOWwAmQAMdwD0ry3T/EWtabdz3en6tf211P/AK6aG4dXk7/MQcn8arahqd9qT79Rvbm6fcz5nlZzubljyep70Ad34Y0sax4E8Q3dtZS3Wo209osXkqzuqsz78AeuBWJocS3mv22l3rSWjSTCKQkANH68OVAP1IrG0fXdW0R5G0bU72waQAObadoy2OmdpGao3VxNd3EtxdSyTTysXeSRizMx6kk9TQB3XxG0q28L31rBYX0l6s0ZctIYvlOcf8s3cfmRXFS300n8WPpVWigD3f8AZNsbq7+JVjqH2ASwW7Sq97KxxFmCQBEA43nPOf4Qfavt2vgv9lXUr6D4y6DYQ3lxHY3BuDNbrIRHIRbSkFl6HBA6+lfelABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ewing's sarcoma of the right femur in a 16-year-old boy. Left panel, T1-weighted coronal MRI image of the right femur showing extensive destruction of the entire mid femur by tumor (arrows). Right panel, T1-weighted axial MRI image through the proximal femur with gadolinium and fat saturation. The tumor appeas hyperintense relative to the surrounding tissues (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas DeLaney, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21093=[""].join("\n");
var outline_f20_38_21093=null;
var title_f20_38_21094="Dissecting cellulitis of the scalp";
var content_f20_38_21094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dissecting cellulitis of the scalp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluctuant nodules and areas of scarring alopecia are present on the scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21094=[""].join("\n");
var outline_f20_38_21094=null;
var title_f20_38_21095="Esomeprazole: Pediatric drug information";
var content_f20_38_21095=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Esomeprazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"    see \"Esomeprazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/25/24981?source=see_link\">",
"    see \"Esomeprazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NexIUM&reg;;",
"     </li>",
"     <li>",
"      NexIUM&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Esomeprazole&reg;;",
"     </li>",
"     <li>",
"      Mylan-Esomeprazole;",
"     </li>",
"     <li>",
"      Nexium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastric Acid Secretion Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Proton Pump Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12859455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 0.5 mg/kg/dose given once daily for 7 days; has been shown to reduce esophageal acid exposure and gastric acidity, but did not decrease bolus reflux in 26 preterm and term infants with symptoms of GERD (GA: 23-41 weeks) (Omari, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=see_link\">",
"      see \"Esomeprazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children 1-24 months: 0.25 mg/kg/dose or 1 mg/kg/dose once daily (Omari, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-11 years: Manufacturer's recommendations: Safety and efficacy of doses &gt;1 mg/kg/day and/or therapy beyond 8 weeks have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Symptomatic GERD or nonerosive reflux disease: 10 mg once daily for up to 8 weeks:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Erosive esophagitis (healing):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &lt;20 kg: 10 mg once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;20 kg: 10 or 20 mg once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents 12-17 years: 20-40 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Erosive esophagitis (healing): Initial: 20-40 mg once daily for 4-8 weeks; if incomplete, continue for an additional 4-8 weeks; maintenance: 20 mg once daily (controlled studies did not extend beyond 6 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Symptomatic GERD: 20 mg once daily for 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pathological hypersecretory conditions including Zollinger-Ellison syndrome: 40 mg twice daily; dosage may be increased depending upon the response to therapy; doses up to 240 mg/day have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjunctive therapy of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     (in combination with antibiotic therapy): 40 mg once daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention of NSAID-induced gastric ulcers: 20-40 mg once daily for up to 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: GERD with history of erosive esophagitis (short-term treatment):",
"     <b>",
"      Note:",
"     </b>",
"     Change to oral therapy as soon as appropriate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants 1-11 months: 0.5 mg/kg/dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;55 kg: 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;55 kg: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 20 mg or 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate liver impairment (Child-Pugh Class A or B): No dosage adjustment needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe liver impairment (Child-Pugh Class C): Not to exceed 20 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral, as magnesium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NexIUM&reg;: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, delayed release, oral, as magnesium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NexIUM&reg;: 10 mg/packet (30s); 20 mg/packet (30s); 40 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NexIUM&reg; I.V.: 20 mg, 40 mg [contains edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15241701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     NexIUM&reg; capsules, granules for oral suspension:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322355.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322355.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer at least 1 hour before food or meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Swallow whole, do not chew or crush; capsule may be opened and the enteric coated pellets may be mixed with applesauce (applesauce should not be hot) and swallowed immediately; do not store mixture for future use; esomeprazole pellets also remain intact when mixed with tap water, orange juice, apple juice, and yogurt; due to small pellet size, the entire contents of an opened capsule may be completely delivered via small caliber and standard NG tubes when mixed with 50 mL water (White, 2002); administer immediately; do not administer if the pellets have dissolved or disintegrated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Granules: Mix contents of packet with 15 mL water and leave for 2-3 minutes to thicken; stir and drink within 30 minutes. Granules may be administered by nasogastric or gastric tube: Add 15 mL of water to a catheter-tip syringe, add granules from packet. Shake the syringe, leave 2-3 minutes to thicken. Shake the syringe and administer through nasogastric or gastric tube (French size 6 or greater) within 30 minutes. Refill the syringe with 15 mL of water, shake and flush tube.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Reconstitute vial (20 mg or 40 mg) with 5 mL of NS; further dilute to a final volume of 50 mL to final concentration of 0.4 mg/mL or 0.8 mg/mL, respectively; withdraw the appropriate amount to administer the intended dose and infuse over 10-30 minutes. The manufacturer recommends that children receive intravenous esomeprazole by intermittent infusion only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Reconstitute vial (20 mg or 40 mg) with 5 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR. May administer dosage without further dilution over at least 3 minutes. May also be diluted in 50 mL D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR (0.4-0.8 mg/mL) and infused over 10-30 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.4 mg/mL",
"     <b>",
"      or",
"     </b>",
"     0.8 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, granules: Esomeprazole stability is a function of pH; it is rapidly degraded in acidic media, but has acceptable stability under alkaline conditions. Each capsule of esomeprazole contains enteric-coated granules to prevent esomeprazole degradation by gastric acidity. Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep container tightly closed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for injection: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Per the manufacturer, following reconstitution, solution for injection prepared in NS, and solution for infusion prepared in NS or LR should be used within 12 hours. Following reconstitution, solution for infusion prepared in D",
"     <sub>",
"      5",
"     </sub>",
"     W should be used within 6 hours. Refrigeration is not required following reconstitution.  Additional stability testing has shown that following reconstitution, solutions for infusion prepared in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, or LR in polyvinyl chloride bags are chemically and physically stable for 48 hours at room temperature (25&deg;C) and for at least 120 hours under refrigeration (4&deg;C) (Kupiec, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral formulation: Treatment and maintenance of healing of severe erosive esophagitis; treatment of symptomatic gastroesophageal reflux disease (GERD) (FDA approved in children &ge;1 year and adults); adjunctive treatment of duodenal ulcers associated with",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     ; prevention of gastric ulcers associated with continuous NSAID therapy; long term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. formulation: Short-term alternative treatment of GERD with a history of erosive esophagitis when oral therapy is not possible or appropriate (FDA approved in ages &ge;1 month and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5730363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Esomeprazole may be confused with ARIPiprazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NexIUM&reg; may be confused with NexAVAR&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F166999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, flatulence, nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction (I.V.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggression, agranulocytosis, alopecia, anaphylaxis, anemia, angioedema, anorexia, arthritis exacerbation, asthma exacerbation, benign polyps/nodules, blurred vision, carcinoid tumor of stomach, cervical lymphadenopathy, chest pain,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), conjunctivitis, creatinine increased, cystitis, depression, dermatitis, dysmenorrhea, epistaxis, erythema multiforme,  fibromyalgia syndrome, fracture, fungal infection, gastroenteritis, GI candidiasis, GI dysplasia, goiter, gynecomastia, hallucinations, hematuria, hepatic encephalopathy, hepatic failure, hepatitis, hernia, hyperhidrosis, hyperparathyroidism, hypersensitivity reactions, hypertension, hypertonia, hyperuricemia, hypoesthesia, hypokalemia, hypomagnesemia, hyponatremia, impotence, insomnia, interstitial nephritis, jaundice, leukocytosis, leukopenia, microscopic colitis, migraine, moniliasis, osteoporosis-related fracture, otitis media, pancreatitis, pancytopenia, parosmia, phlebitis, photosensitivity, pneumonia, polymyalgia rheumatica, proteinuria, pruritus ani, rash (erythematous and maculo-papular), rigors, serum gastrin increased, Stevens-Johnson syndrome, stomatitis, tachycardia, thrombocytopenia, thrombophlebitis, thyroid-stimulating hormone increased, tinnitus, toxic epidermal necrolysis, tremor, vaginitis, vertigo, visual field defect, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency, weight changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to esomeprazole, substituted benzimidazole proton pump inhibitors (eg, omeprazole, lansoprazole, pantoprazole), or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bioavailability may be increased in patients with hepatic dysfunction or patients of Asian descent; consider dosage reductions, especially for maintenance healing of erosive esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Esomeprazole is an enantiomer of omeprazole and may share the same potential long-term side effects as omeprazole. In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy of omeprazole and other proton pump inhibitors. An increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy; patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk. Hypomagnesemia has been reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy), and may be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of esomeprazole may be necessary; magnesium concentrations typically return to normal within 1 week of stopping. Atrophic gastritis has been reported occasionally in gastric corpus biopsies from patients treated long term with omeprazole. Symptomatic response to therapy does not preclude the presence of GI malignancy. Use of gastric acid inhibitors including proton pump inhibitors and H",
"     <sub>",
"      2",
"     </sub>",
"     blockers has been associated with an increased risk for development of acute gastroenteritis and community-acquired pneumonia (Canani, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Proton Pump Inhibitors may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Esomeprazole may enhance the adverse/toxic effect of Cilostazol. Esomeprazole may increase the serum concentration of Cilostazol. Esomeprazole may increase the serum concentration of OPC-13015, an active metabolite of Cilostazol.  Management: Monitor for increased cilostazol effects when coadministered with esomeprazole. The manufacturer recommends considering a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Esomeprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1058497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption is decreased by 43% to 53% when taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. However, there are no adequate and well-controlled studies in pregnant women. Congenital abnormalities have been reported sporadically following omeprazole use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Esomeprazole is the S-isomer of omeprazole. Esomeprazole suppresses gastric acid secretion by inhibiting the parietal cell membrane enzyme (H",
"     <sup>",
"      +",
"     </sup>",
"     /K",
"     <sup>",
"      +",
"     </sup>",
"     )-ATPase or proton pump; demonstrates antimicrobial activity against",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.22 L/kg; V",
"     <sub>",
"      d",
"     </sub>",
"     :  16 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C19 primarily and to a lesser extent via 3A3/4 isoenzymes to hydroxy, desmethyl, and sulfone metabolites (all inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 64% after a single dose; 90% with repeated administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-5 years: Mean: 0.42-0.74 hours (Zhao, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6-11 years: Mean: 0.73-0.88 hours (Zhao, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents 12-17 years: Mean: 0.82-1.22 hours (Li, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-5 years: Mean: 1.33-1.44 hours (Zhao, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years: Mean: 1.75-1.79 hours (Zhao, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents 12-17 years: Mean: 1.96-2.04 hours (Li, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (80%, primarily as inactive metabolites; &lt;1% excreted as active drug); feces (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance (with repeated dosing):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 1-5 years: Mean: 6-19.44 L/hour (Zhao, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 6-11 years: Mean: 7.84-9.22 L/hour (Zhao, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents 12-17 years: Mean: 8.36-15.88 L/hour (Li, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/25/24981?source=see_link\">",
"      see \"Esomeprazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dry mouth; do not chew or crush granules. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Canani RB, Cirillo P, Roggero P, et al, \"Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 117(5):e817-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/16651285/pubmed\" id=\"16651285\" target=\"_blank\">",
"        16651285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dohil R, Fidler M, Barshop B, et al, \"Esomeprazole Therapy for Gastric Acid Hypersecretion in Children With Cystinosis,\"",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2005, 20(12):1786-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/16133039/pubmed\" id=\"16133039\" target=\"_blank\">",
"        16133039",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons TE and Gold BD, &ldquo;The Use of Proton Pump Inhibitors in Children: A Comprehensive Review,&rdquo;",
"      <i>",
"       Paediatr Drugs",
"      </i>",
"      , 2003, 5(1):25-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/12513104/pubmed\" id=\"12513104\" target=\"_blank\">",
"        12513104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kupiec TC, Aloumanis V, Ben M, et al, \"Physical and Chemical Stability of Esomeprazole Sodium Solutions,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1247-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/18614750/pubmed\" id=\"18614750\" target=\"_blank\">",
"        18614750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li J, Zhao J, Hamer-Maansson JE, et al, \"Pharmacokinetic Properties of Esomeprazole in Adolescent Patients Aged 12 to 17 Years With Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2006, 28(3):419-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/16750456/pubmed\" id=\"16750456\" target=\"_blank\">",
"        16750456",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Omari T, Davidson G, Bondarov P, et al, \"Pharmacokinetics and Acid-Suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2007, 45(5):530-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/18030229/pubmed\" id=\"18030229\" target=\"_blank\">",
"        18030229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Omari T, Lundborg P, Sandstr&ouml;m M, et al, \"Pharmacodynamics and Systemic Exposure of Esomeprazole in Preterm Infants and Term Neonates With Gastroesophageal Reflux Disease,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2009, 155(2):222-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/19394048/pubmed\" id=\"19394048\" target=\"_blank\">",
"        19394048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White CM, Kalus JS, Quercia R, et al, &ldquo;Delivery of Esomeprazole Magnesium Enteric-Coated Pellets Through Small Caliber and Standard Nasogastric Tubes and Gastrostomy Tubes",
"      <i>",
"       In Vitro",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2002, 59(21):2085-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/ 12434721 /pubmed\" id=\" 12434721 \" target=\"_blank\">",
"        12434721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhao J, Li J, Hamer-Maansson JE, et al, \"Pharmacokinetic Properties of Esomeprazole in Children Aged 1 to 11 Years With Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2006, 28(11):1868-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/38/21095/abstract-text/17213007/pubmed\" id=\"17213007\" target=\"_blank\">",
"        17213007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13281 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-221.10.40.236-8B04AB009B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21095=[""].join("\n");
var outline_f20_38_21095=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166971\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166972\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058488\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12859455\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058482\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166946\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166932\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241701\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058492\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472624\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058485\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058491\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5730363\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166999\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058495\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058481\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058480\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166987\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166940\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058497\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166942\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166955\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058479\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058494\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058487\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13281|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/39/15993?source=related_link\">",
"      Esomeprazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/25/24981?source=related_link\">",
"      Esomeprazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_38_21096="Perinatal mortality";
var content_f20_38_21096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perinatal mortality",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21096/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21096/contributors\">",
"     Nikolaos Zacharias, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21096/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21096/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21096/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21096/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/38/21096/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates in the perinatal period are used to evaluate the outcome of pregnancy and monitor the quality of perinatal (prenatal and neonatal) care. The perinatal mortality rate encompasses late fetal and early neonatal mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of standard terminology facilitates comparisons of mortality rates among states and countries. Standard definitions for reporting reproductive health statistics are published by the National Center for Health Statistics (NCHS) (available at",
"    <a class=\"external\" href=\"file://www.cdc.gov/nchs\">",
"     www.cdc.gov/nchs",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/1\">",
"     1",
"    </a>",
"    ] and are adopted both by the American Academy of Pediatrics (AAP) Committee on Fetus and Newborn and the American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The following definitions are recommended and used in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Live birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn shows signs of life after complete expulsion or extraction from the mother (ie, heartbeats, umbilical cord pulsations, breathing, or voluntary muscle movement). Heartbeats should be distinguished from transient cardiac contractions and breathing distinguished from fleeting respiratory efforts or gasps.",
"   </p>",
"   <p>",
"    In the United States, the 2002 Born-Alive Infants Protection Act defined live birth as \"the complete expulsion or extraction from his or her mother of that member, at any stage of development, who after such expulsion or extraction breaths or has a beating heart, pulsation of the umbilical cord, or definite movement of voluntary muscles regardless of whether the umbilical cord has been cut, and regardless of whether the expulsion or extraction occurs as a natural or induced labor, cesarean section, or induced abortion\" [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fetal death (stillbirth)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death of the fetus occurs prior to expulsion or extraction from the mother. Fetal death is determined by no signs of life after delivery. Signs of life include heartbeats, umbilical cord pulsations, breathing, or voluntary muscle movement, as noted above. Heartbeats should be distinguished from transient cardiac contractions, and breathing from fleeting respiratory efforts or gasps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NCHS reports fetal deaths that occur &ge;20 weeks gestation, which are also referred to as \"stillbirth\". For statistical purposes, fetal death is further subdivided as \"early\" (20 to 27 weeks gestation) or late (&ge;28 weeks gestation). Pregnancies resulting in fetal demise before 20 weeks are categorized as miscarriages.",
"   </p>",
"   <p>",
"    However, because birth weight can be more objectively and accurately measured than estimated gestational age, Guidelines for Perinatal Care and ACOG recommend that requirements for reporting fetal deaths should be based upon birth weight &ge;500 g. This has not been adopted by all states or the NCHS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Fetal death rate'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Fetal death rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal death rate is the number of fetal deaths &ge;20 weeks gestation that occur during a year divided by the sum of live births plus fetal deaths during the same year, and expressed per 1000 live births plus fetal deaths. NCHS defines late fetal death rate as the number of fetal deaths &ge;28 weeks gestation during a year divided by the sum of live births plus late fetal deaths during the same year, expressed per 1000 live births plus late fetal deaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175936185\">",
"    <span class=\"h2\">",
"     Infant death and mortality rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infant death is defined as a live birth that results in death within the first year of life (&lt;365 days). The infant mortality rate (IMR) is the number of infant deaths less than one year of age (0 to 365 days of life) during a year, divided by the number of live births reported during the same year, expressed per 1000 live births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Neonatal death and mortality rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal death is defined as an infant death before 28 days of age. Early neonatal deaths occur within the first seven days of birth, and late neonatal deaths occur between 8 and 27 days of age.",
"   </p>",
"   <p>",
"    The neonatal mortality rate (NMR) is the number of neonatal deaths during a year, divided by the number of live births during the same year, expressed per 1000 live births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175936208\">",
"    <span class=\"h3\">",
"     Postneonatal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postneonatal death is defined as an infant death occurring between 28 to 365 days of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Perinatal mortality rate (PMR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NCHS uses two different definitions of perinatal mortality rate (PMR) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first PMR definition is the sum of fetal deaths (&ge;20 weeks gestation) plus neonatal deaths (ie, deaths within the first 28 days of birth) during a year divided by the sum of live births plus late fetal deaths during the same year, expressed per 1000 live births plus late fetal deaths.",
"     </li>",
"     <li>",
"      The second PMR definition is the sum of fetal deaths (&ge;20 weeks gestation) plus early neonatal deaths (ie, deaths within the first seven days of birth) during a year divided by the sum of live births plus late fetal deaths during the same year, expressed per 1000 live births plus late fetal deaths.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H175936280\">",
"    <span class=\"h1\">",
"     REPORTING REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, live births, deaths, and fetal deaths are reported as vital events. The National Association for Public Health Statistics and Information Systems (NAPHSIS) has developed a flowchart to assist hospitals with the appropriate reporting of fetal and infant deaths, and live births (",
"    <a class=\"graphic graphic_algorithm graphicRef69524 \" href=\"UTD.htm?3/46/3813\">",
"     algorithm 1",
"    </a>",
"    ) based on the National Center for Health Statistics (NCHS) definitions.",
"   </p>",
"   <p>",
"    Although the Model State Vital Statistics Act and Regulations recommends reporting all fetal deaths with births weights &ge;350 g or, if the birth weight is unknown, gestational age &gt;20 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/6\">",
"     6",
"    </a>",
"    ], states have the right to determine registration criteria, which results in variation of the reporting of these events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, the quality and quantity of reported clinical information also varies among the states.",
"   </p>",
"   <p>",
"    In addition to demographic information (eg, maternal ethnicity and age) and maternal medical history, the following minimal information should be obtained for each of these events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For live births, reported information should include birth weight, gestational age, and other pertinent information (eg, Apgar scores). In the event of infant death, the time to survival, and the cause of death should be listed.",
"     </li>",
"     <li>",
"      For fetal deaths, deaths should be reported based on the state criteria and should include birth weight, gestational age, and cause of fetal demise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMPARISON OF MORTALITY RATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparison of mortality statistics across states or countries is challenging for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differences in the definitions employed &mdash; In the United States, the minimum gestational age used to calculate fetal death is 20 weeks, and the postnatal days used to calculate perinatal mortality rate (PMR) is either 7 or 28 days [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/3,7,8\">",
"       3,7,8",
"      </a>",
"      ]. In comparison, the minimum gestational age ranges from 16 to 28 weeks among European countries, and the perinatal period used to calculate PMR ranges from 7 to 28 postnatal days [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Birth weight versus gestational age &mdash; Use of birth weight rather than gestational age may further limit some comparisons because birth weight data do not identify fetal growth restriction, which frequently compounds prematurity [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Differences in birth and death registration &mdash; The process of birth and death registration varies considerably among countries, especially when infants are born very prematurely or die soon after delivery. Perinatal statistics are particularly unreliable in developing countries, and whenever a substantial number of births takes place outside of hospitals or birthing centers unattended by trained individuals. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Prematurity'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other countries",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Developing countries",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2000, neonatal deaths accounted for 38 percent of all child deaths worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/10\">",
"     10",
"    </a>",
"    ]. Almost all of the four million neonatal deaths (99 percent) occurred in developing countries. Poverty was strongly associated with neonatal mortality rate (NMR). NMR was almost 10 times greater in countries with moderate and low income than in high income countries (33 versus &lt;4 deaths per 1000 live births). The highest NMR occurred in sub-Saharan Africa (over 45 deaths per 1000 live births), but the greatest absolute number of deaths occurred in south-central Asia. The main causes of death were prematurity (28 percent), infection (26 percent), and perinatal hypoxic insult (23 percent).",
"   </p>",
"   <p>",
"    In a population-based study performed in Bangladesh, maternal complications during labor increased NMR five-fold and accounted for 30 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/11\">",
"     11",
"    </a>",
"    ]. Complications included prolonged or obstructed labor, abnormal fetal position, and hypertensive disorders of pregnancy.",
"   </p>",
"   <p>",
"    A systemic review and cost analysis identified 16 cost-effective interventions (eg, maternal",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation, detection and treatment of mothers with asymptomatic bacteriuria, and antibiotics for preterm rupture of membranes) that would improve neonatal survival in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/12\">",
"     12",
"    </a>",
"    ]. This analysis provided a health system structure to implement these interventions at the family-community and individual patient level (pregnancy, delivery, and birth). With universal application, the study estimated that mortality rates would decrease by 59 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effect of prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differences in the availability of",
"    <span class=\"nowrap\">",
"     timely/accurate",
"    </span>",
"    prenatal diagnosis and pregnancy termination facilities, as well as population acceptance of termination of anomalous pregnancies can greatly influence regional PMR. In developed countries, timely and accurate prenatal diagnosis followed by termination of anomalous pregnancy can decrease PMR up to 50 percent. This was demonstrated by a large screening prenatal ultrasound trial in Finland that reported a 50 percent reduction in PMR for pregnancies in women who were randomly selected to receive ultrasound screening between 16 and 20 weeks gestation compared with controls who received standard of care (4.6 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a birth cohort study of all live births, stillbirths, and infant deaths in Canada for the years 1991 to 1998, infant mortality rate (IMR) decreased about 15 percent from the time period between 1991 to 1995 (range 6.1 to 6.4 percent) and 1996 to 1997 (range 5.4 to 5.5 percent), while fetal deaths caused by pregnancy termination increased [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/15\">",
"     15",
"    </a>",
"    ]. Over this time period, infant deaths from congenital anomalies declined from 1.9 to 1.5 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PERINATAL AND NEONATAL MORTALITY RATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the perinatal mortality rate (PMR) has declined consistently by 25 percent with reported rates of 9 to 6.7 deaths per 1000 live births in 1990 and 2003, respectively (",
"    <a class=\"graphic graphic_figure graphicRef76539 \" href=\"UTD.htm?12/28/12750\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66028 \" href=\"UTD.htm?4/43/4798\">",
"     figure 2",
"    </a>",
"    ). Since 2003, the PMR has not significantly changed and was 6.64 per 1000 live births in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/1,16\">",
"     1,16",
"    </a>",
"    ] despite an evolving obesity epidemic, delayed childbearing with increasing use of assisted reproduction technologies, and higher prevalence of hypertensive and diabetic disorders of pregnancy. Over forty years, the neonatal mortality rate (NMR) has also declined to four per 1000 live births in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major factors that influence mortality rates include ethnicity, gestational age, and multifetal pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative disparities in perinatal and neonatal mortality among different",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    populations have not substantially changed over time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The PMR for black infants was 2.3 times that of white infants in 2005 (12.2 versus 5.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/20\">",
"     20",
"    </a>",
"    ], and the infant mortality rate (IMR) was similarly higher in 2004 (13.6 versus 5.7 percent) (",
"    <a class=\"graphic graphic_figure graphicRef59601 \" href=\"UTD.htm?16/13/16607\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/21\">",
"     21",
"    </a>",
"    ]. The PMR in 2005 for Hispanic infants was 5.9 percent, and the IMR in 2004 was 7.8 for Puerto Rican infants and 5.5 for Mexican infants.",
"   </p>",
"   <p>",
"    The racial disparity is explained largely by the higher incidence of prematurity in blacks. In 2011, the percentages of live births in the United States that were preterm by ethnicity were 16.8, 11.8, and 10.5 in non-Hispanic blacks, Hispanics, and non-Hispanic whites, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gestational age",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Term pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NMR varies with estimated gestational age at delivery among term pregnancies. This was illustrated by a review of linked live birth-infant death files compiled by the United States National Center for Health Statistics (NCHS) of singleton term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/22\">",
"     22",
"    </a>",
"    ]. In the main study sample of non-Hispanic white infants born at 37 to 41 weeks gestation between 1995 and 2001, the NMR had a U-shaped relationship with advancing gestational age: NMR decreased with increasing gestational age from 37 to 39 weeks, remained stable from 39 to 40 weeks gestation, and increased &ge;41 weeks gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prematurity is a major contributor to neonatal and infant mortality. PMR and NMR increase with decreasing gestational age in premature infants (gestational age &lt;37 weeks). (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Low birth weight'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link&amp;anchor=H8#H8\">",
"     \"Incidence and mortality of the premature infant\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NMR of extremely low birth weight infants (ELBW) with birth weights &lt;750 g may be underreported. This was illustrated by a report that demonstrated the deaths of 7 percent of ELBW infants that died in Ohio between January and June of 2006 were not registered [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/23\">",
"     23",
"    </a>",
"    ]. The failure to register deaths was attributed to the short lifespan of these infants, resulting in the potential for their deaths to be misclassified as fetal deaths, thereby falsely lowering the early NMR and increasing the late fetal death rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Multifetal pregnancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple births accounted for 33.2 per 1000 live births in the United States in 2010. This was primarily due to twin births (33.1 per 1000 live births), which have increased from a rate of 22.6 in 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/17\">",
"     17",
"    </a>",
"    ]. Higher-order multiple gestation also increased from 0.07 to 0.14 per 1000 live births between 1990 and 2010.",
"   </p>",
"   <p>",
"    The increased rate of multiple births is associated with the related trends of delayed childbearing and increased use of ovulation-inducing drugs and assisted reproductive technologies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This trend is especially prominent in women &ge;30 years of age and in non-Hispanic whites [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple gestations are a strong risk factor for neonatal mortality. This was illustrated in an analysis of the 1989 to 1991 and 1999 to 2001 United States linked",
"    <span class=\"nowrap\">",
"     birth/infant",
"    </span>",
"    death data sets [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/27\">",
"     27",
"    </a>",
"    ]. Although the overall infant mortality rate (IMR) decreased during the two epochs, IMR increased with plurality as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Singletons (six to five per 1000 live births)",
"     </li>",
"     <li>",
"      Twins (29 to 20 per 1000 live births)",
"     </li>",
"     <li>",
"      Triplets (69 to 47 per 1000 live births)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Quadruplets/quintuplets",
"      </span>",
"      (120 to 94 per 1000 live births)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A high proportion of multiple births (approximately one-half of twins, and the majority of triplets, quadruplets, and quintuplets) are preterm or low birth weight (LBW), which contributes to the higher mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/28\">",
"     28",
"    </a>",
"    ]. They also are at higher risk for birth defects [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=see_link\">",
"     \"Twin pregnancy: Prenatal issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of infant mortality in twin births is increased by young maternal age, in contrast to the U-shaped relationship with age that occurs in singleton births. In a retrospective cohort study in the United States during three epochs (1985 to 1986, 1990 to 1991, and 1995 to 1996), the infant mortality rate for twin births was 7, 2.7, and 2.0 percent for women &lt;20 years, 30 to 34 years, and 40 to 49 years of age, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/30\">",
"     30",
"    </a>",
"    ]. Neonatal mortality was slightly elevated in the younger mothers. Postneonatal infant mortality (28 to 365 days) was most affected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CAUSES OF FETAL DEATH (STILLBIRTH)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of fetal deaths remain unexplained [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/31\">",
"     31",
"    </a>",
"    ]. In the remaining two-thirds of fetal deaths, identifiable causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal (eg, structural defects, arrhythmias, syndromes, aberrant growth) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"       \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link&amp;anchor=H17#H17\">",
"       \"Fetal growth restriction: Evaluation and management\", section on 'Mortality'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link\">",
"       \"Incidence, etiology, and prevention of stillbirth\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Placental (eg, chorioamnionitis, abruption, large chorioangiomas, vasa previa, umbilical cord accidents, prolonged pregnancy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=see_link&amp;anchor=H3#H3\">",
"       \"Placental infections\", section on 'Chorioamnionitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link&amp;anchor=H8#H8\">",
"       \"Incidence, etiology, and prevention of stillbirth\", section on 'Abruptio placenta'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/18/20775?source=see_link&amp;anchor=H9#H9\">",
"       \"Velamentous umbilical cord insertion and vasa previa\", section on 'Vasa previa'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link&amp;anchor=H13#H13\">",
"       \"Incidence, etiology, and prevention of stillbirth\", section on 'Umbilical cord complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=see_link&amp;anchor=H6#H6\">",
"       \"Postterm pregnancy\", section on 'Fetal and neonatal risks'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maternal (eg, obesity, hypertension, diabetes mellitus, autoimmune disorders, intrahepatic cholestasis of pregnancy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link&amp;anchor=H31#H31\">",
"       \"The impact of obesity on fertility and pregnancy\", section on 'Perinatal mortality'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=see_link&amp;anchor=H3#H3\">",
"       \"Infant of a diabetic mother\", section on 'Fetal effects'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link&amp;anchor=H10703426#H10703426\">",
"       \"Intrahepatic cholestasis of pregnancy\", section on 'Morbidity and mortality'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H53704432#H53704432\">",
"       \"Management of hypertension in pregnant and postpartum women\", section on 'General approach'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal factors that increase the risk of fetal death include extremes of maternal age, unmarried status, smoking, prior stillbirth, and multiple gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Black race is a strong confounding factor. In the report noted above of fetal death and linked infant birth-death certificate data for 1995 to 1998, blacks had twice the perinatal mortality rate (PMR) and a higher ratio of late fetal to neonatal deaths compared with whites [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/34\">",
"     34",
"    </a>",
"    ]. This difference persisted even when rates were adjusted for socioeconomic status and medical complications.",
"   </p>",
"   <p>",
"    From 1980 to 1998, the United States fetal death rate decreased by 26.4 percent (9.1 to 6.7 per 1000 live births plus late fetal deaths) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/28\">",
"     28",
"    </a>",
"    ]. From 1994 to 2005, the early fetal death rate has remained stable at 3.2 per 1000 live births plus late fetal deaths, while the late fetal death rate has declined from 4.3 to 3.1 per 1000 live births plus late fetal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/1,20,28\">",
"     1,20,28",
"    </a>",
"    ]. This decline is likely related to the widespread use of prenatal sonography, fetal surveillance with biophysical profile and Doppler velocimetry in high-risk pregnancies, improved management of gestational disorders (eg, diabetes mellitus and hypertension), decreasing TORCH infections and fetal anemia, and the practically universal use of continuous intrapartum fetal heart rate monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/32,35\">",
"     32,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a large Swedish population-based study of 656,134 singleton pregnancies between 1987 and 1997, the time point when the fetal death rate exceeded the neonatal mortality rate (NMR) was identified as 40 weeks and 3 days, thus providing a functional definition of prolonged pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/36\">",
"     36",
"    </a>",
"    ].Causes and management of fetal deaths are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link\">",
"     \"Incidence, etiology, and prevention of stillbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CAUSES OF INFANT DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, the five leading causes of infant death in the United States were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Congenital malformations or chromosome abnormalities &mdash; 21 percent",
"     </li>",
"     <li>",
"      Low birth weight or prematurity &mdash; 17 percent",
"     </li>",
"     <li>",
"      Sudden infant death syndrome (SIDS) &mdash;7 percent",
"     </li>",
"     <li>",
"      Neonatal death due to maternal complications &mdash; 7 percent",
"     </li>",
"     <li>",
"      Unintentional injuries &mdash; 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among term infants, the major causes of neonatal death were asphyxia and infection, and in postneonatal infancy, SIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With improved perinatal care, neonatal deaths caused by fetal hypoxia and perinatal hypoxic events have decreased substantially in the United States (71.5 and 85.2 percent, respectively, from 1979 to 1997) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. Substantial reduction in the number of deaths caused by prematurity has been associated with increased use of antenatal glucocorticoids and the availability of surfactant treatment of respiratory distress syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In China, the neonatal mortality rate has fallen from 34 to 10.2 deaths per 1000 live births, and the postnatal infant (1 to 11 months of age) mortality rate from 53.5 to 14.9 deaths per 1000 live births from 1990 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/38\">",
"     38",
"    </a>",
"    ]. In 2008, the proportional contribution of causes of neonatal deaths included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Birth asphyxia &mdash; 29 percent",
"     </li>",
"     <li>",
"      Other (eg, tetanus, intracranial hemorrhage, accidents, scleroderma, accidental asphyxia, and meningitis) &mdash; 27 percent",
"     </li>",
"     <li>",
"      Prematurity &mdash; 26 percent",
"     </li>",
"     <li>",
"      Congenital anomalies &mdash; 10 percent",
"     </li>",
"     <li>",
"      Infections (ie, sepsis, diarrhea, and pneumonia) &mdash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The proportional contribution of causes of postnatal infant deaths included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumonia &mdash; 47 percent",
"     </li>",
"     <li>",
"      Congenital abnormalities &mdash; 16 percent",
"     </li>",
"     <li>",
"      Sudden infant death syndrome &mdash; 12 percent",
"     </li>",
"     <li>",
"      Diarrhea &mdash; 9 percent",
"     </li>",
"     <li>",
"      Accidents &mdash; 7 percent",
"     </li>",
"     <li>",
"      Other (birth asphyxia, neonatal sepsis, prematurity) &mdash; 9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Low birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birth weight is a major determinant of neonatal morbidity and mortality (",
"    <a class=\"graphic graphic_figure graphicRef70737 \" href=\"UTD.htm?10/56/11150\">",
"     figure 4",
"    </a>",
"    ). Low birth weight includes infants with fetal growth restriction and those born preterm.",
"   </p>",
"   <p>",
"    The proportion of deaths associated with prematurity likely is greater, as other attributed causes (eg, respiratory distress, hemorrhage, and necrotizing enterocolitis) primarily affect this population. This was illustrated in an analysis of the 2002 United States linked birth-infant death file, which contains information from birth and death certificates for all infants born in 2002 who died during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/39\">",
"     39",
"    </a>",
"    ]. Results from this study demonstrated that 34 percent of the 22,273 infant deaths that occurred in 2002 were attributable to prematurity. Of these 9596 deaths, 95 percent occurred in infants &le;32 weeks gestation with birth weights &le;1500 g, and two-thirds of the deaths occurred during the first 24 hours of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mortality rates of preterm infants and limit of viability are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Regional differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional differences exist in the United States in the incidence of perinatal mortality and neonatal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/40\">",
"     40",
"    </a>",
"    ]. Neonatal mortality also may differ among local institutions, even when adjustments are made for prematurity rates. These differences may be due in part to specific characteristics of newborn care, and suggest that infants at high risk should be delivered in hospitals with tertiary level neonatal intensive care units (NICU). This was illustrated by two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Canadian Neonatal Network, risk-adjusted outcomes were compared in infants born &le;32 weeks gestation and admitted to 17 NICUs in Canada during 1996 and 1997 [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/42\">",
"       42",
"      </a>",
"      ]. Infants born outside of tertiary care centers who required transfer to a NICU were at greater risk of death (adjusted odds ratio 1.7, 95% CI 1.2-2.5) and other adverse outcomes compared with inborn infants.",
"     </li>",
"     <li>",
"      In a report that evaluated outcomes of infants with birth weight &lt;2000 g born in 1992 and 1993 in California, survival was more likely with birth at a regional center [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/41\">",
"       41",
"      </a>",
"      ]. Risk-adjusted mortality was higher when infants were born in hospitals with no NICU (odds ratio 2.38, 95% CI 1.81-3.13), an intermediate NICU (odds ratio 1.92, 95% CI 1.44-2.54), or a small community NICU with average census &lt;15 (odds ratio 1.42, 95% CI 1.14-1.76) compared with hospitals with a regional NICU (average census of &ge;15 patients and availability of tertiary care).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The availability of neonatologists likely affects neonatal mortality. In a study of the relationship of the distribution of neonatologists and neonatal death, the supply of specialized services varied across regions and was not consistently related to improved outcome, even after adjustment for the numbers of extremely low birth weight infants (birth weight &lt;1000 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/43\">",
"     43",
"    </a>",
"    ]. The risk-adjusted mortality rate was lower in regions with 4.3 compared with 2.7 neonatologists per 10,000 live births (odds ratio 0.93, 95% CI 0.88-0.99); additional increases did not further reduce the risk of death, suggesting that the supply of neonatologists in most regions was adequate or possibly excessive, and inadequate in some. However, the effect of the regional distribution of neonatologists on proliferation of smaller NICUs (associated with higher mortality) or on neonatal morbidity is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital malformations, including syndromes and chromosomal abnormalities, account for approximately 20 percent of neonatal deaths. These conditions are associated with higher rates of fetal death, preterm birth, and fetal growth restriction. Congenital anomalies occur in 3 percent of live born infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link\">",
"     \"Genetic and environmental causes of birth defects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Timely and accurate prenatal diagnosis can reduce morbidity and mortality from congenital anomalies by modifying perinatal management. More importantly, timely and accurate prenatal diagnosis of fetal structural defects, followed by termination of anomalous pregnancies, substantially decreases the neonatal mortality rate (NMR). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Effect of prenatal diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other maternal characteristics are associated with increased neonatal mortality, and are similar to risk factors for fetal death. These include age less than 20 years or more than 40 years, late or no prenatal care, unmarried status, smoking, and lower education level [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21096/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates in the perinatal period are used to evaluate the outcome of pregnancy and monitor the quality of perinatal (prenatal and neonatal) care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of standard terminology facilitates comparisons of mortality rates among states and countries. Standard definitions for reporting reproductive health statistics are published by the National Center for Health Statistics (NCHS) (available at",
"      <a class=\"external\" href=\"file://www.cdc.gov/nchs\">",
"       www.cdc.gov/nchs",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Comparison of mortality rates across states or countries is challenging because different definitions are often used, and there are regional differences in the level of perinatal care, the availability of prenatal diagnosis and pregnancy termination facilities, and societal acceptance of termination of anomalous pregnancies. Neonatal mortality rates are almost 10 times greater in countries with moderate and low income than in high-income countries. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Comparison of mortality rates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Regional differences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, the perinatal mortality rate (PMR) declined to 6.7 per 1000 live births plus late fetal deaths in 2003, and has remained stable through 2005 (",
"      <a class=\"graphic graphic_figure graphicRef76539 \" href=\"UTD.htm?12/28/12750\">",
"       figure 1",
"      </a>",
"      ). Neonatal mortality rates are higher in infants who are non-Hispanic black, premature, or a product of a multifetal pregnancy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Perinatal and neonatal mortality rates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of fetal death can be divided into fetal (eg, structural defects, syndromes, and aberrant growth), placental (eg, chorioamnionitis, chorioangiomas, abruption, infarction, prolonged pregnancy), and maternal causes (eg, obesity, hypertension, diabetes mellitus, autoimmune disorders, intrahepatic cholestasis of pregnancy). However, one-third of fetal deaths remain unexplained. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Causes of fetal death (stillbirth)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of infant deaths are attributed to congenital malformations or chromosome abnormalities, low birth weight or prematurity, sudden infant death syndrome, maternal complications, unintentional injuries, and complications of the placenta, cord, or membranes. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Causes of infant death'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Center for Health Statistics www.cdc.gov/nchs (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     Standard terminology for reporting of reproductive health statistics in the United States. In: Guidelines for Perinatal Care, 6th, Lockwood CJ, Lemons JA (Eds), American Academy of Pediatrics, Elk Grove Village 2007. p.389.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/3\">",
"      Barfield WD, Committee on Fetus and Newborn. Standard terminology for fetal, infant, and perinatal deaths. Pediatrics 2011; 128:177.",
"     </a>",
"    </li>",
"    <li>",
"     Born-Alive Infants Protection Act of 2002 file://thomas.loc.gov/cgi-bin/query/D?c107:5:./temp/~c107UE5Bcc (Accessed on February 04, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/5\">",
"      ACOG Committee opinion. Perinatal and infant mortality statistics. Number 167, December 1995. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1996; 53:86.",
"     </a>",
"    </li>",
"    <li>",
"     Model State and Viatal Statistics Act and Regulations. www.cdc.gov/nchs/data/misc/mvsact92b.pdf (Accessed on July 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/7\">",
"      Richardus JH, Graafmans WC, Verloove-Vanhorick SP, Mackenbach JP. The perinatal mortality rate as an indicator of quality of care in international comparisons. Med Care 1998; 36:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/8\">",
"      Graafmans WC, Richardus JH, Macfarlane A, et al. Comparability of published perinatal mortality rates in Western Europe: the quantitative impact of differences in gestational age and birthweight criteria. BJOG 2001; 108:1237.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. International statistical classification of disease and related health problems. Tenth revision. Geneva: World Health Organization, 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/10\">",
"      Lawn JE, Cousens S, Zupan J, Lancet Neonatal Survival Steering Team. 4 million neonatal deaths: when? Where? Why? Lancet 2005; 365:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/11\">",
"      Kusiako T, Ronsmans C, Van der Paal L. Perinatal mortality attributable to complications of childbirth in Matlab, Bangladesh. Bull World Health Organ 2000; 78:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/12\">",
"      Darmstadt GL, Bhutta ZA, Cousens S, et al. Evidence-based, cost-effective interventions: how many newborn babies can we save? Lancet 2005; 365:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/13\">",
"      Saari-Kemppainen A, Karjalainen O, Yl&ouml;stalo P, Heinonen OP. Ultrasound screening and perinatal mortality: controlled trial of systematic one-stage screening in pregnancy. The Helsinki Ultrasound Trial. Lancet 1990; 336:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/14\">",
"      Saari-Kemppainen A, Karjalainen O, Yl&ouml;stalo P, Heinonen OP. Fetal anomalies in a controlled one-stage ultrasound screening trial. A report from the Helsinki Ultrasound Trial. J Perinat Med 1994; 22:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/15\">",
"      Liu S, Joseph KS, Kramer MS, et al. Relationship of prenatal diagnosis and pregnancy termination to overall infant mortality in Canada. JAMA 2002; 287:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/16\">",
"      Heron M, Sutton PD, Xu J, et al. Annual summary of vital statistics: 2007. Pediatrics 2010; 125:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/17\">",
"      Hamilton BE, Hoyert DL, Martin JA, et al. Annual summary of vital statistics: 2010-2011. Pediatrics 2013; 131:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/18\">",
"      MacDorman MF. Race and ethnic disparities in fetal mortality, preterm birth, and infant mortality in the United States: an overview. Semin Perinatol 2011; 35:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/19\">",
"      Rowland Hogue CJ, Silver RM. Racial and ethnic disparities in United States: stillbirth rates: trends, risk factors, and research needs. Semin Perinatol 2011; 35:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/20\">",
"      MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep 2009; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/21\">",
"      Mathews TJ, MacDorman MF. Infant mortality statistics from the 2004 period linked birth/infant death data set. Natl Vital Stat Rep 2007; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/22\">",
"      Zhang X, Kramer MS. Variations in mortality and morbidity by gestational age among infants born at term. J Pediatr 2009; 154:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). Unregistered deaths among extremely low birthweight infants--Ohio, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/24\">",
"      Centers for Disease Control and Prevention (CDC). Contribution of assisted reproductive technology and ovulation-inducing drugs to triplet and higher-order multiple births--United States, 1980-1997. MMWR Morb Mortal Wkly Rep 2000; 49:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/25\">",
"      Wright VC, Schieve LA, Reynolds MA, et al. Assisted reproductive technology surveillance--United States, 2002. MMWR Surveill Summ 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/26\">",
"      Martin JA, Park MM. Trends in twin and triplet births: 1980-97. Natl Vital Stat Rep 1999; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/27\">",
"      Luke B, Brown MB. The changing risk of infant mortality by gestation, plurality, and race: 1989-1991 versus 1999-2001. Pediatrics 2006; 118:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/28\">",
"      Hoyert DL, Mathews TJ, Menacker F, et al. Annual summary of vital statistics: 2004. Pediatrics 2006; 117:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/29\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics, Society for Maternal-Fetal Medicine, ACOG Joint Editorial Committee. ACOG Practice Bulletin #56: Multiple gestation: complicated twin, triplet, and high-order multifetal pregnancy. Obstet Gynecol 2004; 104:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/30\">",
"      Misra DP, Ananth CV. Infant mortality among singletons and twins in the United States during 2 decades: effects of maternal age. Pediatrics 2002; 110:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/31\">",
"      Pitkin RM. Fetal death: diagnosis and management. Am J Obstet Gynecol 1987; 157:583.",
"     </a>",
"    </li>",
"    <li>",
"     Gaudino JA, Hoyert DL, MacDorman MF, et al. Fetal Deaths. In: From Data to Action, CDC's Public Heath Surveillance for Women, Infants, and Children, Wilcox LS, Marks JS (Eds), US Department of Health and Human Services, Public Health Service, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/33\">",
"      ACOG Practice Bulletin No. 102: management of stillbirth. Obstet Gynecol 2009; 113:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/34\">",
"      Barfield WD, Tomashek KM, Flowers LM, Iyasu S. Contribution of late fetal deaths to US perinatal mortality rates, 1995-1998. Semin Perinatol 2002; 26:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/35\">",
"      Vintzileos AM. Evidence-based compared with reality-based medicine in obstetrics. Obstet Gynecol 2009; 113:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/36\">",
"      Divon MY, Ferber A, Sanderson M, et al. A functional definition of prolonged pregnancy based on daily fetal and neonatal mortality rates. Ultrasound Obstet Gynecol 2004; 23:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/37\">",
"      Hoyert DL, Kochanek KD, Murphy SL. Deaths: final data for 1997. Natl Vital Stat Rep 1999; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/38\">",
"      Rudan I, Chan KY, Zhang JS, et al. Causes of deaths in children younger than 5 years in China in 2008. Lancet 2010; 375:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/39\">",
"      Callaghan WM, MacDorman MF, Rasmussen SA, et al. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 2006; 118:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/40\">",
"      Kochanek KD, Kirmeyer SE, Martin JA, et al. Annual summary of vital statistics: 2009. Pediatrics 2012; 129:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/41\">",
"      Cifuentes J, Bronstein J, Phibbs CS, et al. Mortality in low birth weight infants according to level of neonatal care at hospital of birth. Pediatrics 2002; 109:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/42\">",
"      Chien LY, Whyte R, Aziz K, et al. Improved outcome of preterm infants when delivered in tertiary care centers. Obstet Gynecol 2001; 98:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/43\">",
"      Goodman DC, Fisher ES, Little GA, et al. The relation between the availability of neonatal intensive care and neonatal mortality. N Engl J Med 2002; 346:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21096/abstract/44\">",
"      MacDorman MF, Atkinson JO. Infant mortality statistics from the 1997 period linked birth/infant death data set. Natl Vital Stat Rep 1999; 47:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4973 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21096=[""].join("\n");
var outline_f20_38_21096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Live birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fetal death (stillbirth)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Fetal death rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H175936185\">",
"      Infant death and mortality rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Neonatal death and mortality rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H175936208\">",
"      - Postneonatal death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Perinatal mortality rate (PMR)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H175936280\">",
"      REPORTING REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMPARISON OF MORTALITY RATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other countries",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Developing countries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effect of prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PERINATAL AND NEONATAL MORTALITY RATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gestational age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Term pregnancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Multifetal pregnancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CAUSES OF FETAL DEATH (STILLBIRTH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CAUSES OF INFANT DEATH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Low birth weight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Regional differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4973\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4973|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?3/46/3813\" title=\"algorithm 1\">",
"      Fetal and infant deaths and live births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4973|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/28/12750\" title=\"figure 1\">",
"      Perinatal mortality US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/43/4798\" title=\"figure 2\">",
"      Fetal infant mortality US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/13/16607\" title=\"figure 3\">",
"      Infant mortality based on race and ethnicity of mother",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/56/11150\" title=\"figure 4\">",
"      Infant mortality birth wt",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/48/44809?source=related_link\">",
"      Infant of a diabetic mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=related_link\">",
"      Intrahepatic cholestasis of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4089?source=related_link\">",
"      Placental infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=related_link\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/18/20775?source=related_link\">",
"      Velamentous umbilical cord insertion and vasa previa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_38_21097="Basic principles of genetic disease";
var content_f20_38_21097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Basic principles of genetic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21097/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21097/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21097/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21097/contributors\">",
"     Anne Slavotinek, MBBS, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21097/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21097/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/38/21097/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1497080\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of genetics and genomics in clinical medicine is ever increasing. As of 2012, the molecular basis of rare, Mendelian diseases (diseases inherited in a Mendelian pattern, for example, autosomal dominant, autosomal recessive, and sex-linked) has been identified for more than 3000 conditions. Advances in next-generation sequencing (NGS) have lead to the supposition that the genes for all known Mendelian conditions will be identified in the near future.",
"   </p>",
"   <p>",
"    Large-scale genomic technologies such as NGS and array comparative genomic hybridization (array CGH) are also providing insights into the important role of genetic variation in more common multifactorial or polygenic disorders, including discoveries of genetic variants that influence disease susceptibility, prognosis, and treatment response.",
"   </p>",
"   <p>",
"    The indications for genetic testing are expanding across virtually all fields of clinical medicine, foreshadowing prospects of an era of &ldquo;precision medicine,&rdquo; whereby clinical decision making will be individually tailored, informed by a patient&rsquo;s genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Integrating these new approaches into clinical practice requires understanding of the basic principles of heredity, genome organization, and molecular genetics.",
"   </p>",
"   <p>",
"    The role of genomics in clinical medicine, however, remains in a nascent stage. Several issues increase the complexity of the field of genomics (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=see_link\">",
"     \"Genomic disorders: An overview\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The polygenic inheritance of most non-Mendelian conditions, whereby several common polymorphisms may each contribute a small increase in risk",
"     </li>",
"     <li>",
"      The uncertainty of the magnitude of risk conferred by a particular genetic variant across differing kindreds and differing populations",
"     </li>",
"     <li>",
"      The role of gene-gene and gene-environment interactions in gene expression and disease risk",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review basic concepts in genetics, serving as a primer for further reading. The topic will review the organization of the human genome, the basic principles of molecular biology, the types of genetic variation that contribute to disease pathogenesis, modes of inheritance, and the role genetics plays in clinical medicine today. Detailed reviews of the principles of inheritance, genetic variation, molecular genetic techniques, and the application of genetic information in screening, diagnosis, and treatment of multiple specific conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=see_link\">",
"     \"Glossary of genetic terms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43750?source=see_link\">",
"     \"Non-Mendelian inheritance patterns of monogenic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497087\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES OF MOLECULAR GENETICS",
"    </span>",
"   </p>",
"   <p>",
"    Molecular genetics is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497096\">",
"    <span class=\"h2\">",
"     DNA, RNA, and protein: The building blocks of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are linear, polymerized strands of linked nucleotides (",
"    <a class=\"graphic graphic_figure graphicRef62789 \" href=\"UTD.htm?40/35/41520\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60245 \" href=\"UTD.htm?14/24/14724\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56556 \" href=\"UTD.htm?13/44/14017\">",
"     figure 3",
"    </a>",
"    ). A nucleotide is a nucleoside, or a combination of a sugar (ribose or deoxyribose) and a base, that is linked to a phosphate group. RNA differs from DNA in that the hydrogen at the 2&rsquo; position in DNA is replaced by a less stable hydroxyl group in RNA. There are four DNA bases: adenine (A), cytosine (C), guanine (G), and thymidine (T). In RNA, thymidine is replaced by uracil (U). DNA or RNA polymers are formed by the linking of the 5&rsquo; phosphate of one nucleotide to the 3&rsquo; hydroxyl group of another.",
"   </p>",
"   <p>",
"    Proteins are composed of one (or more) linear peptide sequences. Like nucleic acids, this sequence is also modular, consisting of linked amino acids. Amino acids consist of an amino and carboxyl group linked to one another by a central carbon (",
"    <a class=\"graphic graphic_figure graphicRef78753 \" href=\"UTD.htm?1/29/1496\">",
"     figure 4",
"    </a>",
"    ). In humans, there are 20 different types of amino acids, distinguishable from one another by specific side chains also linked to the central carbon. The linear polypeptide chain is formed by fusion of the amino-group of one amino acid to another&rsquo;s carboxyl-group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497103\">",
"    <span class=\"h2\">",
"     Organization of the human genome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human genome&mdash;the complete DNA sequence&mdash;consists of approximately 3 billion (3x10",
"    <sup>",
"     9",
"    </sup>",
"    ) base pairs of DNA organized as 23 chromosomes (",
"    <a class=\"graphic graphic_figure graphicRef55530 \" href=\"UTD.htm?26/55/27518\">",
"     figure 5",
"    </a>",
"    ). Humans are diploid (2n), meaning that somatic cells normally contain two sets of 23 chromosomes (46 chromosomes total), each set derived from one parent. Germ cells (egg and sperm) are haploid (n) (ie, contain 23 chromosomes). Each haploid genome consists of 22 autosomes (numbered 1 to 22) and one sex chromosome (either an X or Y). The Y chromosome contains the",
"    <em>",
"     SRY",
"    </em>",
"    gene that initiates the development of male genitalia and the production of anti-M&uuml;llerian hormone to suppress the formation of female gonads. As such, individuals who have an XY chromosome complement and an intact",
"    <em>",
"     SRY",
"    </em>",
"    gene are phenotypically male, and those who are XX are phenotypically female.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101353333\">",
"    <span class=\"h3\">",
"     Alleles, genotypes, and haplotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different DNA sequences at a gene or locus are called alleles. An individual&rsquo;s genotype refers to the combination of allele(s) or nucleotide(s) at a locus in an individual. If a person has two copies of the same allele at a particular locus, that person is said to be homozygous. If the two alleles differ, the person is said to be heterozygous. The term haplotype refers to the combination of alleles in a region of DNA sequence, usually across multiple loci (",
"    <a class=\"graphic graphic_figure graphicRef60253 \" href=\"UTD.htm?11/53/12125\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183956\">",
"    <span class=\"h3\">",
"     Identifying loci on chromosomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several ways to describe the physical position of a gene on a chromosome. Prior to the availability of the complete human genome sequence, the location of a gene (a locus) was described with reference to cytogenetic bands. With the exception of chromosome 22 and the X and Y chromosome, chromosomes are numbered in order of decreasing length (ie, chromosome 1 is the longest chromosome, followed by chromosome 2, etc.). Chromosome 21 is the smallest, approximately 3 million bases shorter than chromosome 22.",
"   </p>",
"   <p>",
"    Within a chromosome, physical position is specified by the chromosome arm and in relation to specific banding patterns observed on the chromosome with Giemsa staining (also known as G-banding). The centromere, visualized as a constriction between the short and long arms of a chromosome, is a distinct structural element necessary for chromosomal alignment and segregation during cell division. The centromere divides the chromosome into two arms: the short arm, &ldquo;p&rdquo; (from the French &ldquo;petite&rdquo;&mdash;small), and the long arm &ldquo;q&rdquo; (the letter following &ldquo;p&rdquo;). Giemsa staining results in distinct banding patterns for each chromosome arm, enabling division and subdivision of each chromosome arm into numbered segments. As such, gene positions can be described with reference to the chromosome number, arm, region, band, sub-band, and secondary sub-bands. For example, the beta-globin gene (",
"    <em>",
"     HBB",
"    </em>",
"    ) resides on a chromosome 11q15.4 (read &ldquo;eleven &ndash; Q &ndash; one five point four,&rdquo; not &ldquo;15 point four&rdquo;).",
"   </p>",
"   <p>",
"    With high-resolution karyotyping, chromosomes can be subdivided into hundreds of sub-bands, with an average length of approximately 3.5 million base pairs. This level of resolution is sufficient only for characterizing large structural chromosomal abnormalities, such as chromosome translocations and inversions or large copy number variants. High-resolution karyotyping is still used routinely in cytogenetic investigation. (See",
"    <a class=\"local\" href=\"#H1031916\">",
"     'Copy number variation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Greater precision is needed for smaller genetic variants, including small copy number variants and single base pair changes. With the availability of data from completely sequenced genomes, researchers now refer to chromosomal position at the resolution of a single base pair. For example, the specific location of the beta-globin gene is chromosome 11, base pairs 5,246,696 to 5,248,301 (based on the most recently updated Genome Reference Consortium sequence build from February 2009&mdash;GRCh37) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/3\">",
"     3",
"    </a>",
"    ]. It is important to note that, although the relative position of most DNA sequences is stable, due to ongoing additions and editing of the genome, absolute base pair numbering is not static, and varies from one sequence build to the next. It is therefore critical to note the build number when using absolute base numbering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183970\">",
"    <span class=\"h3\">",
"     Mitochondrial genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondria harbor a distinct genome consisting of 16,589 base pairs. The mitochondrial genome encodes 37 genes, including 13 proteins. Mitochondria are transmitted only in the egg, and as such, all mitochondrial DNA is maternally inherited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183977\">",
"    <span class=\"h3\">",
"     Coding and noncoding genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 3 percent of human DNA sequence encodes for genes and thereby serves as functional DNA sequences that can be expressed through the process of transcription and translation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link\">",
"     \"Principles of molecular genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two types of genes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coding genes: DNA sequences that encode messenger RNA (mRNA) that is subsequently translated into protein.",
"     </li>",
"     <li>",
"      Noncoding genes: DNA sequences that code for RNA with intrinsic functional properties that do not require translation to protein. Examples include small nucleolar RNAs (snRNAs) and microRNAs (miRNAs).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are approximately 27,000 genes that encode proteins. The DNA sequence of these genes consists of exons and introns (",
"    <a class=\"graphic graphic_figure graphicRef67310 \" href=\"UTD.htm?16/42/17058\">",
"     figure 7",
"    </a>",
"    ). The exons represent the portion of the gene that codes for amino acids, and the introns represent the intervening sequence between the exons. The intronic sequence does not contribute to protein specification and is spliced out during transcription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497110\">",
"    <span class=\"h2\">",
"     Gene transcription",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of gene activation (expression) is initiated by the binding of specific initiating factors (proteins) called transcription factors and enhancers to specific DNA sequences flanking the target gene of interest.",
"   </p>",
"   <p>",
"    Typically, the most important of these DNA binding sites (promoter region) are situated a few hundred base pairs upstream of the gene. Once the transcription factors bind, they recruit an RNA polymerase, the enzyme that synthesizes the protein-coding messenger RNA. &nbsp;",
"   </p>",
"   <p>",
"    DNA is double stranded, formed by the pairing of complementary bases across strands. The base pairing is strict: adenine pairs with thymidine, guanine with cytosine. For a given gene, only one of the two strands (called the sense strand) has the correct DNA code for protein synthesis. The other strand, called the anti-sense strand, serves as the template for making the desired RNA sequence. RNA polymerase &ldquo;reads&rdquo; the anti-sense DNA sequence in a 3' to 5' orientation, synthesizing its complementary RNA sequence in a 5' to 3' direction with the same base sequence as the desired sense strand, except that uracil (U) is substituted for thymidine (T) in RNA.",
"   </p>",
"   <p>",
"    Transcription, the process of synthesizing RNA from a DNA template, results in the synthesis of a linear pre-messenger RNA chain (pre-mRNA) consisting of both exons and introns (",
"    <a class=\"graphic graphic_figure graphicRef67310 \" href=\"UTD.htm?16/42/17058\">",
"     figure 7",
"    </a>",
"    ). Following strand synthesis, introns are excised from the primary RNA transcript and the ends of the exons are fused together through a process called splicing. Additional modifications to the RNA strand include the addition of a Gm-cap at the 5&rsquo; end and a chain of adenines (polyadenylation) at the 3&rsquo; end. These modifications provide stability to the messenger RNA (mRNA) and facilitate transport of this mature mRNA from the nucleus to the endoplasmic reticulum (ER) for protein synthesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link&amp;anchor=H8#H8\">",
"     \"Principles of molecular genetics\", section on 'Post-transcription modification of mRNA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497117\">",
"    <span class=\"h2\">",
"     Protein synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once transported to the endoplasmic reticulum, the mature mRNA transcript serves as the template for protein synthesis (ie, translation) (",
"    <a class=\"graphic graphic_figure graphicRef59052 \" href=\"UTD.htm?14/48/15109\">",
"     figure 8",
"    </a>",
"    ). Every amino acid is coded for by three consecutive bases, termed a codon. With four RNA bases (A, G, C, or U) and three base-positions in each codon, there are 64 possible codons (",
"    <a class=\"graphic graphic_figure graphicRef57764 \" href=\"UTD.htm?25/46/26350\">",
"     figure 9",
"    </a>",
"    ). There are 20 amino acids, so there is more than one codon for most of the amino acids. In addition, there are three stop codons: UAA, UGA, and UAG.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Translation is initiated by the binding of ribosomal proteins to the 5&rsquo; end of mRNA. The ribosomal protein structure contains two pockets, each containing a three-nucleotide sequence. Upon binding, the leading pocket exposes an initiation codon (AUG), to which binds a methionine-specific transfer RNA. The ribosomal unit advances three bases, exposing the next 3-base pair codon. A corresponding transfer RNA (complementary to the exposed codon) binds, approximating the corresponding amino acid to the leading methionine and catalyzing their fusion. This process of elongation continues the length of the mRNA reading frame. Translation is terminated once a stop codon (UAA, UGA, and UAG) is encountered, resulting in chain termination. The synthesized polypeptide then undergoes modification (for example, cleavage, glycosylation, or phosphorylation) and transport to its needed cellular or extracellular location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497124\">",
"    <span class=\"h1\">",
"     GENETIC VARIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human genome encodes all of the organelles necessary for normal cellular function. Variation of the DNA sequence can therefore impact the normal functioning of cells and organs and contributes to the inter-individual variability for a wide range of physical characteristics.",
"   </p>",
"   <p>",
"    There are three broad categories of genetic variation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DNA sequence variation",
"     </li>",
"     <li>",
"      Structural (cytogenetic) variation",
"     </li>",
"     <li>",
"      Epigenetic variation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497131\">",
"    <span class=\"h2\">",
"     DNA sequence variation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497140\">",
"    <span class=\"h3\">",
"     Single nucleotide polymorphisms (SNPs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common form of DNA variation is a single base substitution, or the replacement of one base (ie, A, C, G, or T) for another base in the DNA sequence. A single nucleotide polymorphism (SNP) is the term used to describe such substitutions when they occur relatively frequently in the population and are not associated with a Mendelian disorder. On average, SNPs are observed every 200 to 300 base pairs. Single nucleotide substitutions that are seen less frequently and that are associated with disease are called missense mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497147\">",
"    <span class=\"h4\">",
"     Nonsense mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substitution that changes a codon for an amino acid to a stop codon, leading to premature termination of translation of the mRNA transcript and a truncated protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497154\">",
"    <span class=\"h4\">",
"     Missense mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substitution that changes the codon for one amino acid to the codon for another amino acid. The size of the mRNA and protein are not changed, but the composition and possibly the function of the protein does change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497161\">",
"    <span class=\"h4\">",
"     Splice site mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substitution in one of the base pairs inside or flanking the intron-exon boundaries that alters normal pre-mRNA splicing. Such mutations can result in intron retention (either partial or complete) or exon skipping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497168\">",
"    <span class=\"h4\">",
"     Silent mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A change in one base that results in no change in the amino acid sequence of the protein, due to the redundancy of the genetic code (there is more than one codon for most amino acids) (",
"    <a class=\"graphic graphic_figure graphicRef57764 \" href=\"UTD.htm?25/46/26350\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497175\">",
"    <span class=\"h4\">",
"     Regulatory polymorphism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substitution that alters binding affinities of transcript-related proteins, such as transcription factors, enhancers, silencers, or insulators. Such changes result in altered rates of transcription. Though protein structure is not altered by such noncoding variants, the level of transcript production can result in altered protein production, and in turn confer phenotypic variation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, a common SNP residing on chromosome 17q21 within intronic sequence of the gene",
"      <em>",
"       ZPBP2",
"      </em>",
"      (MIM# 608499), results in altered binding of a CCCTC-binding factor (CTCF) insulator protein that regulates the transcription of four genes:",
"      <em>",
"       IKZF3",
"      </em>",
"      (MIM# 606221),",
"      <em>",
"       ZPBP2",
"      </em>",
"      ,",
"      <em>",
"       GSDMB",
"      </em>",
"      (MIM# 611221), and",
"      <em>",
"       ORMDL3",
"      </em>",
"      (MIM# 610075). These four genes demonstrate different levels of gene expression that correlate with SNP genotype [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/4\">",
"       4",
"      </a>",
"      ]. This SNP, and others residing on a shared haplotype have been strongly associated with asthma susceptibility in numerous populations of diverse ancestry [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497182\">",
"    <span class=\"h2\">",
"     Indels: Insertions and deletions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insertions or deletions of one or more nucleotides represent the second most abundant form of sequence variation. When situated within the coding sequence of a gene, these variants can result in significant alterations in protein sequence. They commonly result in a shift in the open reading frame (so-called frameshift mutations) and subsequent synthesis of an incorrect protein sequence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, a single base pair insertion of a cytosine (C) at nucleotide position 3020 of the",
"      <em>",
"       NOD2",
"      </em>",
"      gene (MIM# 605956) results in a frameshift and subsequent protein truncation immediately downstream of the insertion site. This variant, with a frequency of 4 percent of Caucasians, confers increased susceptibility to inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though the vast majority of indels consist of 1 to 2 bases, larger indels have been described, including a 32-base pair deletion of the chemokine receptor 5 (",
"    <em>",
"     CCR5",
"    </em>",
"    ) gene.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals carrying two copies of this 32-base pair deletion in the",
"      <em>",
"       CCR5",
"      </em>",
"      gene (ie, homozygotes) are relatively protected from the development of persistent HIV infection. Heterozygotes, although not protected from HIV infection, exhibit delayed immunodeficiency and disease progression due to a reduced rate of intracellular viral spread [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insertions (or deletions) of multiples of three bases result in insertions (or deletions) of additional amino acids but do not shift the reading frame, and therefore downstream sequences remain intact.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The best known example of a deletion with an intact reading frame is the delta F508",
"      <span class=\"nowrap\">",
"       (&Delta;F508)",
"      </span>",
"      mutation of the cystic fibrosis transmembrane conductance regulator (",
"      <em>",
"       CFTR",
"      </em>",
"      ) gene. This mutation results in a 3-base pair deletion of amino acid 508, in this case a phenylalanine (symbolized with an &lsquo;F&rsquo;) residue, of the CTFR protein. This deletion is the commonest mutation among patients with cystic fibrosis and does not alter the function of the residual protein, but interferes with intracellular transport of the CFTR protein to the epithelial cell surface.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497189\">",
"    <span class=\"h2\">",
"     Triplet-repeat expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are regions in the genome in which a short, tandemly-repeated sequence of DNA, usually two to four bases in length, can expand from a normal repeat size (eg, 20 to 30 repeats, although the normal number is often disease specific) to more than 100 or even 1000 repeats. The expansion occurs due to an error in DNA replication called slip-mispairing. When the repeated sequence is three base pairs in length, these disorders are often given the name of &ldquo;triplet&rdquo; or &ldquo;trinucleotide&rdquo; repeat diseases. Myotonic dystrophy and Huntington's disease are disorders caused by expansion of such triplet repeat sequences. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=see_link\">",
"     \"Myotonic dystrophy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Triplet repeat diseases are notorious for showing anticipation, defined as (1) earlier onset of disease manifestations in successive generations of affected individuals",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    (2) more severe disease phenotypes in successive generations of affected individuals. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497196\">",
"    <span class=\"h2\">",
"     Structural genetic variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural genetic variants are those that affect large segments of DNA (ie, &gt;1000 bases) or whole chromosomes, commonly affecting the function of multiple genes and having pronounced phenotypic effects. This class includes copy number variation, translocations, inversions, and rearrangements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1031916\">",
"    <span class=\"h3\">",
"     Copy number variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Copy number variants (CNVs), the most prevalent type of structural variation, are DNA segments spanning thousands to millions of bases whose copy number varies between different individuals in comparison to the reference genome, with the result being that individuals may have one, two, or three copies of a particular chromosome region. CNVs are quite common. Many CNVs do not produce pathologic or disease phenotypes but facilitate normal population variation. However, larger CNVs are often de novo and are increasingly associated with human disease. Specific pathogenic CNVs have been implicated in the cause of intellectual disability, autism, and schizophrenia, although these same CNVs can also be present in healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An extensive discussion of CNVs is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=see_link&amp;anchor=H16722199#H16722199\">",
"     \"Genomic disorders: An overview\", section on 'Copy number variations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497203\">",
"    <span class=\"h3\">",
"     Chromosome translocations and inversions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chromosome translocation occurs when there is an exchange of genetic material between two non-homologous chromosomes. A chromosome inversion occurs when a chromosome breaks in two places, inverts itself, and then reinserts itself.",
"    <strong>",
"    </strong>",
"    Inversions can be either pericentric (the breaks occur on different chromosome arms that are separated by a centromere) or paracentric (the breaks occur on the same chromosome arm). If a chromosome break occurs in the middle of a gene, the gene may be disrupted or a new fusion gene may result. Often these fusion genes are oncogenes. Alternatively, structural chromosome rearrangements can affect gene regulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=see_link\">",
"     \"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497210\">",
"    <span class=\"h2\">",
"     Epigenetic variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epigenetic variation refers to modifications of DNA or chromatin (the DNA-packaging proteins) that do not directly alter the DNA sequence. These forms of variation can have dramatic effects on protein expression.",
"   </p>",
"   <p>",
"    Examples of epigenetic variation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CpG methylation, where methyl groups are added to the cytosines in CG-rich DNA sequences surrounding genes (so-called &ldquo;CpG islands&rdquo;). Methylation of CpG islands in promoter regions of genes can result in silencing of gene expression. In female carriers of an",
"      <em>",
"       FMR1",
"      </em>",
"      (Fragile X mental retardation) gene expansion, methylation of the normal gene can lead to manifestations of Fragile X syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12713?source=see_link&amp;anchor=H23#H23\">",
"       \"Primary care of the adult with intellectual disability (mental retardation)\", section on 'Fragile X syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Histone modifications (acetylation or deacetylation) of histone proteins, the DNA packaging proteins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most epigenetic modification is either programmed in the gametes prior to fertilization, or is acquired over one&rsquo;s lifetime. In utero and environmental exposures can produce epigenetic change. As such, epigenetic modification represents one mechanism linking genetic and environmental disease risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497224\">",
"    <span class=\"h1\">",
"     MEIOSIS: GAMETE FORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meiosis is the process of cell division that leads to the formation of haploid gametes (ova and sperm). This process is distinguished from mitosis, the process of somatic cell division that aims to produce two diploid daughter cells with identical genomes to that of the parental cell. In contrast, the goal of meiosis is to generate four haploid cells of distinct and varied genetic content. These haploid cells can then participate in fertilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=see_link&amp;anchor=H6#H6\">",
"     \"Principles of molecular genetics\", section on 'Meiosis and sustained genetic diversity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The process of meiosis involves the following unique attributes (",
"    <a class=\"graphic graphic_figure graphicRef61539 \" href=\"UTD.htm?38/34/39460\">",
"     figure 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef52419 \" href=\"UTD.htm?20/35/21040\">",
"     figure 11",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two sets of cell division occur, resulting in four haploid cells.",
"     </li>",
"     <li>",
"      Recombination: A mandatory exchange of chromosomal information occurs between homologous chromosome pairs (maternal and paternal chromosomes). This recombination results in swapping of homologous chromosomal segments and the creation of novel haplotypes that are a chimera of genetic information from both previous parental chromosomes (",
"      <a class=\"graphic graphic_figure graphicRef59656 \" href=\"UTD.htm?6/11/6323\">",
"       figure 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Independent assortment: Chromosomes segregate independently from each other during both sets of cell division, yielding four haploid genomes that each contain a mix of the previous maternal and paternal genomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combined processes of recombination and independent assortment assure that each gamete contains a unique haploid genome, different from that of the organism in which they are formed, and different from those of the organism's parents. These mechanisms are the primary forces of increasing genetic diversity during reproduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497231\">",
"    <span class=\"h1\">",
"     MODES OF INHERITANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inheritance patterns describe the manner in which a trait is expressed in an individual and family, as determined by the phenotypes and genotypes of the individual and family members. Broadly, inheritance patterns are described as either Mendelian or non-Mendelian. For the most part, single gene (monogenic) genetic disorders exhibit Mendelian patterns of inheritance, where there is a very tight correlation (often 1:1) between the presence of the disease genotype and the trait or disease of interest. In these situations, knowledge of an individual&rsquo;s genotype status can predict the development of disease. Thus, the clinical utility of such information is usually very high, and many molecular genetic diagnostic tests, in which different disease genes are sequenced for mutations, have been developed accordingly for clinical use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The tight correlation between genotype and phenotype in monogenic disease occurs because the types of mutations causing such disease usually confer significant functional consequences to the target gene, resulting in overt cellular or organ dysfunction. Because these types of mutations are severe, they are often infrequent, and the diseases that they cause are correspondingly rare",
"   </p>",
"   <p>",
"    In contrast, many &ldquo;common&rdquo; diseases, such as hypertension or diabetes, are typically caused by the cumulative and interactive effects of genetic variation in more than one gene (often dozens). Moreover, the risk of developing more common disease is influenced not only by genetics, but by developmental, environmental, and social factors. In these disorders, a 1:1 correlation between risk genotype and disease is never observed, and each risk variant contributes only a fraction of the total genetic risk for disease. As a result, the clinical utility of such information is much lower than for monogenic disease. Though several clinical applications have been developed for common genetic variants (largely in the field of pharmacogenetics), validated predictive panels are currently not available for most common diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101353539\">",
"    <span class=\"h2\">",
"     Mendelian inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monogenic or Mendelian disorders (genetic disorders caused by mutations in only one gene) are relatively rare and are often first recognized clinically by their predictable patterns of inheritance in families. These patterns were first observed in plants by the Augustinian monk and botanist Gregor Mendel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=see_link\">",
"     \"Overview of Mendelian inheritance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497239\">",
"    <span class=\"h3\">",
"     Autosomal dominant",
"    </span>",
"    &nbsp;&mdash;&nbsp;In autosomal dominant disorders, a single mutation in one copy of a gene on an autosomal chromosome (chromosomes 1 to 22, not X or Y) causes disease. Affected individuals are therefore usually heterozygous for a disease mutation. Males and females are both affected in an equal ratio in large pedigrees or population studies of autosomal dominant disorders. In each pregnancy, there is a 50 percent risk that an affected parent will pass a mutated allele to the child. Thus, if one parent is affected (the usual situation), on average 50 percent of the parent's offspring will be heterozygous (and affected) for the mutation and 50 percent will be normal (",
"    <a class=\"graphic graphic_figure graphicRef63306 \" href=\"UTD.htm?4/23/4479\">",
"     figure 13",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497246\">",
"    <span class=\"h3\">",
"     Autosomal recessive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal recessive disorders require the presence of a mutation on both alleles of a gene on an autosome, either as two compound heterozygous mutations (two different mutations affecting the same gene) or one homozygous mutation (the same mutation on both alleles of a gene). Both males and females are equally likely to be affected. Carriers of autosomal recessive mutations have one allele with a mutation and one normal allele, and are usually unaffected.",
"   </p>",
"   <p>",
"    If parents of an affected individual are heterozygous carriers of a mutation, there is a 25 percent chance that an offspring of each pregnancy will inherit both mutations, and therefore be affected; a 50 percent chance that the offspring will inherit one mutation and one normal allele, and be a carrier; and a 25 percent chance that an offspring will have two normal alleles. Thus, on average, 25 percent of the couple's children will be affected, and 75 percent will be unaffected. Two-thirds of unaffected offspring will be heterozygous carriers and one-third homozygous noncarriers (",
"    <a class=\"graphic graphic_figure graphicRef50124 \" href=\"UTD.htm?10/10/10415\">",
"     figure 14",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497253\">",
"    <span class=\"h3\">",
"     Sex-linked",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex-linked inheritance describes traits that are passed on either the X or Y chromosome. X-linked recessive inheritance is most common, and there are traits with both X-linked dominant and X-linked recessive inheritance.",
"   </p>",
"   <p>",
"    X-linked recessive disorders are recognized by being more prevalent in males, since males carry only one X chromosome and are reliant on normal functioning of the genes carried on that chromosome. Inherited mutations will thus manifest in males. Females, however, would only manifest the phenotype if they were homozygous for the gene (which would only occur in the rare event that both the father and mother are carriers) (",
"    <a class=\"graphic graphic_figure graphicRef55180 \" href=\"UTD.htm?6/8/6287\">",
"     figure 15",
"    </a>",
"    ) or through skewed X-inactivation. Two examples of X-linked recessive diseases are Hemophilia VIII and IX.",
"   </p>",
"   <p>",
"    X-linked dominant traits occur in both sexes, but are typically more severe among males due to the absence of a normal X chromosome (",
"    <a class=\"graphic graphic_figure graphicRef75137 \" href=\"UTD.htm?41/12/42190\">",
"     figure 16",
"    </a>",
"    ). There are few examples of Y-linked inheritance. Although male sexual dysfunction has been linked to mutations on the Y chromosome, there are no confirmed examples of other types of Y-linked diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497260\">",
"    <span class=\"h2\">",
"     Situations affecting Mendelian inheritance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several reasons why Mendelian disorders may not be physically apparent even if an individual has a mutation(s) in a known disease-causing gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497267\">",
"    <span class=\"h3\">",
"     Penetrance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The penetrance of a disease is defined as the proportion of persons carrying a pathogenic mutation who will manifest the disease, or the probability that a pathogenic mutation will result in disease. Mutations have complete penetrance when all individuals who have that mutation are affected. Complete penetrance is rare, but Huntington disease is one example (",
"    <a class=\"graphic graphic_figure graphicRef79882 \" href=\"UTD.htm?29/22/30061\">",
"     figure 17",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduced penetrance can be caused by a variety of modifying factors, including age and gender.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497274\">",
"    <span class=\"h4\">",
"     Age-related penetrance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of disease is often age-dependent, with a higher prevalence of disease as one becomes older. For example, the neoplastic complications of",
"    <em>",
"     MEN1",
"    </em>",
"    mutations are more prevalent in older subjects. In one study, the age-related penetrance of",
"    <em>",
"     MEN1",
"    </em>",
"    was 7 percent by age 10 years and nearly 100 percent by age 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Definition and genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497281\">",
"    <span class=\"h4\">",
"     Sex-influenced and sex-limited expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some autosomal dominant disorders, phenotypic manifestation differs between males and females; this is termed sex-influenced expression. A disease expressed in only one sex is said to have sex-limited expression (for example, male-pattern baldness). If a disease is expressed only in males, the presence of male-to-male transmission rules out the possibility of X-linked recessive inheritance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497288\">",
"    <span class=\"h3\">",
"     Mosaicism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mosaicism",
"    <strong>",
"    </strong>",
"    refers to heterogenous expression of a disease at the cellular or tissue level, resulting from cell-specific differences in the expression of a mutation or the presence of a chromosome aberration. This occurs when two or more distinct genotypes or chromosome complements exist in different cell populations. Mosaicism can result from an error in mitosis after fertilization and the initiation of development (termed postzygotic mosaicism). As a consequence, the affected individual is mosaic, with some cells carrying the mutation, while others do not.",
"   </p>",
"   <p>",
"    Germline or gonadal mosaicism refers to the finding of normal and abnormal cells with a mutation or chromosome aberration in the eggs or sperm prior to fertilization. Germline mosaicism is important in some autosomal dominant disorders, in which recurrence risks for a further affected child should take the possibility of germline mosaicism in a parent into account, even if both parents appear to be healthy.",
"   </p>",
"   <p>",
"    As an example, a mutation occurring at the eight-cell stage would (theoretically) lead to one of eight cells in the body carrying the mutation. The expression of disease phenotype will then depend on which cell types harbor the pathogenic mutation. X-linked diseases can manifest mosaicism due to cell-specific inactivation of one X chromosome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497295\">",
"    <span class=\"h3\">",
"     Anticipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of some diseases increases as the disease is passed on through generations. This is termed anticipation and is most commonly associated with expanded triplet-repeat mutations. (See",
"    <a class=\"local\" href=\"#H1497189\">",
"     'Triplet-repeat expansion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The repeated sequence expands in successive generations, leading to a more abnormal phenotype. Examples of diseases frequently exhibiting anticipation include myotonic dystrophy (especially when the expanded allele is passed on from an affected mother) and Huntington's disease (especially when the expanded allele is passed on from an affected father).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497302\">",
"    <span class=\"h3\">",
"     Imprinting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imprinting is the differential expression of genetic material depending on whether it was inherited from the male or female parent. If a gene is maternally imprinted, the maternally-derived allele is inactive and only the paternal allele is expressed. If, on the other hand, a gene is paternally imprinted, only the maternal allele is expressed. For imprinted genes, the sex of the parent transmitting the disorder is important, not the sex of the affected offspring (",
"    <a class=\"graphic graphic_figure graphicRef54712 \" href=\"UTD.htm?28/36/29248\">",
"     figure 18",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497309\">",
"    <span class=\"h1\">",
"     THE ROLE OF GENETIC TESTING IN MODERN CLINICAL MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a brief description of the various forms of genetic testing used in clinical practice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497316\">",
"    <span class=\"h2\">",
"     Perinatal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal screening can serve three main purposes (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=see_link\">",
"     \"Basic principles of genetic counseling for the obstetrical provider\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preimplantation testing, also known as preimplantation genetic diagnosis (PGD) &mdash; Screening of embryos to identify and select out mutations or chromosomal abnormalities prior to in-utero implantation, to avoid decisions regarding pregnancy termination if testing is performed later in pregnancy. PGD requires in-vitro fertilization (IVF) and the availability of an appropriate testing laboratory.",
"     </li>",
"     <li>",
"      Prenatal testing &mdash; Testing of fetal cells for chromosome aberrations and fetal DNA obtained from the fetal cells for chromosome aberrations and mutations. Prenatal testing is typically offered to women at high risk (eg, advanced maternal age, abnormal fetal ultrasound examination or screening serological tests, family history of a genetic condition in which the chromosome aberration or mutation has previously been determined). The most common prenatal diagnostic test procedures are amniocentesis and chorionic villus sampling.",
"     </li>",
"     <li>",
"      Newborn screening &mdash; Routine testing for panels of common monogenic disorders in all newborns, depending on the frequency of the disorder and the availability of an appropriate intervention. Newborn screening enables early identification of affected children and thus facilitates early intervention and treatment.",
"     </li>",
"     <li>",
"      Fetal DNA can also be present in the maternal bloodstream during a pregnancy and can be tested for chromosome disorders, such as trisomy 21 or disease-causing mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497323\">",
"    <span class=\"h2\">",
"     Carrier testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carrier testing is used to identify asymptomatic individuals who are heterozygous (ie, carry one copy of an altered gene) for a mutation that can cause a genetic disorder in homozygotes (individuals who carry two copies of a mutated or altered gene). Carrier testing is also used to screen at-risk subjects who are relatives of individuals affected by autosomal recessive conditions. Presymptomatic genetic testing is similar to carrier screening, but involves testing an at-risk individual before the onset of symptoms or signs of a disease. Presymptomatic testing can involve screening for autosomal dominant conditions, such as",
"    <em>",
"     BRCA1",
"    </em>",
"    testing in the children of confirmed a",
"    <em>",
"     BRCA1",
"    </em>",
"    -affected parent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testing for disease alleles can be performed in families with a family history for a specific genetic condition (for example, mutation screening of the",
"    <em>",
"     APC",
"    </em>",
"    gene in families with Familial Adenomatous Polyposis). Alternatively, carrier testing or screening can target a particular ethnic group or population in which mutations are present at a relatively high frequency (eg, Tay Sachs screening among Ashkenazi Jews). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=see_link\">",
"     \"Prenatal screening for genetic disease in the Ashkenazi Jewish population\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For many highly-penetrant genes, carrier testing of asymptomatic relatives of affected individuals can have important benefits, not only for identified carriers, but also for noncarriers. For example, Familial Adenomatous Polyposis is an autosomal dominant syndrome caused by mutations in the",
"    <em>",
"     APC",
"    </em>",
"    gene and is characterized by the development of hundreds of adenomatous polyps in the large intestine. A proportion of these polyps undergo malignant transformation. Detection and removal of polyps at their earliest stages, prior to malignant transformation, requires regular endoscopic surveillance beginning in adolescence. Mutation screening may indicate the need for early and more frequent colonoscopy in those individuals found to carry the disease-causing mutation, while those who are found to be noncarriers can be reassured that their risk for polyp development is not higher than the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497330\">",
"    <span class=\"h2\">",
"     Diagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic gene testing is used to confirm a specific diagnosis in symptomatic patients. The diagnostic utility of genetic testing (for example, the sensitivity of testing) varies based on the mutational spectrum of the disease and the type of testing performed.",
"   </p>",
"   <p>",
"    As an example, current diagnostic panels for cystic fibrosis mutations include only a fraction of the more than 1600 confirmed CFTR mutations. Therefore, although these panels typically include the most commonly-observed mutations (ie, those found in ~95 percent of individuals), the inability to confirm two pathogenic mutations does not necessarily exclude the diagnosis, which should be based primarily on the combination of clinical presentation and a positive sweat chloride test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H22#H22\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Molecular diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role for diagnostic testing in the management of monogenic disease is well established for many conditions. In contrast, the utility of genotyping for common variants associated with polygenic traits remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497337\">",
"    <span class=\"h2\">",
"     Pharmacogenetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacogenetics is the study of variability in drug response due to genetic factors or genotype. Application of pharmacogenetics can detect genetic variants that may help guide therapeutic decisions, including drug dosing (for example,",
"    <em>",
"     VKORC1",
"    </em>",
"    haplotyping and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/11\">",
"     11",
"    </a>",
"    ]); likelihood of response to therapy (",
"    <em>",
"     KRAS",
"    </em>",
"    testing and treatment of colorectal cancer); or the identification of patients at high risk of &ldquo;idiosyncratic&rdquo; reactions, such as HLA-class I alleles and the development of carbamazepine-induced Stevens Johnson Syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link\">",
"     \"Overview of pharmacogenomics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H14#H14\">",
"     \"Therapeutic use of warfarin\", section on 'Pharmacokinetic and pharmacogenetic dosing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=see_link&amp;anchor=H32#H32\">",
"     \"Pathology and prognostic determinants of colorectal cancer\", section on 'K-ras and benefit from EGFR-targeted treatments'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link&amp;anchor=H20#H20\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1497344\">",
"    <span class=\"h2\">",
"     The future of genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of genetic testing in clinical medicine is continuously expanding. Most current clinical assays test for one, or several, individual risk variants, and clinicians order specific diagnostic panels to evaluate risk for distinct genetic disorders.",
"   </p>",
"   <p>",
"    The advent of single nucleotide polymorphism (SNP) microarray technologies enables simultaneous genotyping of more than one million SNPs; similarly, array comparative genomic hybridization (array CGH) simultaneously screens the whole genome for copy number variants and chromosome aberrations. Next-generation sequencing (NGS) technologies provide complete exome or whole genome sequencing data [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/13\">",
"     13",
"    </a>",
"    ]. These new technologies are expected to transform the way genetic information is gathered and integrated into clinical practice, as these technologies generate more genetic data than previous methods and enable genome-wide screening and the detection of multiple disorders with one test. Because an individual&rsquo;s genomic sequence remains largely invariant over one&rsquo;s lifetime, it is possible that such genome-wide data will be routinely generated in early childhood, providing data that can be used across clinical disciplines, at different stages of life.",
"   </p>",
"   <p>",
"    NGS technologies are just starting to be integrated into clinical medicine, and exome sequencing is currently available in several clinical laboratories in the USA. However, there are questions related to data interpretation (particularly for complex, multi-genic traits), ethical concerns regarding which results should be released to patients, and issues regarding data storage, transmission, and retrieval. As an example, if a complete DNA sequence is generated during childhood, should that data reside with that individual&rsquo;s pediatrician (who would be most concerned with conditions of early onset, but not those of later onset for which childhood interventions are not effective or needed), with the patient, or some independent body? Although some aspects of NGS are currently controversial, exome sequencing is likely to prove diagnostically powerful for disease identification.",
"   </p>",
"   <p>",
"    Direct-To-Consumer (DTC) marketing of genetic testing, offered currently by several private companies, has prompted an accelerated discussion of bioethical issues and has raised a range of questions regarding the oversight of genetic testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Should DTC tests in the United States be regulated by the Food and Drug Administration (FDA), as are other diagnostic assays?",
"     </li>",
"     <li>",
"      Even if FDA oversight is mandated, by what criteria should such tests be judged?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The accuracy of identifying mutations or SNPs is one concern, and the accuracy of using the resulting information to predict risk is another of equal or possibly greater interest. A head-to-head comparison of results from two direct-to-consumer companies in the US regarding 13 diseases for five individuals found strong agreement in genotyping (99.7 percent), but the predicted disease risk for the 13 diseases disagreed in 36 percent",
"    <span class=\"nowrap\">",
"     (21/58",
"    </span>",
"    comparisons) of cases. For 7 of the 13 diseases (including risk prediction for systemic lupus erythematosus, heart disease, Crohn&rsquo;s disease, and type 2 diabetes), the predictions conflicted in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21097/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101353982\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The DNA molecule, a polymer with four different nucleotides or bases linked on a sugar-phosphate backbone, supplies genetic information through the sequence of nucleotides. A corresponding molecule, RNA, which is synthesized from the DNA template, determines the sequence of amino acids in a protein through the process of translation, whereby specific groups of three nucleotides (codons) correspond to one of 20 amino acids. (See",
"      <a class=\"local\" href=\"#H1497096\">",
"       'DNA, RNA, and protein: The building blocks of life'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Human genetic information primarily is contained within chromosomal genes, inherited from both parents, but is also present in mitochondria inherited from the maternal line. Alleles are differing sequences of a given gene. Variations in the DNA sequence of a gene may be silent (synonymous sequence alterations) or may affect protein structure or synthesis (non-synonymous sequence alterations or mutations). (See",
"      <a class=\"local\" href=\"#H1497103\">",
"       'Organization of the human genome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1497124\">",
"       'Genetic variation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Meiosis, the process of gamete production, results in recombination of alleles from the parental chromosomes and genetic diversity among offspring. (See",
"      <a class=\"local\" href=\"#H1497224\">",
"       'Meiosis: Gamete formation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic Mendelian patterns of inheritance of monogenic traits can be described as autosomal dominant, autosomal recessive, and sex-linked. Phenotypic variation results from variable penetrance, mosaicism, and other processes. Most traits, however, are multifactorial or polygenic and are further influenced by environmental factors. (See",
"      <a class=\"local\" href=\"#H1497231\">",
"       'Modes of inheritance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic testing currently has applications for perinatal screening, carrier testing, diagnostic testing, and in pharmacogenetics. The ability to rapidly sequence the entire genome is expected to have far-reaching clinical consequences in the future, though multiple issues related to ethics, data accuracy and interpretation, and data retrieval remain to be explored. (See",
"      <a class=\"local\" href=\"#H1497309\">",
"       'The role of genetic testing in modern clinical medicine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/1\">",
"      Chopra SS. STUDENTJAMA. Preparing for personalized medicine. JAMA 2004; 291:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/2\">",
"      Kansagra S, List J. STUDENTJAMA. The clinical relevance of genomic variation. JAMA 2004; 291:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/3\">",
"      Dolgin E. Human genomics: The genome finishers. Nature 2009; 462:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/4\">",
"      Verlaan DJ, Berlivet S, Hunninghake GM, et al. Allele-specific chromatin remodeling in the ZPBP2/GSDMB/ORMDL3 locus associated with the risk of asthma and autoimmune disease. Am J Hum Genet 2009; 85:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/5\">",
"      Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/6\">",
"      Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/7\">",
"      Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/8\">",
"      Southard AE, Edelmann LJ, Gelb BD. Role of copy number variants in structural birth defects. Pediatrics 2012; 129:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/9\">",
"      Kruyer H, Mil&agrave; M, Glover G, et al. Fragile X syndrome and the (CGG)n mutation: two families with discordant MZ twins. Am J Hum Genet 1994; 54:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/10\">",
"      Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998; 62:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/11\">",
"      Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/12\">",
"      Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/13\">",
"      Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21097/abstract/14\">",
"      Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature 2009; 461:724.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15540 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21097=[""].join("\n");
var outline_f20_38_21097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H101353982\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1497080\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1497087\">",
"      BASIC PRINCIPLES OF MOLECULAR GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497096\">",
"      DNA, RNA, and protein: The building blocks of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497103\">",
"      Organization of the human genome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H101353333\">",
"      - Alleles, genotypes, and haplotypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6183956\">",
"      - Identifying loci on chromosomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6183970\">",
"      - Mitochondrial genes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6183977\">",
"      - Coding and noncoding genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497110\">",
"      Gene transcription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497117\">",
"      Protein synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1497124\">",
"      GENETIC VARIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497131\">",
"      DNA sequence variation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497140\">",
"      - Single nucleotide polymorphisms (SNPs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1497147\">",
"      Nonsense mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1497154\">",
"      Missense mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1497161\">",
"      Splice site mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1497168\">",
"      Silent mutation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1497175\">",
"      Regulatory polymorphism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497182\">",
"      Indels: Insertions and deletions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497189\">",
"      Triplet-repeat expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497196\">",
"      Structural genetic variation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1031916\">",
"      - Copy number variation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497203\">",
"      - Chromosome translocations and inversions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497210\">",
"      Epigenetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1497224\">",
"      MEIOSIS: GAMETE FORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1497231\">",
"      MODES OF INHERITANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101353539\">",
"      Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497239\">",
"      - Autosomal dominant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497246\">",
"      - Autosomal recessive",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497253\">",
"      - Sex-linked",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497260\">",
"      Situations affecting Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497267\">",
"      - Penetrance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1497274\">",
"      Age-related penetrance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1497281\">",
"      Sex-influenced and sex-limited expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497288\">",
"      - Mosaicism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497295\">",
"      - Anticipation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1497302\">",
"      - Imprinting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1497309\">",
"      THE ROLE OF GENETIC TESTING IN MODERN CLINICAL MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497316\">",
"      Perinatal screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497323\">",
"      Carrier testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497330\">",
"      Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497337\">",
"      Pharmacogenetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1497344\">",
"      The future of genetic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101353982\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/15540\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15540|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/35/41520\" title=\"figure 1\">",
"      Chemical structure DNA and RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/24/14724\" title=\"figure 2\">",
"      Nucleotides building blocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/44/14017\" title=\"figure 3\">",
"      Structure of DNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/29/1496\" title=\"figure 4\">",
"      Structure amino acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/55/27518\" title=\"figure 5\">",
"      Human genome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/53/12125\" title=\"figure 6\">",
"      Alleles genotypes and haplotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/42/17058\" title=\"figure 7\">",
"      Transcription",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/48/15109\" title=\"figure 8\">",
"      Translation RNA to protein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/46/26350\" title=\"figure 9\">",
"      Codons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/34/39460\" title=\"figure 10\">",
"      Meiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/35/21040\" title=\"figure 11\">",
"      Mitosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/11/6323\" title=\"figure 12\">",
"      Chromosomal recombination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/23/4479\" title=\"figure 13\">",
"      Autosomal dominant--pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/10/10415\" title=\"figure 14\">",
"      Autosomal recessive--pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/8/6287\" title=\"figure 15\">",
"      X-linked recessive--pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/12/42190\" title=\"figure 16\">",
"      X-linked dominant--pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/22/30061\" title=\"figure 17\">",
"      Incomplete penetrance--pedigree",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/36/29248\" title=\"figure 18\">",
"      Imprinting--pedigree",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/0/31751?source=related_link\">",
"      Basic principles of genetic counseling for the obstetrical provider",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28087?source=related_link\">",
"      Genomic disorders: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43717?source=related_link\">",
"      Glossary of genetic terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=related_link\">",
"      Huntington disease: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17174?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Definition and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/26/19882?source=related_link\">",
"      Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43750?source=related_link\">",
"      Non-Mendelian inheritance patterns of monogenic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/20/43337?source=related_link\">",
"      Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35718?source=related_link\">",
"      Overview of Mendelian inheritance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41514?source=related_link\">",
"      Pathology and prognostic determinants of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12681?source=related_link\">",
"      Prenatal screening for genetic disease in the Ashkenazi Jewish population",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12713?source=related_link\">",
"      Primary care of the adult with intellectual disability (mental retardation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17846?source=related_link\">",
"      Principles of molecular genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_38_21098="Cancer pain management: Interventional therapies";
var content_f20_38_21098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cancer pain management: Interventional therapies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21098/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21098/contributors\">",
"     Ronald Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21098/contributors\">",
"     Russell K Portenoy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21098/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21098/contributors\">",
"     Janet Abrahm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/38/21098/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/38/21098/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/38/21098/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H380436940\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain that is severe enough to warrant long-term opioid therapy is experienced by 30 to 50 percent of cancer patients undergoing active antineoplastic therapy and by 75 to 90 percent of those with advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Treatment guidelines for cancer pain emphasize the primary role of systemic opioid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], which can yield adequate relief in 70 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=see_link\">",
"     \"Cancer pain management with opioids: Optimizing analgesia\"",
"    </a>",
"    .) This favorable statistic underscores the need to provide patients with access to opioid-based systemic pharmacotherapy for moderate to severe cancer pain.",
"   </p>",
"   <p>",
"    However, despite optimization of opioid therapy and the use of analgesic adjuvants, a substantial number of patients with cancer pain do not obtain satisfactory relief with first-line analgesic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=see_link\">",
"     \"Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs\"",
"    </a>",
"    .) When effective pain relief cannot be achieved through pharmacologic means, nonpharmacologic approaches offer an important alternative.",
"   </p>",
"   <p>",
"    The most important of these nonpharmacologic approaches are the so-called &ldquo;interventional&rdquo; pain management strategies. Interventional strategies comprise a very diverse group of invasive therapies, most of which are nondestructive and performed using needles (",
"    <a class=\"graphic graphic_table graphicRef64399 \" href=\"UTD.htm?4/30/4587\">",
"     table 1",
"    </a>",
"    ). Interventional therapies include injections, non-neurolytic and neurolytic nerve blocks, and implanted neurostimulation and neuraxial drug infusion techniques. The evidence base for all of these approaches is limited and includes very few controlled trials. Nevertheless, there is acceptance of these approaches in cancer pain management.",
"   </p>",
"   <p>",
"    With the exception of some simple injections (eg, trigger point injections), interventional therapies for pain management are implemented by professionals who have received specialized training. Ideally, all patients with cancer pain that does not respond promptly to systemic pharmacotherapy should have access to a specialist who can assess the appropriateness of interventional treatments.",
"   </p>",
"   <p>",
"    This topic review will cover interventional therapies for cancer pain. General principles of cancer pain assessment and management, the use of pharmacologic therapies for cancer pain, including opioids, analgesic adjuvants,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and NSAIDs, and psychologic, rehabilitative, and integrative therapies are discussed elsewhere. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436947\">",
"    <span class=\"h1\">",
"     INJECTION THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436955\">",
"    <span class=\"h2\">",
"     Soft tissue and joint injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injections into soft tissue and joints are the most common interventions performed in the management of chronic non-cancer pain. Trigger point injections are used to address focal musculoskeletal pain, including pain that occurs in patients with cancer. These injections are within the scope of routine medical practice and can be performed by non-specialists.",
"   </p>",
"   <p>",
"    Although the evidence to support benefit of trigger point injections in cancer patients is limited to anecdotal experience [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], this is a reasonable option for patients with cancer pain who have a focal area of myofascial pain and no contraindication to injection, such as a coagulopathy or severe leukopenia. If the pain is primarily myofascial, and not secondary to an active, untreated cause such as local nerve injury, relief following a trigger point injection often lasts for days or weeks. An injection of 1 to 3 mL of dilute local anesthetic (such as 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    or 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) typically is given directly into the painful site in the muscle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=see_link&amp;anchor=H19#H19\">",
"     \"Prevention and management of complex regional pain syndrome in adults\", section on 'Tender point injections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the age distribution of neoplastic disease, patients with cancer commonly have age-related painful comorbidities, such as painful joints related to osteoarthritis. Just as injection of a glucocorticoid into a painful joint is widely applied in populations without cancer, it may be considered to treat a painful joint in the cancer population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the population with chronic non-cancer pain, injections are also commonly performed to address acute and chronic low back and neck pain. Epidural steroid injections, facet joint injections, facet denervation approaches, and sacroiliac injections are rarely discussed in terms of their utility in the cancer population. However, non-cancer-related low back or neck pain may represent important comorbidities in these patients. In fact, it is likely that improved survival in some cancers will increase the prevalence of painful spinal disorders within the survivor community, and the decision to employ interventional strategies as are used in chronic non-cancer pain will be encountered more frequently as a result. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=see_link\">",
"     \"Treatment of neck pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=see_link\">",
"     \"Acute lumbosacral radiculopathy: Prognosis and treatment\"",
"    </a>",
"    .) A cancer diagnosis does not, by itself, contraindicate the use of any of these options, as long as certain conditions, such as coagulopathy or leukopenia, are absent. If the patient with cancer and pain is appropriately assessed, and the diagnosis (eg, radiculopathy associated with herniated nucleus pulposus) would support the use of an intervention (eg, epidural steroid injection), then the decision to proceed or not should be based on a careful, parallel assessment of potential contraindications and the overall goals of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436962\">",
"    <span class=\"h2\">",
"     Vertebroplasty and kyphoplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two specialized injection approaches, vertebroplasty and kyphoplasty, have been developed to address pain that originates from vertebral collapse, either from osteoporosis or neoplastic disease. Vertebroplasty involves the percutaneous injection of bone cement (methylmethacrylate) under fluoroscopic guidance into a collapsed vertebral body. Kyphoplasty involves the introduction of inflatable bone tamps into the vertebral body; once inflated, the bone tamps variably restore the height of the vertebral body, while creating a cavity that can then be filled with viscous bone cement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Kyphoplasty and vertebroplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with osteoporotic vertebral compression fractures, the benefits of vertebroplasty and kyphoplasty are controversial. A short-term placebo-controlled (sham procedure) trial of vertebroplasty in patients with osteoporotic compression fractures failed to show a significant benefit in reducing pain; a second trial of kyphoplasty versus non-surgical conservative treatment (no sham control) showed better pain control with kyphoplasty one month after treatment, but the benefits were no longer evident at one year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14458?source=see_link\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two prospective uncontrolled trials suggest that carefully selected cancer patients with pathologic vertebral body fractures can experience prompt and sustained pain relief from vertebroplasty and kyphoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]; a single randomized trial, reported only in abstract form, also supports benefit of balloon kyphoplasty over nonsurgical management for vertebral compression fractures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the only prospective trial of vertebroplasty, 33 patients with painful malignant vertebral compression fracture underwent percutaneous vertebroplasty of 42 symptomatic vertebrae [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/9\">",
"       9",
"      </a>",
"      ]. Pain control was &ldquo;significantly effective&rdquo; (pain on visual analog scale [VAS (",
"      <a class=\"graphic graphic_form graphicRef82442 \" href=\"UTD.htm?42/4/43084\">",
"       form 1",
"      </a>",
"      )] &le;2 or a decrease of &ge;5 points compared with before therapy) in 20 patients (61 percent), moderately effective (VAS score did not reach &le;2 but there was a decrease between two and five points compared to the VAS prior to therapy) in three (9 percent), and ineffective (VAS score increased, or decreased by &lt;2 points, or there was an increased need for analgesics) in 10 (30 percent).",
"     </li>",
"     <li>",
"      The clinical benefit of kyphoplasty was addressed in a phase II study of 65 patients with metastatic vertebral body fractures who underwent 99 balloon kyphoplasty procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/10\">",
"       10",
"      </a>",
"      ]. The mean pain VAS score dropped from 8.3 presurgery to 3.3 postsurgery, and continued to improve at the three month time point; benefit was sustained for up to 24 months.",
"     </li>",
"     <li>",
"      The benefit of balloon kyphoplasty over nonsurgical treatment was directly addressed in a phase III trial in which 134 patients with cancer and fewer than three painful vertebral compression fractures were randomly assigned to balloon kyphoplasty or nonsurgical management, and followed for 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/11\">",
"       11",
"      </a>",
"      ]. Crossover to kyphoplasty was allowed for patients undergoing nonsurgical management at one month.",
"      <br/>",
"      <br/>",
"      Patients who underwent kyphoplasty had significantly less self-reported disability, and showed significant improvement in pain at one and four weeks, while there was no change in either disability or pain status in those who had nonsurgical management. In addition, those undergoing kyphoplasty reported significantly fewer days with limited activity due to back pain and greater quality of life. All patients who underwent kyphoplasty (whether initially or after crossover from the control group) had sustained improvements over 12 months. There were two adverse events in the kyphoplasty group: one non-Q wave infarction attributed to anesthesia, and one cement leakage to the disc resulting in an adjacent fracture one day following the kyphoplasty procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no comparative studies of kyphoplasty versus vertebroplasty; kyphoplasty is more expensive. However, cement extravasation is more common with vertebroplasty. Some practitioners favor kyphoplasty in cases of significant kyphosis (deformity more than 20 degrees) or there is posterior vertebral cortex involvement which makes cement extravasation from vertebroplasty more likely [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/12\">",
"     12",
"    </a>",
"    ]. On the other hand, vertebroplasty may be preferred when insertion of the balloon device is technically difficult due to severe vertebral collapse (&gt;65 percent reduction in vertebral height) or if the fracture is more than three months old, in which case elevation of the endplate is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contraindications include the presence of neurologic damage related to fracture, fracture with a burst component (where bone fragments extend into the spinal canal), systemic or local infection, uncorrected hypercoagulable state, and severe cardiopulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436969\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of adverse outcomes appears to be low when the procedure is performed by an experienced physician, but serious complications have occurred, including pulmonary embolism, spinal cord compression and",
"    <strong>",
"    </strong>",
"    paraplegia. Intradural cement leakage requiring operation is a rare complication [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H950360331\">",
"    <span class=\"h3\">",
"     Vertebroplasty/kyphoplasty versus pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    may effectively relieve pain associated with a vertebral compression fracture",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    The best data come from a randomized placebo-controlled trial conducted in 31 patients with a recent (&lt;21 days old) osteoporotic vertebral compression fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/16\">",
"     16",
"    </a>",
"    ]. IV pamidronate (30 mg IV daily for three consecutive days) provided approximately 50 percent improvement in pain to about 50 percent of patients. Benefit was sustained for at least 30 days.",
"   </p>",
"   <p>",
"    There are no prospective trials evaluating the benefit of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (or IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ), and no trials directly comparing",
"    <span class=\"nowrap\">",
"     vertebroplasty/kyphoplasty",
"    </span>",
"    versus bisphosphonates in patients with a malignant vertebral compression fracture. However, given the relative ease of treatment and less invasive nature, and the occasionally dramatic pain relief we have seen with this agent, we suggest a trial of IV pamidronate before attempting vertebroplasty or kyphoplasty. Relative contraindications to IV pamidronate are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Renal insufficiency",
"     </li>",
"     <li>",
"      Recent dental work (to minimize the risk of jaw osteonecrosis)",
"     </li>",
"     <li>",
"      Hypocalcemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is necessary to provide supplemental calcium and vitamin D for at least 30 days to minimize the risk of hypocalcemia after its administration.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    treatment for 48 to 72 hours is useful to attenuate myalgias associated with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    . Slow administration may help reduce myalgias as well as renal insufficiency.",
"   </p>",
"   <p>",
"    Another option is nasal calcitonin, which is used for patients with acute osteoporotic vertebral compression fractures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14458?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\", section on 'Calcitonin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link&amp;anchor=H5#H5\">",
"     \"Calcitonin in the prevention and treatment of osteoporosis\", section on 'Bone pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436976\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with severe back pain related to a pathologically fractured vertebra, we suggest an initial trial of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or nasal calcitonin. For patients with persistent pain, vertebroplasty or kyphoplasty is a reasonable option as long as there are no contraindications and a physician with appropriate knowledge and experience in each is available. Additional discussion of the role of vertebroplasty and kyphoplasty in patients with myeloma is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of the complications of multiple myeloma\", section on 'Kyphoplasty and vertebroplasty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436983\">",
"    <span class=\"h1\">",
"     NEURAL BLOCKADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical image of a &ldquo;nerve block&rdquo;, a physician holding a needle and injecting a local anesthetic in and around a nerve or a nerve bundle, undoubtedly arose from the application of local anesthetic injections for surgical anesthesia. In the context of chronic pain management, a broader definition is appropriate. The term &ldquo;nerve block&rdquo; encompasses any procedure that utilizes a needle to deliver an agent or device for the purpose of modulating nociceptive afferent input to the central nervous system. While this definition could incorporate many interventions, it is typically applied to a group of procedures in which either a nondestructive analgesic or a neurolytic drug is injected.",
"   </p>",
"   <p>",
"    There are numerous types of nerve blocks, all of which must address a range of anatomic, physiologic, and pharmacologic challenges (",
"    <a class=\"graphic graphic_table graphicRef80802 \" href=\"UTD.htm?39/58/40875\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/19\">",
"     19",
"    </a>",
"    ]. The challenges vary according to the overall objective of the injection, which may be diagnostic, prognostic, therapeutic, or",
"    <span class=\"nowrap\">",
"     analgesic/anesthetic",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436990\">",
"    <span class=\"h2\">",
"     Diagnostic nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnostic nerve block is performed in an effort to better understand the &ldquo;generator&rdquo; of the pain or the neural basis for afferent transmission of noxious stimuli. Although this strategy has limitations, it can nevertheless be useful. In contrast, the use of a placebo or sham injection, in an attempt to determine if pain is \"real\" or \"psychogenic\", is never appropriate and should not be done.",
"   </p>",
"   <p>",
"    Local anesthetic blocks of somatic nerves, which interrupt both sensory and motor neural activity, can be useful in localizing the afferent pathway involved in sustaining the pain. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A block may distinguish truncal pain that is arising from the abdominal wall from pain that is referred from a visceral source.",
"     </li>",
"     <li>",
"      The administration of a local anesthetic into the cerebrospinal fluid to create a spinal anesthetic up to a spinal cord level above the level of the patient&rsquo;s pain can be used to determine if the pain generator is central or peripheral. If pain persists despite complete interruption of neural input from the painful area, it is not plausibly arising from activation of nerves in the periphery and is said to have a central nervous system (CNS) etiology. In some cases, pain referable to the CNS is clearly understood to involve neurologic disease (known as central pain, or more generically as &ldquo;deafferentation pain&rdquo;); in others, in others, it may be psychogenic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to helping to localize the afferent pathway involved in sustaining the pain, diagnostic blocks may help to clarify whether the pain is sympathetically maintained (ie, sustained by efferent activity in a sympathetic nerve or transmitted via afferent nerves [nociceptors] traveling with the sympathetic nerves). Sympathetic blocks with local anesthetic interrupt catecholamine release from specific sympathetic nerves and may provide relief if the pain is sympathetically maintained. This possibility is believed to be more likely when the clinical findings are consistent with a complex regional pain syndrome (also called reflex sympathetic dystrophy or causalgia). (See",
"    <a class=\"local\" href=\"#H380437852\">",
"     'Sympathetic blocks'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380436997\">",
"    <span class=\"h2\">",
"     Prognostic nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurolytic (neurodestructive) blocks are performed less often now than in the past; however, denervation of a painful region is sometimes a useful consideration. (See",
"    <a class=\"local\" href=\"#H380437032\">",
"     'Neurolytic blocks'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In such cases, local anesthetic nerve blocks are usually performed beforehand to determine if blocking afferent input has a reasonable chance of relieving the pain. These &ldquo;prognostic&rdquo; blocks also allow the patient to experience the sensory loss that will follow denervation and determine whether the sensory loss is tolerable.",
"   </p>",
"   <p>",
"    However, relief of pain with a local anesthetic nerve block does not guarantee that a destructive procedure will be successful, and the outcomes of these blocks should be interpreted conservatively. If there is no meaningful benefit for at least the duration of the local anesthetic effect, then a subsequent neurolysis should not be undertaken. If meaningful benefit is attained, it is reasonable to proceed with neurolysis, although there is no guarantee that the outcome will be positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437004\">",
"    <span class=\"h2\">",
"     Therapeutic nerve block",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;therapeutic&rdquo; nerve block can be applied to any injection that addresses the underlying etiology of the patient&rsquo;s pain. Examples of therapeutic nerve blocks are epidural blood patches for post-dural puncture headache and epidural steroids for an acute herniated disc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437067\">",
"    <span class=\"h3\">",
"     Epidural blood patch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal taps done for diagnostic or therapeutic purposes are sometimes followed by a post-dural puncture headache. The occurrence is influenced by the age and sex of the patient (younger patients and females are more susceptible) and the size and type of the needle used for the tap (larger bore needles are more likely to be associated with headache, as are cutting versus pencil point tip needles). The etiology is presumably related to low cerebrospinal fluid pressure which results from leakage of spinal fluid from the puncture site. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link\">",
"     \"Post-lumbar puncture headache\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While these headaches are often short lived, they can be debilitating and interfere with quality of life if patients are forced to remain bedbound to avoid the onset of severe headache when assuming an upright position. In addition, the headache may be associated with nausea, vomiting, photophobia or phonophobia, and in some cases, a sixth cranial nerve palsy with diplopia on lateral gaze.",
"   </p>",
"   <p>",
"    There is an extensive experience supporting the use of an epidural blood patch for patients with debilitating pain. The intervention is accomplished by injecting 10 to 20 mL of the patient&rsquo;s own blood into the epidural space at the site of the dural tap. Relief is immediate in a very high proportion of patients. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=see_link&amp;anchor=H11#H11\">",
"     \"Post-lumbar puncture headache\", section on 'Epidural blood patch'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437011\">",
"    <span class=\"h3\">",
"     Epidural steroids for acute herniated disc pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute herniated disc produces symptoms primarily because of the inflammatory response that is generated when the nucleus pulposus extrudes beyond the annulus fibrosis. Although symptoms and signs typically resolve over a few weeks to months, some patients develop persistent pain, possibly from scarring that occurs in response to inflammation, or possibly as a result of a non-healing annular tear. This is a common problem in the general population and presumably occurs with the same incidence in the cancer population.",
"   </p>",
"   <p>",
"    The duration of the pain associated with an acute herniated disc can be shortened by epidural administration of a corticosteroid. The best candidate is a patient with acute pain associated with radicular symptoms or signs. In well-selected patients, pain usually resolves within 48 hours. The epidural steroid injection in this case is therapeutic as it addresses inflammation, the underlying etiology of the pain. Given the potential benefits associated with attenuating intense pain, a patient with cancer who develops an acute herniated disc with an accompanying radiculopathy should be considered for this intervention, if the goals of care and medical condition support its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of acute low back pain\", section on 'Injections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437018\">",
"    <span class=\"h2\">",
"     Analgesic and anesthetic nerve blocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous examples of injections being performed for the primary purpose of inducing analgesia in patients with refractory cancer pain (",
"    <a class=\"graphic graphic_table graphicRef64399 \" href=\"UTD.htm?4/30/4587\">",
"     table 1",
"    </a>",
"    ). These may be broadly divided into those that are non-neurolytic (analgesic) and those that are neurolytic (anesthetic). In general, there is little high-quality evidence comparing these approaches with other analgesic strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/22\">",
"     22",
"    </a>",
"    ], with the exception of celiac plexus neurolysis. (See",
"    <a class=\"local\" href=\"#H380437032\">",
"     'Neurolytic blocks'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437025\">",
"    <span class=\"h3\">",
"     Non-neurolytic blocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-neurolytic analgesic blocks can be performed using bolus injection or continuous infusion of a local anesthetic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=see_link\">",
"     \"Overview of peripheral nerve blocks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link\">",
"     \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A trial of a bolus injection of a local anesthetic may be undertaken in a patient who has pain that is either acute or chronic. Transitory interruption of afferent input from the painful area may result in pain relief that far outlasts the pharmacologic duration of drug effect. The reason why some patients who undergo temporary denervation of a painful site experience prolonged pain relief is unknown, but it occurs commonly enough that repeated local anesthetic blocks could be considered if lessened pain is observed following each procedure.",
"   </p>",
"   <p>",
"    Non-neurolytic blocks may also be performed using an infusion of a local anesthetic, which can be delivered via a catheter that is placed into the epidural space or one whose tip is placed adjacent to a peripheral nerve or nerve plexus. The infusion of local anesthetic can be short term (hours or days), or occasionally, long term. Experienced pain specialists may consider perineural local anesthetic infusion in selected patients who have a focal regional pain syndrome that is expected to last a short time (but longer than the duration of a bolus injection), and who have demonstrated short-term relief from trials of bolus injection. For patients with larger areas of pain, or when prolonged infusion of a local anesthetic is undertaken, an epidural catheter can be tunneled under the skin and connected to an external pump that delivers the drug continuously. Epidural infusions of a local anesthetic may be combined with opioids and other drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H380437053\">",
"     'Neuraxial infusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While there have been no controlled studies of these techniques for cancer pain, efficacy is supported by many case reports and clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Diverse types of pain syndromes that have not been responsive to more conservative therapies may be amenable to effective denervation of this type. Examples include continuous brachial plexus block via an interscalene catheter for persistent shoulder pain or continuous epidural infusion for pelvic or lower extremity pain.",
"   </p>",
"   <p>",
"    The open-ended use of a perineural or neuraxial (epidural or intrathecal) local anesthetic infusion may also be helpful for patients with challenging pain syndromes who have advanced illness and are believed to be near the end of life. In this situation, the potential benefits associated with pain relief exceed the risk of infection and toxicity from the local anesthetic, and the burden and cost in maintaining the infusion, is a reasonable trade-off for pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H380437053\">",
"     'Neuraxial infusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437852\">",
"    <span class=\"h4\">",
"     Sympathetic blocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral cancer pain, which can be difficult to control with opioids and other analgesics, is especially suited to sympathetic blockade. As described above, blockade of a sympathetic nerve interrupts both the efferent sympathetic fibers and the afferent fibers that travel within the same nerve. Some of these afferents are nociceptors. Among patients with visceral pain who are undergoing injection of sympathetic nerves or plexuses that supply visceral structures (eg, the celiac plexus), sympathetic efferents may be relevant, but the efficacy of neural blockade relates mainly to interruption of the nociceptive nerves supplying those viscera.",
"   </p>",
"   <p>",
"    In contrast, when pain involves somatic structures, such as an extremity, the choice of a sympathetic rather than somatic nerve block is usually predicated on the perception that the pain syndrome is being maintained by sympathetic efferent activity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/27\">",
"     27",
"    </a>",
"    ]. Based upon clinical observation, it is widely accepted that the entity referred to as Complex Regional Pain Syndrome (CRPS, also known as Reflex Sympathetic Dystrophy, RSD, or causalgia) is likely characterized by a component of sympathetically-maintained pain. Cancer patients who have regional pain that is associated with focal autonomic dysfunction (such as vasomotor instability or sweating) or trophic changes (such as thinning of the skin, increased hair growth, or brittle, ridged nails) have &ldquo;possible&rdquo; CRPS. These characteristics suggest that a trial of sympathetic block should be entertained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=see_link&amp;anchor=H8#H8\">",
"     \"Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults\", section on 'Clinical stages'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efferent sympathetic nervous system originates in the intermediate-lateral horn cells of spinal cord levels T1-L2. The organization of the sympathetic nervous system facilitates isolated sympathetic neural blockade at specific anatomic locations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=see_link\">",
"     \"Prevention and management of complex regional pain syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The stellate ganglion, which is formed from fusion of the first thoracic and inferior cervical sympathetic ganglion, receives innervation from the T1-T4 sympathetic outflow. Sympathetic interruption of the head, neck, upper extremities and intrathoracic structures can be accomplished through a stellate ganglion block, which is performed by local anesthetic injection of the ganglion where it lies on the anterior surface of the vertebral column, through placement of a needle in the anterior neck.",
"     </li>",
"     <li>",
"      A sympathetic block of the lower extremities can be accomplished through a paraspinal lumbar sympathetic block, which interrupts the fibers that originate in the lower thoracic and L1 segments and coalesce in the lumbar sympathetic chain.",
"     </li>",
"     <li>",
"      Block of the sympathetic nerves innervating abdominal and pelvic viscera (nerves that also carry the visceral afferents, including nociceptors) involve interruption of nerves that originate from T5-L1 and distribute through the greater (T5-T10), lesser (T10-T12) and least (T12-L1) splanchnic nerves. These nerves coalesce in the celiac plexus, superior hypogastric plexus, and ganglion impar (which is located anterior to the sacrococcygeal junction), respectively. Sympathetic block of these structures may be performed using a bolus injection of local anesthetic. Following a successful local anesthetic injection, a neurolytic substance, such as alcohol",
"      <strong>",
"      </strong>",
"      is used in the hope of achieving long-term relief. (See",
"      <a class=\"local\" href=\"#H380437032\">",
"       'Neurolytic blocks'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In contrast to these anatomic areas, segmental thoracic sympathetic blocks are not recommended. The stellate ganglion, lumbar sympathetic ganglia, celiac plexus, hypogastric plexus and impar ganglion are anatomically separated from somatic nerves, and this distribution allows sparing of sensory and motor fibers during block procedures. It is more difficult to perform segmental blocks of the thoracic sympathetic ganglia without also blocking somatic nerves. Furthermore, the presence of the pleural fold near the sympathetic chain makes a pneumothorax very likely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sympathetic blocks are usually performed by bolus injection directly into the plexus or ganglion. However, a sympathetic block may also be accomplished, at least in theory, by performing a differential spinal block. This involves the injection of a relatively low concentration of local anesthetic into the epidural or subarachnoid space. The goal is blockade of sympathetic nerves without interruption of the somatic or motor fibers. As an example, in a patient with refractory foot pain, an epidural injection at the T12-L1 interspace with a few mL of local anesthetic will often produce block of the sympathetics to the lower extremity, but spare the lumbosacral plexus, which carries the somatic nerves innervating the foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437975\">",
"    <span class=\"h4\">",
"     Somatic nerve blocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bolus injections and continuous epidural or perineural infusions can be performed to denervate specific areas of the body [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/28\">",
"     28",
"    </a>",
"    ]. As noted above, a single bolus injection can sometimes be followed by prolonged relief; repeated boluses or a switch to a local anesthetic infusion can further increase the duration of relief.",
"   </p>",
"   <p>",
"    Common types of somatic nerve blocks include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paravertebral or intercostal blocks to denervate a region of the chest or abdominal wall",
"     </li>",
"     <li>",
"      Brachial plexus block to denervate the shoulder or arm",
"     </li>",
"     <li>",
"      Gasserian ganglion block to denervate a part of the face",
"     </li>",
"     <li>",
"      Epidural or intrathecal blocks to denervate various areas of the body",
"     </li>",
"     <li>",
"      Anesthetic infusions to denervate peripheral nerves may also be used when the spinal approach is not possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all cases, the smallest amount of anesthetic should be used that will accomplish the desired goal of denervation. This is to prevent unwanted spread of agent to other areas not involved with the nociceptive afferent process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437032\">",
"    <span class=\"h3\">",
"     Neurolytic blocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurolytic (anesthetic) techniques produce analgesia by destroying afferent neural pathways or sympathetic structures that may be a pathway for either sympathetic efferents or afferent nerves that are involved in pain transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Neural destruction can be achieved with surgery, cold (cryotherapy) or heat (radiofrequency thermal coagulation), or the injection of a material that damages the nerve (eg, water, hypertonic saline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"     glycerin",
"    </a>",
"    , phenol, or alcohol) (",
"    <a class=\"graphic graphic_table graphicRef69377 \" href=\"UTD.htm?21/27/21947\">",
"     table 3",
"    </a>",
"    ). Chemical neurolysis using alcohol or phenol is usually applied for refractory pain associated with advanced cancer.",
"   </p>",
"   <p>",
"    All neurolytic techniques result in Wallerian degeneration to some degree. If the axolemma is intact, nerve regeneration occurs, leading to a return of sensation in about three to six months. The extent of the degeneration, and the extent and time course of functional recovery, varies with each technique.",
"   </p>",
"   <p>",
"    All neurolytic interventions carry the risk of producing a new &ldquo;deafferentation pain&rdquo;. Those methods that preserve neural architecture and allow for regeneration are less likely to be followed by a deafferentation pain syndrome. Once deafferentation pain syndrome develops, it can be as difficult to treat as the original pain for which the procedure was performed. Although uncommon overall, the true incidence of this complication is unknown, and the possibility must be weighed when deciding on a therapeutic approach. Patients who undergo neurolysis should be told about this possibility in the informed consent process.",
"   </p>",
"   <p>",
"    Traditional methods for peripheral nerve block mainly consist of neurolytic agents such as phenol or alcohol. In addition, in the past, intrathecal injection of small volumes of these neurolytic agents was used to block somatic innervation by destroying the spinal roots that comprise the regional somatic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, given the development of other nondestructive analgesic approaches to blocking somatic and sympathetic nerves, these and most other neurolytic procedures have been largely relegated to the population of cancer patients with advanced disease whose pain is not amenable to more conservative therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/26,32\">",
"     26,32",
"    </a>",
"    ]. Given the risks of late deafferentation pain, the possibility of unwanted tissue damage induced by the neurolytic process at the time of administration (",
"    <a class=\"graphic graphic_table graphicRef76959 \" href=\"UTD.htm?2/50/2859\">",
"     table 4",
"    </a>",
"    ), and the likelihood that even successful neurolysis may not provide more than a few months of relief, this &ldquo;last resort&rdquo; perspective on neurolytic therapies is justified, with two major exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Celiac plexus neurolysis (CPN) is frequently used for pain originating from upper abdominal malignancy, particularly pancreatic cancer. This particular block is sufficiently safe and effective that it is commonly recommended as the next step if one to two trials of systemic opioid therapy are ineffective in relieving pain.",
"      <br/>",
"      <br/>",
"      The celiac plexus can be accessed intraoperatively, percutaneously, or endoscopically, using ultrasound guidance. There are no high-quality studies comparing these varied techniques for accessing the celiac plexus, and the decision to employ one or the other typically depends on the discipline and training of the physician. Although the majority of randomized trials demonstrating benefit from CPN for pancreatic cancer pain in adults have been conducted using the percutaneous approach [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/33\">",
"       33",
"      </a>",
"      ], the benefit of endoscopic ultrasound-guided CPN has been shown in at least one randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/34\">",
"       34",
"      </a>",
"      ], and this approach is becoming popular as a minimally invasive technique with few risks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link&amp;anchor=H3#H3\">",
"       \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\", section on 'Non-EUS methods (for celiac \"plexus\" neurolysis and block)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=see_link&amp;anchor=H7#H7\">",
"       \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\", section on 'EUS methods (for performing celiac \"plexus\" neurolysis and block)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Superior hypogastric plexus neurolysis may be tried for patients with visceral pelvic pain that is refractory to medical management. The superior hypogastric plexus lies in the retroperitoneum and extends from the anterior aspect of L5 to the superior sacrum. Afferent fibers from the pelvic viscera pass through the plexus, which also contains sympathetic postganglionic fibers. As with celiac plexus block, only visceral pain responds to superior hypogastric plexus block; somatic pain from sacral or muscle involvement and neuropathic pain from nerve root compression or infiltration do not improve. An initial local anesthetic block is used to predict response to neurolytic block [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H380437025\">",
"       'Non-neurolytic blocks'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The superior hypogastric plexus is accessed intraoperatively or percutaneously via a bilateral posterior approach. Fluoroscopy is used to facilitate needle placement and to confirm the appropriate spread of neurolytic agent.",
"      <br/>",
"      <br/>",
"      No randomized studies have been published, but several prospective case series indicate good to excellent pain relief in more than 70 percent of patients, reduced opioid consumption, and a favorable adverse event profile [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Hypotension, diarrhea, and injury to the aorta or spinal cord are unlikely since the plexus lies over the sacrum. Lumbar plexus injury, bladder puncture, and iliac artery puncture with retroperitoneal bleeding or cholesterol plaque embolization can occur. No significant complications occurred in the study cited above [",
"      <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For intractable facial pain, neurolysis (chemical or radiofrequency) of the trigeminal nerve branches could lead to deafferentation pain, and is generally avoided. Glycerol injection of the ganglion itself in the trigeminal cistern (Meckel&rsquo;s cave) has the lowest risk for adverse effects and longest duration of activity, and is the preferred approach.&nbsp;For patients who have undergone radical",
"      <span class=\"nowrap\">",
"       neck/oral",
"      </span>",
"      surgery, branches of&nbsp;the trigeminal nerve are sacrificed and the facial pain might be of a deafferentation nature, not nociceptive from tumor, and therefore likely to be refractory to further destructive lesioning. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=see_link&amp;anchor=H22#H22\">",
"       \"Trigeminal neuralgia\", section on 'Rhizotomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437039\">",
"    <span class=\"h1\">",
"     IMPLANTED NEUROSTIMULATION AND NEURAXIAL INFUSION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some interventional strategies share the intent of implanting either an electrode or a catheter for analgesic purposes. Implanted catheters can be used for prolonged perineural or neuraxial infusion of local anesthetics. Other implantation approaches may be performed for neuraxial delivery of analgesic drugs, or to provide electrical stimulation of the peripheral nerves or the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. These procedures share the advantage of avoiding or limiting the side effects associated with systemic pharmacotherapy. The main disadvantages are cost, risk of infection, and mechanical failure. Proper patient selection is critical to the successful use of these interventions, and selection usually includes a preliminary percutaneous trial with a temporary electrode or catheter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437046\">",
"    <span class=\"h2\">",
"     Implanted neurostimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of implanted neurostimulatory treatment is spinal cord stimulation (dorsal column stimulation). In this technique, an electrode is passed into the epidural space at the specific spinal level where the peripheral afferent input enters the cord and an electrical current is applied. Patients who experience paresthesias that are localized to the region of the pain may report substantial pain relief. Some patients do not benefit and others do not like the sensation, even if pain is lessened. For those who experience analgesia, however, the benefits can be substantial.",
"   </p>",
"   <p>",
"    There are no randomized trials addressing the benefit of spinal cord stimulation for cancer-related pain. A systematic review included four before-after case series totaling 92 participants [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/42\">",
"     42",
"    </a>",
"    ]. Pain relief was obtained in two studies, pain scores (as determined by a visual analog scale [VAS]) were diminished in two others, and analgesic use was largely reduced in all. However, there was heterogeneity in baseline characteristics, electrode and stimulator parameters, and level and route of implantation, and a high risk of bias in all studies (due to their nonrandomized nature), leading the authors to conclude that the evidence was insufficient to establish a role for spinal cord stimulation in treating refractory cancer-related pain. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Spinal cord stimulation is not typically used for treatment of pain due to spine disease, and only rarely for patients with advanced cancer. It may be an option, however, for patients with neuropathic pain related to cancer or its treatment. The best candidate for spinal cord stimulation is a patient with intractable, focal, isolated pain of neuropathic origin (eg, a painful lumbosacral plexopathy or polyneuropathy, or phantom limb pain). The cost of SCS and the need for patient involvement in its use make it unsuitable for debilitated cancer patients near the end of life.",
"   </p>",
"   <p>",
"    Long-term peripheral nerve stimulation using an implanted electrode has been explored as a treatment for refractory headache and other conditions. There is no reported experience with these techniques in the cancer population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437053\">",
"    <span class=\"h2\">",
"     Neuraxial infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuraxial (intraspinal) infusion refers to the intervention by which one or more drugs are infused into the epidural or intrathecal (subarachnoid) space (",
"    <a class=\"graphic graphic_figure graphicRef51884 \" href=\"UTD.htm?16/14/16612\">",
"     figure 1",
"    </a>",
"    ). In the cancer population, a variety of approaches are used, generally depending on life expectancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A patient who has pain that is refractory to systemic pharmacotherapy and a life expectancy of days to weeks may benefit from a percutaneously-placed catheter with an external pump.",
"     </li>",
"     <li>",
"      If survival is likely to be measured in months, the catheter can be tunneled under the skin to reduce the risk of dislodgement and serious infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The proximal end of the tunneled catheter can remain subcutaneous and connected to a port, which is accessed percutaneously and connected to an external pump.",
"     </li>",
"     <li>",
"      More often, it is safer and more convenient for the patient to have the tunneled catheter connected to a fully implanted infusion pump.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both fixed-rate and programmable pumps are available. Implanted catheters and infusion pumps are generally viewed as cost-effective if estimated life expectancy is more than three to six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5386240\">",
"    <span class=\"h3\">",
"     Intrathecal versus epidural catheter placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuraxial drug infusion can be administered into the intrathecal or epidural space (",
"    <a class=\"graphic graphic_figure graphicRef51884 \" href=\"UTD.htm?16/14/16612\">",
"     figure 1",
"    </a>",
"    ). Epidural delivery permits analgesia to be restricted to fewer dermatomes, but drug doses up to 10-fold higher are needed, possibly producing more systemic side effects than with intrathecal delivery. For intrathecal infusion, approximately 1 percent of the total daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    or morphine equivalent oral dose is a reasonable starting point, while for epidural delivery, the starting dose is approximately 10 percent of the daily morphine equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials comparing the efficacy of epidural versus intrathecal drug infusions in patients with cancer pain. A systematic review of uncontrolled studies concluded that the frequency of pain relief was similar, but no conclusions could be reached as to the comparative side effect profile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/44\">",
"     44",
"    </a>",
"    ]. An epidural catheter is often used for an initial trial of neuraxial anesthesia when the site of nociception is higher than the lower",
"    <span class=\"nowrap\">",
"     thoracic/lumbar",
"    </span>",
"    region. For example, a patient with upper extremity pain or high thoracic or cervical spine involvement with tumor can have the epidural catheter placed in those regions and specific agents trialed for analgesia. (See",
"    <a class=\"local\" href=\"#H5385911\">",
"     'Choice of agent'",
"    </a>",
"    below.) If the infusions provide analgesia and an implanted infusion system is considered, it is important to place the tip of the subarachnoid (intrathecal) catheter at the spinal cord level of the nociception to minimize the doses of drugs required and their resultant side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5385911\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the past two decades, the number of drugs used for neuraxial infusion has increased dramatically. Originally, the approach was limited to an opioid, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , and a local anesthetic, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    . The opioid was targeted to receptors in the dorsal horn of the spinal cord and the local anesthetic, which targeted sodium channels in the spinal nerve roots, was used at doses that yielded subanesthetic concentrations in the cerebrospinal fluid. This combination appears to be synergistic, allowing smaller amounts of each drug to be used to treat regional pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/45\">",
"     45",
"    </a>",
"    ] with better efficacy and fewer side effects than when either drug is used alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This synergy may be especially valuable in treating neuropathic, pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other opioids, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/49\">",
"     49",
"    </a>",
"    ], have also been used. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    is the only opioid approved for intraspinal use by the US Food and Drug Administration (FDA).",
"   </p>",
"   <p>",
"    Clinical trials have also demonstrated the efficacy of epidural",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/50\">",
"     50",
"    </a>",
"    ], an alpha-2 adrenergic agonist that acts at the dorsal horn by modulating the transmission of noxious sensory signals. This drug has become a commonly used component of both epidural and subarachnoid infusion, particularly for patients with a predominant neuropathic pain component [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/51\">",
"     51",
"    </a>",
"    ]. A preservative-free formulation of clonidine for intraspinal use is approved by the US FDA.",
"   </p>",
"   <p>",
"    The benefits of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    to intraspinal opioid therapy were illustrated in a study of 85 patients with cancer pain who received either epidural clonidine or placebo in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/50\">",
"     50",
"    </a>",
"    ]. Clonidine was effective in 56 percent of patients with neuropathic pain, but did not improve morphine analgesia in the remainder. Hypotension and bradycardia were occasionally problematic with clonidine infusion. Importantly, sensory and motor block, respiratory depression, pruritus, nausea, and urinary retention were not seen with intraspinal clonidine therapy.",
"   </p>",
"   <p>",
"    Intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    , a GABA-B agonist, is approved for use in neuraxial infusion for the treatment of severe spasticity, and off-label use for pain also has become common.",
"   </p>",
"   <p>",
"    Another nonopioid agent for intrathecal use is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/55/38773?source=see_link\">",
"     ziconotide",
"    </a>",
"    , a highly selective neural N-type calcium channel blocker. Ziconotide has been approved for use in patients who are intolerant of or refractory to other treatments for pain including intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , but its use is limited by cost and potentially serious neurologic side effects (confusion, somnolence). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other drugs have begun to be used off-label, based on limited trials. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    . Further information about agents considered useful in neuraxial analgesia can be found in the 2007 Polyanalgesic Consensus Conference report [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are minimal data comparing different pharmacologic agents, and current regimens have been empirically derived. A large survey published in 2000 defined practice patterns among pain specialists, reflecting the experience of over 400 physicians in managing 13,300 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/53\">",
"     53",
"    </a>",
"    ]. Single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    was the most common approach, used in 56 percent of patients. In another 20 percent either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    was added to the opioid. More complex regimens and other agents were used in the remainder of the patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73805244\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data directly comparing neuraxial analgesia with conventional medical treatment. The advantages of an intrathecal drug delivery system were shown in a trial that randomly assigned 202 patients with unrelieved cancer pain to intrathecal analgesia or conventional medical management (all pain therapy except spinally administered drugs or other neurosurgical interventions) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients assigned to intrathecal therapy were required to have a successful screening trial with intrathecal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    before pump implantation, and clinical benefit was assessed after four weeks.",
"   </p>",
"   <p>",
"    At four weeks, both groups had an improvement in pain scores and toxicity, but significantly more patients treated with the intrathecal infusion had a &ge;20 percent reduction in the pain visual analog score ((",
"    <a class=\"graphic graphic_form graphicRef82442 \" href=\"UTD.htm?42/4/43084\">",
"     form 1",
"    </a>",
"    ), 85 versus 71 percent) and they had less treatment-related toxicity (58 versus 38 percent). In particular, fatigue and depressed level of consciousness were significantly less common in the intrathecal therapy group. In addition, there was a trend towards longer six month survival in the intrathecal therapy group (54 versus 37 percent, p = 0.06).",
"   </p>",
"   <p>",
"    Benefits appear to be sustained. In a later publication with six month follow-up of this trial, the authors again concluded that the use of intrathecal therapy improved clinical success of analgesic therapy, reduced treatment-related toxicity, and was associated with increased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5386296\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter insertion can be associated with bleeding. Gradual cephalad spread of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    in the cerebrospinal fluid can cause respiratory depression 12 to 18 hours after injection. This is more of a problem during the treatment of patients who are opioid-na&iuml;ve (for example, when neuraxial therapy is used for acute pain in the postoperative setting) and when hydrophilic drugs like morphine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    are used; it is rarely encountered during treatment of cancer patients who have received prior opioid treatment or when lipophilic agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    are administered.",
"   </p>",
"   <p>",
"    When given intrathecally, local anesthetics can block incoming sensory nerves and produce complete anesthesia. The numbness may be unpleasant and the proprioceptive loss may interfere with motor function. In addition, motor blockade itself may occur, causing weakness, and sympathetic nervous system blockade may result in hypotension. Serious acute complications of neuraxial infusion are uncommon if initial drug doses are low and titration is carefully performed. The risks are greatest at the start of treatment and patients must be closely monitored in the first 24 hours for potentially life-threatening respiratory depression, weakness, urinary retention, hypotension, and intraspinal hematoma.",
"   </p>",
"   <p>",
"    Significant delayed complications of catheter placement are epidural abscess and meningitis. However, few intraspinal systems become infected with proper maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/48,55-57\">",
"     48,55-57",
"    </a>",
"    ]. Cerebrospinal fluid hygroma and pump pocket seroma may occur after pump placement but are usually self-limited. Catheter migration and blockage are rare, especially with continuous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/55\">",
"     55",
"    </a>",
"    ]. To avoid complications, systemic infection, thrombocytopenia, and coagulation defects must be treated before catheter placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73805292\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in neuraxial infusion techniques, which include both the number of drugs that may be used, and the types of infusion devices that can be implanted, has greatly increased the options for clinicians who perform interventional strategies. Although experience is limited in patients with cancer, neuraxial infusion is an important option for patients who are refractory or intolerant of systemic pharmacotherapy. Referral to a specialist to evaluate the feasibility and appropriateness of these treatments and others should be considered in the setting of refractory cancer pain.",
"   </p>",
"   <p>",
"    The decision to try one or another type of neuraxial infusion is made on the basis of the medical status of the patient, the goals of care, the availability of professional and family support, and the cost. The simplest approach for a patient who has significant side effects to opioids (but obtains some degree of analgesia) is to calculate the neuraxial equivalent of the current oral or parenteral dosing and perform a trial of epidural or intrathecal opioid. A local anesthetic can be added if necessary. When neuropathic pain is a significant component of the pain process, or pain is not responding satisfactorily despite dose titration, consideration is given to adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    first, and then possibly other drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73805433\">",
"    <span class=\"h2\">",
"     Intraventricular opioid delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    may be injected into the cerebral ventricles after placement of an Omaya reservoir. This technique may be appropriate for certain patients with pain from head and neck cancer, but the available evidence to support superiority of intraventricular over systemic opioid delivery is weak [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/58\">",
"     58",
"    </a>",
"    ]. The relatively small experience with this procedure suggests that 50 to 90 percent of patients obtain good to excellent initial relief [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/44,59\">",
"     44,59",
"    </a>",
"    ]. However, a systematic review of uncontrolled studies concluded that intraventricular infusion was associated with more respiratory depression, sedation, and confusion as compared to the epidural or intrathecal route [",
"    <a class=\"abstract\" href=\"UTD.htm?20/38/21098/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       \"Patient information: Managing pain when you have cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H380437060\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid-based systemic pharmacotherapy is the mainstay of treatment for patients with moderate to severe pain related to cancer. However, interventional procedures can be extremely valuable in patients with refractory pain, or intolerance to systemic opioids or for management of pain related to comorbid conditions. &nbsp;",
"   </p>",
"   <p>",
"    Clinicians should understand the array of approaches available and develop an alliance with a pain medicine physician who has knowledge and skills in the use of interventional approaches. Although the evidence to support benefit of these strategies is generally limited and includes very few controlled trials, there is broad acceptance of these approaches in cancer pain management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trigger point injection can be used to address focal musculoskeletal pain as long as there is no clinically significant coagulopathy or leukopenia. (See",
"      <a class=\"local\" href=\"#H380436955\">",
"       'Soft tissue and joint injections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with refractory back pain related to a malignant vertebral compression fracture, we suggest an initial trial of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      rather than kyphoplasty or vertebroplasty (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients without significant or sustained pain relief, we suggest vertebroplasty or kyphoplasty if there are no contraindications and a physician with appropriate experience is available to perform the procedure (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H380436962\">",
"       'Vertebroplasty and kyphoplasty'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term &ldquo;nerve block&rdquo; is best viewed very broadly to encompass any procedure that utilizes a needle to deliver an agent or device for analgesic purposes; they may be diagnostic, prognostic, therapeutic, or",
"      <span class=\"nowrap\">",
"       anesthetic/analgesic.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H380436983\">",
"       'Neural blockade'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A diagnostic nerve block may help to localize the afferent pathway involved in sustaining the pain. (See",
"      <a class=\"local\" href=\"#H380436990\">",
"       'Diagnostic nerve block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to a planned neurolytic block, a prognostic nerve block using a local anesthetic should be performed; however, relief of pain is not a guarantee of benefit for the subsequent neurolytic procedure. (See",
"      <a class=\"local\" href=\"#H380436997\">",
"       'Prognostic nerve block'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A therapeutic epidural blood patch is a reasonable approach for patients with moderate to severe post lumbar puncture headache that is prolonged (&gt;24 hours) and refractory to conservative measures. (See",
"      <a class=\"local\" href=\"#H380437067\">",
"       'Epidural blood patch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidural administration of a glucocorticoid may lessen the duration of the pain associated with an acute herniated disc. (See",
"      <a class=\"local\" href=\"#H380437011\">",
"       'Epidural steroids for acute herniated disc pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-neurolytic (analgesic) nerve blocks using bolus dosing or infusional drug administration may provide benefit for a diverse array of pain syndromes that have not been responsive to more conservative therapies. Visceral cancer pain, which can be difficult to control with opioids and other analgesics, is especially suited to sympathetic blockade. (See",
"      <a class=\"local\" href=\"#H380437852\">",
"       'Sympathetic blocks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H380437025\">",
"       'Non-neurolytic blocks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurolytic (anesthetic) techniques produce analgesia by destroying afferent neural pathways or sympathetic structures that may be a transit point for either sympathetic efferents or afferent nerves involved in pain transmission. With the exceptions of celiac plexus and superior hypogastric plexus neurolysis, these techniques are considered &ldquo;last resort&rdquo; options. (See",
"      <a class=\"local\" href=\"#H380437032\">",
"       'Neurolytic blocks'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Implanted neurostimulation and neuraxial infusion procedures share the advantage of avoiding or limiting the side effects associated with systemic pharmacotherapy. The main disadvantages are cost, risk of infection, and mechanical failure. Proper patient selection is key to the appropriate use of these interventions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The best candidate for implanted spinal cord or peripheral nerve stimulation is a patient with focal, isolated pain of neuropathic origin (eg, a painful lumbosacral plexopathy). (See",
"      <a class=\"local\" href=\"#H380437046\">",
"       'Implanted neurostimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neuraxial drug infusion should be considered in any patient who has moderate to severe pain that is refractory to conventional opioid pharmacotherapy, or in any patient who is intolerant of opioid therapy.",
"     </li>",
"     <li>",
"      For patients with a life expectancy of days to weeks, a percutaneously-placed catheter with an external pump is a reasonable option. If survival is likely to be measured in months, the catheter can be tunneled under the skin to reduce the risk of dislodgement and serious infection. In such cases, it is it is safer and more convenient for the patient to have the tunneled catheter connected to a fully implanted infusion pump. (See",
"      <a class=\"local\" href=\"#H380437053\">",
"       'Neuraxial infusion'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/1\">",
"      van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007; 132:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/2\">",
"      Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34:94.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Cancer Pain Relief, 2nd, World Health Organization, Geneva 1996.",
"    </li>",
"    <li>",
"     American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 6th, American Pain Society, Glenview, IL, 2008.",
"    </li>",
"    <li>",
"     Fine, P, Portenoy, RK. Opiod analgesia, McGraw Hill, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/6\">",
"      Quigley C. Opioids in people with cancer-related pain. Clin Evid (Online) 2008; 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/7\">",
"      Sist T, Miner M, Lema M. Characteristics of postradical neck pain syndrome: a report of 25 cases. J Pain Symptom Manage 1999; 18:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/8\">",
"      Sist T, Wong C. Difficult problems and their solutions in patients with cancer pain of the head and neck areas. Curr Rev Pain 2000; 4:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/9\">",
"      Kobayashi T, Arai Y, Takeuchi Y, et al. Phase I/II clinical study of percutaneous vertebroplasty (PVP) as palliation for painful malignant vertebral compression fractures (PMVCF): JIVROSG-0202. Ann Oncol 2009; 20:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/10\">",
"      Pflugmacher R, Taylor R, Agarwal A, et al. Balloon kyphoplasty in the treatment of metastatic disease of the spine: a 2-year prospective evaluation. Eur Spine J 2008; 17:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/11\">",
"      Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 2011; 12:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/12\">",
"      Chwistek M, Mehta RS. Vertebroplasty and kyphoplasty for vertebral compression fractures #202. J Palliat Med 2012; 15:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/13\">",
"      Hulme PA, Krebs J, Ferguson SJ, Berlemann U. Vertebroplasty and kyphoplasty: a systematic review of 69 clinical studies. Spine (Phila Pa 1976) 2006; 31:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/14\">",
"      Taylor RS, Taylor RJ, Fritzell P. Balloon kyphoplasty and vertebroplasty for vertebral compression fractures: a comparative systematic review of efficacy and safety. Spine (Phila Pa 1976) 2006; 31:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/15\">",
"      Sabuncuolu H, Din&ccedil;er D, G&uuml;&ccedil;l&uuml; B, et al. Intradural cement leakage: a rare complication of percutaneous vertebroplasty. Acta Neurochir (Wien) 2008; 150:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/16\">",
"      Armingeat T, Brondino R, Pham T, et al. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int 2006; 17:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/17\">",
"      Gangji V, Appelboom T. Analgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fractures. Clin Rheumatol 1999; 18:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/18\">",
"      Abdulla AJ. Use of pamidronate for acute pain relief following osteoporotic vertebral fractures. Rheumatology (Oxford) 2000; 39:567.",
"     </a>",
"    </li>",
"    <li>",
"     Hogan, Q, Abram, S. Diagnostic and prognostic neural blockade. In: Cousins and Bridenbaugh's Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th, Lippencott, Williams &amp; Wilkins, 2009. p.839.",
"    </li>",
"    <li>",
"     Buckley, FP. Regional anesthesia with local anesthetics. In: Bonica's Management of Pain, 3rd, Lippincott, Williams &amp; Wilkins, 2001. p.1893.",
"    </li>",
"    <li>",
"     Stein, C, Kopf, A. Regional anesthesia and treatment of chronic pain. In: Miller's Anesthesia, 7th, Churchill Livingstone Elsevier, 2010. p.1808.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/22\">",
"      Straube S, Derry S, Moore RA, McQuay HJ. Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. Cochrane Database Syst Rev 2010; :CD002918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/23\">",
"      Pacenta HL, Kaddoum RN, Pereiras LA, et al. Continuous tunnelled femoral nerve block for palliative care of a patient with metastatic osteosarcoma. Anaesth Intensive Care 2010; 38:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/24\">",
"      Fujii T, Nagaro T, Tsubota S, et al. Case reports: management of intractable upper extremity pain with continuous subarachnoid block at the low cervical level without impairment of upper extremity function. Anesth Analg 2010; 110:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/25\">",
"      Vranken JH, Zuurmond WW, de Lange JJ. Continuous brachial plexus block as treatment for the Pancoast syndrome. Clin J Pain 2000; 16:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/26\">",
"      Chambers WA. Nerve blocks in palliative care. Br J Anaesth 2008; 101:95.",
"     </a>",
"    </li>",
"    <li>",
"     Burton, AW, Phan, PC, Cousins, MJ. Treatment of cancer pain: Role of neural blockade and neuromodulation. In: Cousins and Bridenbaugh's Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th, Lippincott, Williams &amp; Wilkins, 2009. p.1122.",
"    </li>",
"    <li>",
"     Lema, MJ.  Invasive procedures for cancer pain. Pain: Clinical Updates; 6:1. International Association for the Study of Pain ( IASP) available online at file://www.iasp-pain.org/AM/AMTemplate.cfm?Section=Home&amp;TEMPLATE=/CM/ContentDisplay.cfm&amp;CONTENTID=7603.",
"    </li>",
"    <li>",
"     Rowe DS. Neurolytic techniques for pain management. Jacksonville Medicine; October 1998. file://www.dcmsonline.org/jax-medicine/1998journals/october98/neurolytic.htm (Accessed on March 28, 2011).",
"    </li>",
"    <li>",
"     Ganji, A. Cancer pain management. Biomedical Imaging and Intervention Journal 2007; 3(1):e12, accessed online at file://www.biij.org/2007/1/e12/abstract.asp?ID=230 (Accessed on August 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/31\">",
"      Candido K, Stevens RA. Intrathecal neurolytic blocks for the relief of cancer pain. Best Pract Res Clin Anaesthesiol 2003; 17:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/32\">",
"      Slatkin NE, Rhiner M. Phenol saddle blocks for intractable pain at end of life: report of four cases and literature review. Am J Hosp Palliat Care 2003; 20:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/33\">",
"      Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; :CD007519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/34\">",
"      Wyse JM, Carone M, Paquin SC, et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29:3541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/35\">",
"      Plancarte R, de Leon-Casasola OA, El-Helaly M, et al. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 1997; 22:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/36\">",
"      de Leon-Casasola OA, Kent E, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain 1993; 54:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/37\">",
"      Landau B, Levy RM. Neuromodulation techniques for medically refractory chronic pain. Annu Rev Med 1993; 44:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/38\">",
"      Ferrante FM. Neuraxial infusion in the management of cancer pain. Oncology (Williston Park) 1999; 13:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/39\">",
"      Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040.",
"     </a>",
"    </li>",
"    <li>",
"     Gildenberg, PL. History of electrical neuromodulation for chronic pain. Pain Medicine 2006; 7:S7. Available online at file://www.sld.cu/galerias/pdf/sitios/rehabilitacion-fis/history_of_electrical_neuromodulation_for_chronic_pain.pdf (Accessed on August 30, 2010).",
"    </li>",
"    <li>",
"     McCartney, CJL, Chambers, WA. Central neuraxial techniques for cancer pain. Curr Anaesth Crit Care 2000; 11:166.Available online at file://www.currentanaesthesia.com/article/S0953-7112(00)90268-0/abstract (Accessed on August 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/42\">",
"      Lihua P, Su M, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev 2013; 2:CD009389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/43\">",
"      Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol 2010; 8:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/44\">",
"      Ballantyne JC, Carwood CM. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev 2005; :CD005178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/45\">",
"      van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999; 15:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/46\">",
"      Penning JP, Yaksh TL. Interaction of intrathecal morphine with bupivacaine and lidocaine in the rat. Anesthesiology 1992; 77:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/47\">",
"      Dahl JB, Rosenberg J, Hansen BL, et al. Differential analgesic effects of low-dose epidural morphine and morphine-bupivacaine at rest and during mobilization after major abdominal surgery. Anesth Analg 1992; 74:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/48\">",
"      Sj&ouml;berg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 1994; 80:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/49\">",
"      Do Ouro S, Esteban S, Sibirceva U, et al. Safety and tolerability of high doses of intrathecal fentanyl for the treatment of chronic pain. J Opioid Manag 2006; 2:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/50\">",
"      Eisenach JC, DuPen S, Dubois M, et al. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995; 61:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/51\">",
"      Ackerman LL, Follett KA, Rosenquist RW. Long-term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations. J Pain Symptom Manage 2003; 26:668.",
"     </a>",
"    </li>",
"    <li>",
"     Deer, TR, Krames, ES, Hassensusch, SJ, et al. Polyanalgesic consensus conference 2007: Recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2008; 10:300. Available online at  file://www.ingentaconnect.com/content/bsc/ner/2007/00000010/00000004/art00002 (Accessed on August 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/53\">",
"      Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy--a survey of clinical trends and decision making. J Pain Symptom Manage 2000; 20:S4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/54\">",
"      Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005; 16:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/55\">",
"      Hassenbusch SJ, Pillay PK, Magdinec M, et al. Constant infusion of morphine for intractable cancer pain using an implanted pump. J Neurosurg 1990; 73:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/56\">",
"      Holmfred A, Vikerfors T, Berggren L, Gupta A. Intrathecal catheters with subcutaneous port systems in patients with severe cancer-related pain managed out of hospital: the risk of infection. J Pain Symptom Manage 2006; 31:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/57\">",
"      Mercadante S, Intravaia G, Villari P, et al. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007; 23:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/58\">",
"      Kurita GP, Kaasa S, Sj&oslash;gren P, European Palliative Care Research Collaborative (EPCRC). Spinal opioids in adult patients with cancer pain: a systematic review: a European Palliative Care Research Collaborative (EPCRC) opioid guidelines project. Palliat Med 2011; 25:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/38/21098/abstract/59\">",
"      Dennis GC, DeWitty RL. Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 1990; 26:404.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14248 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21098=[""].join("\n");
var outline_f20_38_21098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H380437060\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H380436940\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H380436947\">",
"      INJECTION THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380436955\">",
"      Soft tissue and joint injections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380436962\">",
"      Vertebroplasty and kyphoplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H380436969\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H950360331\">",
"      - Vertebroplasty/kyphoplasty versus pamidronate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H380436976\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H380436983\">",
"      NEURAL BLOCKADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380436990\">",
"      Diagnostic nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380436997\">",
"      Prognostic nerve block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380437004\">",
"      Therapeutic nerve block",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H380437067\">",
"      - Epidural blood patch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H380437011\">",
"      - Epidural steroids for acute herniated disc pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380437018\">",
"      Analgesic and anesthetic nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H380437025\">",
"      - Non-neurolytic blocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H380437852\">",
"      Sympathetic blocks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H380437975\">",
"      Somatic nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H380437032\">",
"      - Neurolytic blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H380437039\">",
"      IMPLANTED NEUROSTIMULATION AND NEURAXIAL INFUSION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380437046\">",
"      Implanted neurostimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H380437053\">",
"      Neuraxial infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5386240\">",
"      - Intrathecal versus epidural catheter placement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5385911\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73805244\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5386296\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H73805292\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73805433\">",
"      Intraventricular opioid delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H380437060\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PALC/14248\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14248|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/14/16612\" title=\"figure 1\">",
"      Vertebral body - transverse section",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14248|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?42/4/43084\" title=\"form 1\">",
"      Visual analog pain scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PALC/14248|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/30/4587\" title=\"table 1\">",
"      Cancer pain interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/58/40875\" title=\"table 2\">",
"      Challenges neural blockade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/27/21947\" title=\"table 3\">",
"      Resources neurolytic block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/50/2859\" title=\"table 4\">",
"      Risks neural blockade",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=related_link\">",
"      Acute lumbosacral radiculopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=related_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30842?source=related_link\">",
"      Cancer pain management with opioids: Optimizing analgesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4488?source=related_link\">",
"      Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30088?source=related_link\">",
"      Endoscopic ultrasound-guided celiac plexus and ganglia interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32344?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5719?source=related_link\">",
"      Overview of peripheral nerve blocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20198?source=related_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6122?source=related_link\">",
"      Prevention and management of complex regional pain syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=related_link\">",
"      Treatment of neck pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34873?source=related_link\">",
"      Trigeminal neuralgia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_38_21099="Outcome pregnancy after MVA";
var content_f20_38_21099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78058&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pregnancy outcome after motor vehicle accidents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Controls, no crash, percent (N=17,274)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Uninjured, ISS 0, percent (N=189)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nonsevere injury, ISS 1 to 8, percent (N=308)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe injury, ISS 9 or more, percent (N=84)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preterm labor",
"       </td>",
"       <td>",
"        6.6",
"       </td>",
"       <td>",
"        51.3*",
"       </td>",
"       <td>",
"        24.6*",
"       </td>",
"       <td>",
"        13.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abruption",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        8.5*",
"       </td>",
"       <td>",
"        7.4*",
"       </td>",
"       <td>",
"        13.1*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preterm birth",
"       </td>",
"       <td>",
"        8.0",
"       </td>",
"       <td>",
"        13.9",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        5.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fetal death",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"       <td>",
"        9.0*",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PROM: premature rupture of membranes.",
"     <br>",
"      * Significant compared to controls.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Schiff, MA, Holt, VL. Am J Epidemiol 2005; 161:503.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21099=[""].join("\n");
var outline_f20_38_21099=null;
var title_f20_38_21100="Nodules and tumors";
var content_f20_38_21100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F70150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F70150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of nodules and tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Acrochordon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Angioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appendageal tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Basal cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Callus/clavus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chondrodermatitis nodularis helicis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatofibroma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dermatofibrosarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema nodosum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hidradenitis suppurativa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histiocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inclusion cyst",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kaposi's sarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Keloid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lipoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Lymphoma (cutaneous)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Melanoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metastatic carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurofibroma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nevus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prurigo nodularis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyogenic granuloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seborrheic keratosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Squamous cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tuberous sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Venous lake",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wart",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Xanthoma",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21100=[""].join("\n");
var outline_f20_38_21100=null;
var title_f20_38_21101="VO2 and survival in HF";
var content_f20_38_21101=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peak oxygen consumption and survival in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 231px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative survival in patients with heart failure according to maximal oxygen consumption (VO2) in mL/kg per min. Survival is markedly reduced in patients with a peak VO2 below 10 mL/kg per min.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mancini, DM, Eisen, H, Kussmaul, W, et al, Circulation 1991; 83:778.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21101=[""].join("\n");
var outline_f20_38_21101=null;
var title_f20_38_21102="Zenkers diverticulum UGI";
var content_f20_38_21102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52971&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zenker's diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium study of the upper esophagus of an 82-year-old woman with dysphagia demonstrates a large diverticulum arising from the posterior wall of the upper esophagus (large arrow) producing extrinsic narrowing of the more anterior esophageal lumen (arrow head).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21102=[""].join("\n");
var outline_f20_38_21102=null;
var title_f20_38_21103="Management asymptomatic MS";
var content_f20_38_21103=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Management strategy for asymptomatic patients with mitral stenosis (MS)&Delta;",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 542px; background-image: url(data:image/gif;base64,R0lGODlh6gEeAuYAAP///4CAgAAAAH9/f4iIiLu7u0RERCIiIt3d3ZmZmWZmZhERETMzM+7u7szMzFVVVQBmM3d3d6qqqv8AAIi4oP+IiMDAwJnCrUBAQLvWySJ6TkSPaf+7uz8/P2ajhf9ERBFwQf8zMzOFXN3r5KCgoODg4CAgINDQ0GBgYLCwsHBwcDAwML+/v8zg1v+Zme718f9VVf8iIlWZd//d3f9mZv/MzBAQEJCQkFBQUP8REarMu/93d3etkt/f3//u7v+qqh8fH19fXwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADqAR4CAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwocSLCgwYMIEypcyHCYhQAQI0qcSLGixYsYM2rcyLGjx48gQ1K00LBkogAdBqhcybKly5cwY8qcSbOmzZs4c+rcybJDAJNACwUYEDTWgJ9Fgw5N+uooU6BLn7JyKrVh1KqpqGJVeHWrKa1eD3YNOwosWYJjgxkg0KmAgG1m/88KTAvJgAJBCAQUcGuIr6e1j/wqEtyJgIFGhgUlLhVXLkC6j+zi1YuI8CbAnCyrWoyqsWN/kB1JBpB379sECwQIIHBA9QEEDFRHAODWLeoGAAgwOCQgtoAEAAz4vnuAbYMFElCrJsAXtuoHeVUzaGCZgGsHBBYgQLAgQfTe1AW0XvBAdu7DwlXfTaBagILvChIXSN09+HBNnj/zC93IQHvVpgU3myB+PfAAAA4sYBpbABwAnIO8sZVdcIe5hUACBwCAoYCD8PXAYYXkJQFhCToAQAQHRsAAAwxONiJlBxzG3nkU0iYAAoOw18BiiS3A1m0GVHhjJvnppw9/jIxWGv9fBcRmgAN+QRhcAoIZJkGGvBVgIwKA5YXAcU0C16QAT/IlJYL+qUblWzn+h+UBu6HZ3pqCAMZXYl3emIBvN/JogJeC3JgnjpgUaSQ+SC6ipF6EPaCAW7gZiCCjbAJwHIu5LYDbIJRFkOGguTGwQCGOeggiAArs1sBvJC5g4iARGFAcqqqyyqadb+HJlpcHzCZBn3H2KKGmoH5oiaGH2pOoIosGmOYBDjQQ22u+zUZYBJoC8ECLgbqmJairMvgslG85J8AD84lnayHWqcdaAw6wmlprdAbH1p3o7dqnazcm6J589AEHqoLHIpUsaETRAthxm3Kq5WDZYiPBqZQge/D/PMue8mvDhlCmCAMDxmPxxfFkTHIjI5/sjskqK5Jyy+uwvApmA70Mczoyq0IzI5qB8p14lpZnXgMKtPfAq7fYfPM5Oaey8yI9fwLoICvi1qR9OCLwAHC4KL10OU2PUkBrq6XnniBCT+eAbw+QjSVpvZ44HSGGWceeeg0ah5whU0/KcbyE8uL11+OELYqPgwS5pW64sahbh5UOwl3b27WHAGsPC6Ljhhvy7ebYhcwYnJq5DE54OIb7PGSd+iJQdHvvlcdAvaELIIEhi+1pOZizH9I34IQAL8iZtph++jepg4I466QBy7FiB0AaInmvsQti3L/iqNuoACw/WeAArIjj/9UrvlqfsbUYf3w3yX+Sbtmtaztnu79JCzResz4w9yA88otjuAiK2GTakyEuqWYBsyGa0UxEsPQZbH3vaF805oObCHDLEhNL2gMh2A4JQgNk11AfB7PhwZOJcITXKCHJTojCaqjwEpzRRNQy4TFmcQ0TMyzUBluIjtQ1IE1zI9u5wMeIGGYCX56oISK404C7ieeCgYlcJ1jIQ2mkjksNaMCsIMSlAzxPEUbEoRQ5ocRDEGA9WMoOFBuRw0tQsYrQ8CCmzrS3DpFNTGQjAGtaM7c0GSBSB2zQdQDwmwM8Sog0Sld9xtae81jnO9Nxy7RM1Bs1lcZGuImeht72OEUK7P8+rElNJMsFyrWsbhJvhKMzJPi4Bt1wZ/WRwKi8x5ovdedd0tJj9QoRt3MJAnFIRNxtEGij3GhScrZzi4kktRpjououCriLBOLUuWIKk1gHihd2vKhF5rzFUaRxFebcuENVFi5hlkjVpuh4uwFa7pSLcVA0FRPNuwhCgXijDKDwNbUbDQmJclKTX1hDSC1taD6A2pbmOMmAfnKJQb9ZjF3M9J8EhFESqTTnMq7IAHsODzhdLER9BkHL61mUm8WppeYE0Li7eAxx1qERTDUF01yBKFWWWlf4XGpQLAnnQKvaVOeyA5yZ/pAt2UsMd+gETv5RrGLl1Cg4UudEoAnxAc//YyTQ3qdHk46OTLhJk3Z8Y8iCrrSSiQyYhvhFI9rMy1bSwRFlOvcrLRHgQGcVD9c8+dVm0u9AzeHT5Z6KyqhK1RsvJAZBBzNG3IGIAe2MDLcuCoqMHvYYiQVGuxqYiDZyJ7KS2BllP2HZyxYjs4cqrWmHgVojqXa1wWitfl4L21/I9jO0rW0vbuuY3Op2F7yVi29/m4vgnmW4xL0FSnjC3OY697nQja50XeKT5HLjISLJrna3ixEMYIC74A2vdkliXXNCpLzoncZ508veVRq2vfAVxnrjS9/Tvre++C3uffPLX1rMt78AxsV/A0zgWQy4wAh2xYETzOBULLjBECbF/4MjTOFPTLjCGNbEhTPM4UpsuMMghsSHQ0ziRYy4xCg2xIlTzGIArLjFKH4xjEks4xmDuMY25jCOc4zhHfM4HNgVr5CHTOSMeLfISE4ykcl74+8q+clQjrKUp5zk79J4vzb2cX61fGMsJ5jLHQYzfcWcYTLD18wVRjN71RxhNqPXzQ2Gs3Xl/GUvI5jOd7ZzgfG8Zz0TmM9/9nN/TfAfG/y4EIRuj6EzjIL/4ODQhGh0ex6dYRL85waQHoSl24PpDJfgPyfItCA+3Z5Qc3gFqjGBqAeBagGousMqUA0KVi2IWAtg1h1OgWpIQGsA6FoAvAaxakrQa0IKgNggxsAKiv8NAGXTWAXMDgC0Q3yCFDC72szOtra3ze1ue/vb4L5GBiAgjgx4QGUU2AAhxm3acZ8bAO5WBLshkW5fUAACFxDEvfN9ARBAAAIbaMEIROCBDWwg32HZt77xze56D2Leg4CABgTxAhBM/AUb+DcIKPC1cUPgBQDwAATejQiIO8LhvLi3CAShAXy/AAI6AMALZIDwlmfgLCpnOb4HgXJ4k5sQ/475BSQOAB6sHAAXUPfSxr0BClSc4PD2NwjynYGW/xsAA//3udO973+PfARe90DWR16Ie0NABC0AAL41QPIWiODfMgCA2TXQgn7re+Uy+LcIXjDucV9g7mnnuQY0kAH/HWT8Ai/n+CAG7gERHJwsFBh84Q/fcHVX3euFALi6HT9xo4/geH7XAAUKfu6NIx0EFec4u2Vw7hGAoAWRv/kghv4Ch7Me668fRAsgkPaCqz3uhKDA0QHQgtzzQAYVz/fUhQ9yEVBg3BwvftqPH3zRe4DmO0+61kEOb5In3PrYv0DlAWB6k6udAiDQgegv7gF/iwDhNxv3CFregg2IHQKfVzvYP89uq//770p3AW/3byPgcP63c4JwARMHbxMHAbK3eHn3fkPndROXbuoXcl43cvM2gf+2gPqmAWAHAmoHfzInAjxgJJEXgiNYefvnc5l3ASJHAZFXCLS3dPhXb/ZH/34ch36pJ3fkdns8p3QacII6cINHB4SFsHtpJwPq5oCIEHnSRwhgJ3pyt3cP93NRaAgzKAMcx3ABV4KK9xlb2IXiR271Znr39oLFV3sTx4UJiHo2mH8AkIMZIHX8pnfkNnY3qHRzh3/F93UDiH/Bp3dp54SD+H8+qHWC0H7cl3f/B3FmR3aCB3QXMAKOCAHApx8zGHFlKHfqNoFv94KTGHkd+IDhdoqomIqquIqs2Io/1kaFAItSM1KUgAAHAFqm5Rb2pIuytCl5YSIR8BuQgCm10x6ZAwnBKB5IQw52oxjCSCk801idJY2joAADcj/H4UU1NCu/4lEUFDpfFE7HKP8Ir6MalJCM0GISbsFSqHI2I/U4x6E4iaAbWrKOUFRNlHA02oJX5WAdcUIvkBONkCCLnZAXm6Iat8MeGdJU0hMkAtQ7hIAa0EE3AGII82QJ+igpJeEWa3EpdxErw/Mj2nFKHVIe70EIT7NWy8Eu7eEAsqIaL6kdhIAi57BHBTAxz6hV0aMXv9EeoxSR3KMbkBQeeWMpyKFVN9Q80hEettEu6eg2y7gnnKI4DCArANCLqHIgv3gmNIk7B6CPDmOR3sKSquGSZBOT4NOVDWEbxaEAkhEv1JEtBjAbT1M0HoWSa7RSSBMvmaM47KEls0IgMmkOrHFGW5OTfuEW3CIihHH/HEV1Q4yZKxlCULHEPSGSTM1UIifCjw0SMrnhUauBHMWBJcgBJqHSVhpCWINQNJlTRoSgAJY5KX0pIzDSIgiljjfSGi5pTywyTz/zNiXpHuCTkoRQQ/iIK8yzScvIjK8hAKOCmGziFy45J9VhAFcSUOvCO97xH6c0nQLFJlXlReV4l2fEKQlQNLokCCjSOUK0OgmgmqwBloEyjoRAGMd5L7fCIBiynAthIXhiT6FkV3FyHLjIPwzQlwxySVujIQLEl4mDn8wjHOEoDgSlUNBpNWyCU6tCO5MxKxqqUwpwANlCi69ZK/WimSvVUhEZJ4SUAAmyI1gSL5giPRyymaFD/x5EZFbNoyUMYCJuGTw1hJz2Yh8TmhAWkjj2tCpv0iIKwJnlWJHrCDSXtFlJmRstKaRr8TMkSaHAmZP2s5OCqS4cSo7Zki704hd5wSA6WZ9vRTv08x5kdZcGGSg3tFjhMyRNmiPcA5E58kVvuqPy0xvLST8uCaH2oqU56ooDYY04JECKqkpLZQm2WKCPWqmWeqmYmqmaym0WwGSb2l6A9qkwE6qiqjKkalqn2l+pelirumWCpqqvGmOx6qrZ1qoaZav1hauqpKvxxatV5KugOqv4BaxrJqy5aqxdFmLEml7LOkLNWl7PCkHRmlzTejzV+lvXSjjZWlvbujTdulrfOv+qyBpm43pm5Vpm51qstZquzMquFBauLQOvrOqu0EqvDJZoqrFo6FpskqYalLavvbZpqtFpAEtrpKYaplawtNZqr6Zj9spgtoZrDstsvxZsE8tsw5aszOZsGlts0qasD8tg2MZh+CoA+lqqxNWvAvCvKPtbAisABNuyunWwApCwMqtbDHuzyRWxOktcFduzxJWxBxNkVFa0Rnu0IwEUHHswyzVdTvu0UBu1zVVdJvGxF2NcB4Fc6TCyTItOLaO1lYq1BgG2jyq2BUG2imq2BIG2rqi2NROym+q2AsG2rWg4rkkKxBmQktoaeTkJMdRG60ifi0C3rEgXq5I5gVmcgjv/CnlLINToCCDJCX/7uOHTty4Dt5oKGQzJjoVwt4xruQSZCAoluRTTRpwFCYSrWaqJkmRiCIDhuTpjufIAGViZp1BZUHkqIOZyl4RENq8TJ37ElD3pG5+EN+ZiLaRkHuaiFz9aoyrpT0s5KwR6vI7Uk3gTSuARWHizmq5BvXWzpYKQuqkAQsZUpI6lCFjpumwBu6IAUI2LMV4rUhJgmoPQS6aBAIADTtyxjM0UopVTALjEIooZKMNSIxYiKQkSIAisIPozn17SN0OKTBJAUBWaTQoyTm0Co1lUHB5yF/uruPsYQAB8TIcgvqigTZ8FCaOFmoXwuotrChIlu87gAHxr/2HxO5NbkyH4dDaUsRYRQBwVBcKLwbwA+iiVQhkWMihSYgB0ssQYwjU9TAA/3MJs4Z31oyC948S5I1gSZcSCNCcgrMWrG76YWwu6ISlI2Y6ksxayYhiXRKPfYVHSYSIu/FV/pJan+ZomJUnKSAjEiDYRYCGwYza8Owxu4UWooppCw7mcEBoy+iPs2FFmhRoE01QdY1cgohe4xMFHrCWeMqRegsDQKMoFQMq0IaLLCRgfChwhmi2kHE++0ieHsVQdjAiU8cpjDAAmnAoiihuVWaJYQyPzdJGKcRjalMhDqsncxCKyhMzbcjcZ0rwOokwhDCsHIhmu4r5CkqjAcMjQpP/I7WG+lMAfsZE1caqjMYIXgiXEmfwtMEmU3SIe39I61Ku9AjAbNKwuD1OV6utWYto8CVotbeWU+/IcxbS84KNPAr3Cu4wKSsWdl5MaQIMZAAPBidE5oOPCF3lGqzIxEYAayynN9WKnV3lLkDUq7hs/xmAbzFshapXPMjwJcvsI7CsJwEO/y9DQp7AYtCgiJ/IpDCJRDMCZNHLMxuLCm8wWD9AdCRKb0ONW9SLJhLAA2pEdgJUrwKvSxZDEhnQY1yTOmDDTjlDTjhClDKIizqDTMAwia/osQF3MglBX1uOMgprM7gxWmaKiIcJH3RGlDUUqh7GhxeQvbqnVxGAh8UL/Jg41CmL9D2rdCytMCqFbDUdaNF49LGB9CY3tD4+9CyncCpNNDUeaFy7tnFVqw/OgRO+rK2VRxpg602R9CnW8CKptuawtCp3dbbD9wq1A1rUNRvnS2sLwvp9bGLl8FjJTScKYxmxMLc8hOvVkOber3HhEOnw1K16yNgbNP2SzIghpL+X4l4U0SKp9H050F6zdLj1qpXVN3ZGQ28wyWYQV2ZRA3HRz3CzMCfbdVvsNNjdM2wX8y8KBI+izVuTIU7w0G36VIb/81dgNLGb0GmmKzHU8wIRgvyiZTQKANDqiK8fslh9+GAv+3q6t3zJM35PQ34+A4qLA4pdQAiSAAg2r/wzJXY/QazmYcSbQjeA7jOAYgqirk5v0LDtJOcSYbNfFZCnjqaPJ+Ru6oxqDZS8Y7SBYAjpzBZwoU+KXUUon0pKw472mJI9zyRvEax/q8cYslYwbLh95dN75nTY7oh1L5easIR2+cTuvW+bnDR+Aod50fB+RkAIq0GrmyAw1/tPdk5SYUeAWAhsulZCR7OMMnpRGJRmPxN33PZ808rq34xc6slNMPqTZgz2ybC9G/SQbri0i3lMkPtzbnBi241RoY8EjrCUPDL6EVMCKYyHD/Oiy7j0ZHEOMU7ly88drBaOVwxY/+roSApwdDiJrEeIGjOuGcAIBgAHc2R5IW2X/rf8IBFSPbhPB5nLNzinJr2MuZXXlp+wa/rxI0lHQwijrZsXaryM66I7gidMeEuI/6T3H7L3e6o66Wq4Jg5IYda4AO+JVU8IZPlzImp7ErYNQQ3LwCd83T17q3As7w0NNXNzOm76+rH7xUS7lVf7WEJwIgk7o3LntSIYB3Z4Isd0Q8J0IBU8xJj3rsskZY+Mqqt65nmzyQ/JTImVRl12/sTzyirE/6tnGnXmVGE8ZrK3upH45WX3qoDwkwJ4IMC7j/9EMh74VM48INX8cS0nYYO7HIHK6xibPV48jck324AEwy0HQSI828+NF8SLH6jLyUB/c6k73hN3n/j4oLxoJJ3D/Azhwssmw2f0Q9qRgmhnk84vg4stgQee0NI4/CmgN87z92bf68qtA+ZtwJfx5CWOeFQNftqC/GfgdwZpwi/GsSdi4AJ/ikwiQvr+I01+R+mm7+qmA4irOCFJJp5libJD+KXdxHGzxjnEyxZ3B+9wg+o4htqiR9HT+J6kOKZ7kRFSiVi9JJuNxIdnSSuQYMsIIOGRyGFWJ/OEEjNfDIM38/AcRQ78ZNO2RQOUon0whto4JCAALCQCFCQINBAYABgoAD44LBAAJCw0Gk4KTlZeLhwUAB5MHhKSFhQaEhQKECgcAAgQLEqKvBgK4DIQOiAWWhQgCp8PExcbHxwMByMzN/87P0NHS09SKw8EIwwwMDQAFDIwM2QgPqtTn6Onq6+yFAQPt0oq0lAy4AgjWvtjYqwiYAPrB+jepgDBGk+a9Gpbq1L0DDmAlUBCLgC1HAAggAsCAgAKMAQ/Ge6ZspMmTKIkdwuXI4gEB3DLeW3RKIABe3U7xypayp8+f7d4BLRZMVKgIACTgsxbqAE1JGS0ZQKop6qWCBwE2WNCRmAKqEoexcmDJIiOMsrpZXACqkIQFQ4mVjEu3rrFDiQ4g2JqAFyimwO4JOFBg4alDqHCZs8u4cVB4jBX80jh4Kc1PhXwJGERJsWbOAA2iyhTh17AE4FYtZnXK7C1cpgA0GDwsAv9IunMd60aJ+l4+mqQSLAQckudNfMN2noq9u7nzZkKf1wVY7IAElFvb1s0tvfu0A0iV/i5EilfEBzQDG+cozhu4bREFLfZOX3f0+j2V5iRGK/7IqY1xh9+AxVD20nihtJJLeiE9FNBrCyDVAEW4POAfgRgCdV+GHNYnYIcghihiiBuOaKJdH56o4oosxlViizCOlGKMNNZoozMv3qgjNDPu6OOPK+YI5JCn9EjkkUjSJ2SSPhrJ5JNQ1rVklDU6SeWVWMYTQAcDdOnll2CGKeaYZJZp5plopqnmmmy22WUHy2Qp55wjWRDAnXjmqeeefPbp55+ABtonBhgIauihiCb/GqgFdDbq6KPF3AnppJRWuqOklmaq6aYgYsrpp6CGal+copZq6qkmeYrqqqy2Ch2prm6awgmx1oqMqrZWqgKsufbqa6YrYPDrsMQ+WgIuxSarLJUk4JLCsqEyQJVF+0ErJwq4qGDtp+YhMMu2dJqAywrgckoAAw884M1LrEVwz4Xl+niCYCXEq+kBv3D2FizX2UvkDYKR4K+l1gQjWD4vKVDtwDbiIBgKDFPKFGfFUByxjTYIZsLFkDJVGGxb5bIwxzHiSvLJKA9lcsost6wlry7LuXLMLc5Mc5Q233xizjonyXPPJMIM9JM/D81h0UbrKO49NiStItJO14jtPThE/20i1FbD2Ow9N2QtItZer3jsPbSG3SHYZp+4Ai4bp3200G7XqAIuEMeNIdp2g5gCLgLnPSDefnOIS72B1wd44QRiQC7iSsLN+M7aPt7d4ZJ7d8KzlT9Heeac07l556Bf+XnopDM5eumoD3l66qzruHra1LUuuuN+G5TLeqfE3p0A2smuIe15G5SNAeoWo7t0vPvuIvB2C58RKQd9hBAs7FKY2msGNGCQPQtExC5EEjmVvEH7GQyT9rwLthRsEbEiPijkt4bv+QYZlICBDlyCC1zu4uKAAsBJQP1Ygb+wve5mwmsAAxSAGABIDyCxcKBeglEAaimQAPU7yzDAA4viSf9PekQRgAQMkonkkSUiEVCXADzoCBAWwoKiIOFNugeAFMZvFf1yYABleMIaFi9rB6SZ7c7XwAdOInlM4R0IPSIaByqMQgJwRPK8sQCb3OQ1rGgiLECxEthsMTNVRE5raNKIJnaRNu6CikWiOKEdHuSMhrFaEGPmvMzgAwELnB4SacI7GGIwegzcSB6nGI4fFkIB4JiNAEUiwhleiJAGQBcxCjaIJvaQGMopxCDM4otFFuKSZpujy+qYGK44AoJ/4SMosIe+QyoAj7CRonaU0jsqVsaTh8RFPu4hy1PQcpL3UJcWKRPFISpsASJDwEsYUEmREPM2UROl8ibJIJMQ54X/1ZymMaSpzYB8CyXeyuEYu8kMbpLznN4xJzrX2Rx1Ws1b80nHPtgpHXdG7SuJwUUmlAKS/rGRmMW7ZkaMwS4BLAKWrFmHWciTiWJsxTSZs2fSgpGTRnhDABExgAF+8ZZsOEAcZlHmJGaDO3eBhTyLSVdSNqKOhYaioSrBVzwZJ1GjoSZ3GBlEMBxgirf0bqGQKERXiDEhNpLndoLoFyGpx5JcXPQlC3gALpDiUqMQk4wEiEA2aco80nkEp53JBziYcq7NJOQVZFGFAmBKjJcMQ4EqbEtCVzEJVyCAghl0SmdkIhgC8OI61tjJTjlX06F9NZ+sKagYPzmLZ55irQ6l/4jCqJnUVfRuj5ZtYmiEUVUCCAebOkQFNLlKzpuK9hQ3nIpHukGWCsZRqGw16TAKkL0LPkJd+hFLKjObFaw8bzl+xegjskcxTkS0q6Gj6GkP+cNKfOMeZyXqYl9IFHsYtBsInQ9mt6hZ33bWgbBJhfrm+rjCDg2fIxEofoKKOvMCDZ7xmCeBXtOe9iKXnvjt1H3zy18Cube/ALAAowCMjv/218CgQ3B+FUzY/RL4ZQ8+B4PpOeHKVXidFy6vgyO8jgyTlsN08TDiRNxNEgfOxNNEcd5U7DsWx83FrYNx2mScOhobcMMEOoGidszjHvv4x0AOMp8IJeQ9DVh5Ni5nof+KzOQmO/nJUI5yobSZ5FvhuMZXHnGWDbdl0lVZWV/eZpdDF+ZisYAFNSqzv9TMTjbHy83ohDO45ExOOlvLzlQec4L1bDaDHKAbAKQRnpc1aFT5uYVb3RmfGyw7+ylxEZ+Z6dkWfdxG48MABwg0VIwL4qBZGgG8MKhAptvpDBX6VM6jyCLUCNFSm5rSWXNeMCCNTIu5+tW37o6fAZ3oOMM61+g4dGgP/GtgU8PRBQh0pNtcbGNLQ3iY1vQmWl3iZjsbGsILtQFGjbs8a/PMLEq1QauSFgxbW47nBoqsx71sc3v72vp9N7zfJu953y3dTpNzD3oA4FOzSs7+JlbAUQX/cHyv2OBGK3i/ET40Ny8NF02zt4ZjNDVcVE3iH27R1nDRtW5K64V/Pqebx4aLsmmzW9+sM8N/sjYBtI2c51Lpx9r1LizTaG4CqNs58dUNfcGlkTFeuU/2JoC+nbNg6kOYUe1bo8Gtc2IztTWZhe4TxbHTY98L2flsLujIYTzjMLrc1yc+9rKrY+DuTjHVzf6qejvGTlH+8ZELh3ZTKXhLbsr7muBEdiSvfRhT2o2Vbuz2xgReN4P3Wt1LdXfIeOjv21q8qBo/oMQDEfIuozx+LI/uwjPm8I7hfDQx3zLNh9BB6TieM0Sfb9KzzPTEsCKKXA9m2qMM9tdYrEGuk0ep/9Ivffd7Fyb0t5l1KaYYrE+a5EOF+5oI5hVvQU9GYtIRHkLyj/vxOfJtX6zlg6r56vHKRqBYzDfGESBpJID5dCkX7gvc/RwDf3GGQQuNTn8/lry+TvAh9WEkP+HwdzHyt36EgVENkGmPcA+4xFcYhQnGZHy00X5912KkB3oBEoC+4n2fIn/O8X8Nt18cMAET6BgWyBgeCDQ5UwMhMAETEAMVEILp8AEs6AI0w4HNcYI9YzMzkAM0UAgVAAMwGIMVcDM2KHgY2Cs2UwEhQAww6AIsOAE96AI5wIIVoIIsCAPE8AFDWIMV6Hj0gYM6k4Q9OAxBWAhO6AMfsAOnoITHoP+FRNiFlXeEuZKEMcCEIugCK8iCM8ABK/gBNTADMDABIUCDw+CGXOgceKd3imgmfAd2xLCDWAgAPwiDMaCGPzABM3AKMDCGkliHhbiFMaNgcBdkRFZkc3ditMOHLBgCLyiCFcCCMYCJMtiCNfCKM1iItxiKckgNGtgqvbgpdPaLqyKMmRKMu/h6x/hmyRgNxHgqzVgpxkhsnhcky3gyz0gp0chf1zgp2UhPDycAESc73chOFScAFyeO1fgM2/gpGycAHYeONPKN4YhOJCcAJhd0NFKO57hOLfdy8Bgj7fiO64RzOvePMFKP94hORGd0Bgkj/chfTud3ckM3/GV1alf/IwupjV5HgTYSkfgldhdZIxbJdnYTjBtJkjOWjs4AkijpNusYKqMYdzI5kzT5J6dodyoZf1yyiDzZkz75kz/ZiMOYkwLohScDhnPykt9nlCSDlDJDlBFTguDilFlyjUsFjEzJMVSJJVgzRPW1G1r0DFfpELWkKVK5LVs5O8+GHMRjImNpWcyXlReTllTSlchhEQiFFHl5UfZTE9Z1SuDwFg4wc4SACZiGUA8gGpWgTwh1G1C0SzDRPqDge9wwQMLBPrBgXYQwc+r3l8AUmeEzWqYmlxFDlzizXwm0QCrVWqvJFjI0DEHlLRGBLmwhH0kBF5GUDdJnR4wAFrFJQ2R5/xwREWh9RH1/xFYcFEFmARWF8Jv+YR6htUI7Q5odono3YppQYpciExupwJ0LuByCQQjBoJdJRx3MIRrPZQA8FZ66RQkLURhbRH4K0ERFxRJfJBw2oVjm8Fnr8kVXQ50ncZkwUZbOsFTWaQxeiQAGgRELygj3IA5adRhwsR1QyWVraRyryTsZWgBh2ZzQhC7JY2vUsZsXBZsKwF7F0EjQKX3FiX9vJEi99FnM+QiiuaKL8JZHA6AjoRRqxVbncKDF4DzEYzuAFkUatBXBxRMAQqG+iJqLtZd72aEBYV2Xpi6yMJjfMz1TWiGi8RoQgVDTRSGQyQCSmYCecRAIhYDJ8/9ZmhELYLoelEGm/jkiZ5kOD3BSWyoAVHUAy9QAxPdzkwldfAU+7gMSzmMRBjF8pqRBsskRkzBYTPpvFTowdYoODQGb6tJaeMkXN7RFeIkQPZRCHUQMqTmf7uMRFoVFujB9GdFrPYGdRDOpa6aj8YCiKIUK9xNANWRW8YkRmABHc2pHIiM8L+EAqYoWiDAbPCVpPgGrpiOr9lKp56AUmbBWG8oUzLETffRnB+hXwAmXs6V7lqFBFmUVj8BMIwMUzuoz0PpmtBoPsoALBlAAe4mti2SfvKNAm2FVvBSsF2UcpJSqD6EK/HSBTdpv71ou64okopSgQiVGH5ULhSmow+D/o7kUQdnFDt/VKNKqLAt7JA3LlsLEFZnwcRlxSo5gEBciW8PgCv6hUrnVUoZhFBybsFPZrprTbIf6CifKnwxQTeUqdUU1WbPRO9+0VJURRU7lZ5vhe3sKXAwItPLaDYUKFBGQGtBJDTaAAzeQkMfQscnysUQSsnuxQFshAdlxExSinhp0CN12VBeFTBE0ReQVQXaFV8mjV4hBTPr0V61asdzaFdI5FN3KEXgaDRqDAiRAONtks6eQR9MApOB6DNZJGSghpQxhsfEgtqqjsw/aAGcETYjkoMdHVJLFWgchHkd7WbvFXb1Vop3Fn8SxRL0UFHzCb2AUAX/WmJQgtw21/yfjNS4qgDmA57j18KOaG5zIoHpFq6XIgLljibm5Y7E4Kg2cCyRkmztUQT6rGlrlWgwsewr6gggwy1JwmUQc+rqi0Vk2Crh+ahTVOw19gru5NJmOIJtLCnh6ErwCUCheW6fWgbzNEL+qxwuj0QzSi6AiYQzWGb88grOI6Lk8Aakv5U/t8b2ThKBQJZ6aSQzbxTvdBbszW1fhRQys5K8/0UT6mZ7wIhb3sALDW06Oq1wQmADKhBRXqz3sogjqt6avAKaBunXTO6jrqT7mYD7c8D2WyTtI3EoVK3wJkQv/4xvqcL0/opTRYKvP0URa7KHIYAKKy7gyPA3wqUmEsC/e8v8AelEVo0FB7jlclnUu3TBUoxGqifm6xhAMI3QQr0lIehyWfjG90EmcBDoNVuwjWNwM9PW2YImmVPoPmPkYZLwQ64cch3AdNoEJbvxZsaFEgnEbv/p8IZwcWIRLWsQ7xqqAYcmfo8Gf8OnAJAHB7STLdzbDLGVrabzGMwpBhfkK1xoTxuOt/qFZeDq6ihQ/p5xsiZRFCxzIdSxcLNov5UYNh3wptAwtANwvM6cXRvEAlem7ABGnaLVMyeN75BXOvGRGpWtLL5EA+lqAZKkZ7dyhxGSsUQyaYvoAydsM1ew65ya5R6JeJWO8prUpW5GusXywPgHQjcHQ6eWqLFKpkEv/LP18I9zk0HaB0e0g0CZRhiFmvNBS0TZyONszGA6wybZwRNXjVKSbPSVNQ1BUmIrApyOVcqGAme4TngXkPrcAP+Yrqq0xVph5VRAoDIRJDVbYgq0Yg7kIDWBbLCKdZlmmsreF0npUVxO0rX5afcmDwaObm2/Mym2FFIMLEHY8qk6U1r4EF4Gmz3YcyNYQISWqfdKwg2M4iSIohPIL0viRwCCSv0VyzSQ41QeBlz6sR62rRGhhqq4UFV5EHdnRvYVQn0Y6RQABrFO0D9M1GxIwFZXgAHAku9uGHMKTdNLAhmR4h08YhVM4AVWYh5F4CobIjI4HIZfFyMigEb1zqdjG/1kQXaJxgUoKzJvPkLb+J9iGR9hCJUW9jNh/66ncGkOApMc1lNJBPaGHAaP+CSCgNKeRZEjNOQhkAReg1L5qJAz9Bw0VwImF4NFnmIZruITGMNtOzZRXKxa4fRe4sNvMygwcjVoLHBdv6dfIYBsSKKny9KDZIM7Ojb4t7cQPBBvWPdkRdA3WpaZtsRLBh6+zNJblBrmOZT2eABtGnaWn7Ymn0IR5iImq6IeAKIiEKNugWN/FYKukxgxv8Uu5M1OYJq9QpaD4wEs8HOTDGuCFetREbRTYYJlEjQmP+blKLAxRChObER/7ctwKfQ4EPhS+gNAK9dvV8FrUAIk+CIQiWP+JAHCJmVgIm7iGKF4I9K2OXngIa0x+4+Z87GdH9Lqm42XCIw4K0v3ciJp7e+zBxeNzfmsNSo4P1gdYiyDczlfoJdqa6btKGBEMBz6UCe4cJnsS4ZRe+1PI0qCKgrjUthiLMzCLMVCLTxjjADCLro4jTOlSAwENdq4dvJ25wO2Avg1aV6TKRg4KlSzaL1UcZjQcj35EoJDKZ8qb3tlEIITpWI7gBwYZeJQNpYHf0+DGO87AvoUQ65saTGHMzOzBbWEx7WtRGgHknwTNyc4vDrTMi9QNorGh0I4RVx7YWb5gkNEAvkcY2i4N3I6r3r7rfzRDUeQxyDTPwZ4ZWUohemX/O/bA7herVwBBIYvZzu8sGlPe2DUETVEtaMs40fFVRc7I1zTSxcig8vFg3PpO7RliWli0T0bqqLIRQcoKUL7eDMQXE2ck6tCwsaMZJYvsDEXfE4BdCCFfMskYwBpE1Rr1C6Iafbf5WyJ18+vhLZNVE7VlFGKtUCN8Nigftsj9ecxT0oQqHPPJLoTgT6Dtu0XE3Jl21M5XUTllwxjVU/wjCz70WzQKW6brFPHUFV3EVklrPU/VtFPl98VO1IYz9lBd9nbxM1StUoOrfUDXm9nd2Jd/xtjdn6fltufy3N1DpqYfXWl1SJqrEXE0+qchXA6B1XcFwnk74gzYt4303/YB//kULflScvaF/QrJU8lKpzAsHPdfRPyoZRilfNNUrM97vxGOpfqBn+uINDJIm9jpe8DrO8LE/vgts/QwQvkHMUjnHnXmAAnCg0e1m940/L2pRVVRdZviLuZ07E1bDwwkXw69CwgNAIMAAgUABAaDhgUCgwYEAI2IB4QHBA4CDgAPioSfoKGio6SlAAEDpqqrrK2ur7CxsAMBsra3uLmlAbWmjQICDAiFh5IHwAcNC8AMDQbIm88LDArEgwXHApWfBxKP1YMKD4QJCwCZkQ0CEYME24Tqw4QIwPWVCfXaiMALCaCGiDwxcgQAkiRH7ixFUoDMk66Hp1JBnEixokVRtP8uatxoi5eqSRxLJWBgMVHIXA/AnWyFaqXLlyEzwpwZ0qMvgjQHUaNYYIG8nKaeBfsJNFTLokiTmpKptGksm06jSpV6dKrVmUyvav0EdavXrxYDdBhAtqzZs2jTql3Ltq3bt3Djyp3boRdYrV3vksqrt+8gC7wCCx5MuLDhw4gTK17MuLHjx4Et+LXKdzKhypYza97M2Stmy587ix5NuvTF0H5Rm17NurVrUKr1xn5N+2KKE7VzV5wNlrfu37dU2AVO/Olwzr6LK1+1AsPy56ySb5UOvfqgEsCsazd6fDP17ctJAEsBHvx3yt3Lqx+EApiK9dbPT5UPv7YJYCvqQ6f/3/R+PRv6qXdCPiUEqBx/SrVXDw4GgndDPiQ0SByCSYlXzw0SaodDPihk+BuFSGFXD24eQmdDPiaUmBuISK0ATIoqVsdijHilZ5kKwHRI43Mz7jifjZOlAEyEPh4IZJGd9QgUMAUiOeGRTmqmZE4Y5BclcFNeCVSWMwXwnpa6cQkmTGK+dAJ5Y+LCwQQUrTlRmWmeBGecV9UQwgQTxFCBm7J8gKcLFeBJA58PzUmnRoYe6tQMOdAwSAUwEBrLBxU8+gEAkuaSqKIUbcopUhWEAIqbLuA5gaMu5IBnBXbiCQMolFqK6QR3xlCDplB+epWnuuZUgaOfSFqqDx/sQEio/6PECkAFl655Kwyv4sJrr7eIWQJk2GarbWBEgldBDKOy6cKdeM7AwZ0f1DADDLS6AGulyzbL5rLgSpsrtVGJaQEQc/Xr779nBeFceYxGC6mbMRj7wwQzEAIDsPS+KyufIUDc0b34NqVvB6yxMHB55+IZwp5sBponw37mWYPJE7hLSMqACrqmyA3bm/FdG3f88c1vYsxzUTmv5vHPnfpMNE1Bmzb00YUazfRLSZe29NM2U02V07BYwLHQO1ttnNf5Yv2K1qE8Ewk9xbgEEijqvCMUMGkDMDXYsExLN3cckQ2KAccggDZMa39CAAMLFGOASqDMfTdLYi9edN5bf3K4Af8G/P0AMw0wEAkhD7BDSE8C9EPJMc04wAAw4xAATTbvDHKJAuAcPoriQDHguTuCeGi344NE/U0jqhcwuCCaRzCO7AtsQsgCkZTTgDsIKJPA4IQ4kDwAxgd+jQAN9CTI2w4NQntOmTiAwALelLg77wFgsO1hkv0VOSGyX24IQ/UoIEE/g+//CT3yEAACTAKAAyQAAZdjQALwYQ/tAQB/wPCH7ETBAhO8D1vxC8XgHjAObEQQe/VQHigAc8ESmhAy7uNdUUh4wsgQQm+SqwY9DDG8TyzAJwRYwDhsGIkcPs8TBiSEO6wnwkbkbhDKSB/1JhiKCraQMRkMxQEWIAjR+U//AOkbBQufyMUu8iKKKlwNDOkHDoYcwn4C8EcnAKAOf3wCdKIjoAFV90E6CkABmdPHIMoxD00wMXFdQ4pJZliPAR4Dj2FMJEXGSJrxAYWAogtFJBVJSVwwcjSOzAkBPagNZWCukqC0xSVFk8lQmpI0o+xMKU/Jys2kkjOrbKUs/fLKzcRylrj8Si01c8tc+tIq+wKYMIf5FoH98ph9uZYXl9mYbiHzmdCMpjSnSc1qWvOa2MymNrfJzW5685vgDKc4x0nOcprznOhMpzrXyc52uvOd8IynPOdJz3ra8574zKc+98nPfvrznwANqEAHStCCGvSgCE2oQhfK0IY69KEQCY2oRCdKUXEGAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The committee recognizes that there may be variability in the measurement of MVA and that the mean transmitral gradients, PAWP, and PASP should also be taken into consideration.",
"     <br>",
"      &bull; There is controversy as to whether asymptomatic patients with severe MS (MVA &lt;1.0 cm",
"      <sup>",
"       2",
"      </sup>",
"      ) and severe pulmonary arterial hypertension (PASP &gt;60 to 80 mmHg) should undergo mitral valve replacement or percutaneous mitral balloon valvotomy (PMBV) to prevent right ventricular failure.",
"      <br>",
"       &Delta; PASP &gt;50 is an indication for PMBV if there is no other cause for pulmonary hypertension present.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_38_21103=[""].join("\n");
var outline_f20_38_21103=null;
